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Abstract 
Background: Diabetes mellitus (DM) is a chronic disease that requires continuing medical care and 
patient self-management education to prevent acute complications and to reduce the risk of long-term 
complications. Patients with type 2 DM have a two to four fold increase incidence of disease related 
to atheroma.  
 
This is a single centre hospital-based cohort rospective study. Patients data included history, clinical 
evaluation, biochemical investigation, ECG and Echocardiography. Interventional procedures such as 
Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) were performed as 
indicated. A total of 150 consecutive Yemeni patients were recrruited in this study, 100 diabetic 
patients and 50 non diabetic patients (control). The diabetic patients were treated by different methods 
of insulin treatment protocol, 50 patients were treated by insulin infusion therapy (IIT) and the other 
50 patients were treated by sliding scale insulin (SSI) protocol. Anti-ischemic treatment (medications) 
were given to both cases and control groups.  
All patients admitted with AMI to the intensive care unit of the cardiac centre  at Al-Thawra Teaching 
Hospital in Sana’a over 12 months (Jan 2007-Dec2010) were included.  
We evaluated of the impact of IV continuous insulin infusion technique on the outcome of acute MI 
as compared to the sliding scale in diabetic patients.  A post MI surveillance of patients was 
conducted over the next 12 months. 
Results: Male predominance was evident in this study. Mean (±SD) waist circumference (WC) was 
significantly higher in diabetic patients (95.4±15.2 cm) than in the control (90±13.3 cm) (p= 0.032).  
There was no significant difference between diabetic and non diabetic patients as regard to other 
cardiovascular risk factors.  The mean (±SD) admission blood glucose (ABG) level was significantly 
higher in the diabetic group (17.2±5.6 mmol/l) than in the control group, (6.9±1.3 mmol/l), p<0.0001.  
Also the mean (±SD) HbA1c% showed significantly higher value in the diabetic group (11.4±1.42 %) 
compared to the control group, (5.8±0.64 %), p=0.006. 
Heart failure was noted to be more frequent among diabetics treated with (SSI), (34%) than in those 
treated with (IIT) (19.1%), p=0.01. Arrhythmia was less frequent among diabetics treated with IIT 
(12%), than those treated with SSI (20%), p=0.31.  
Recurrent chest pain found to be more likely among diabetics treated with IIT (38%) than those 
treated with SSI (18%), p=0.04. 
In contrast, stroke was found to be significantly higher among SSI patients (20%) than IIT patients 
(0%), p<0.0001. As for mortality, it was noted to be more frequent among SSI treated patients (20%) 
than IIT treated patients (6%), p=0.04. 
  Conclusion: Insulin infusion therapy in diabetic patients with AMI seems to have better outcomes 
regarding arrhythmia, stroke and cardiovascular mortality compared to sliding scale insulin therapy.  
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Ϥϟ΍ΘδκϠΨ  
ΔϣΪϘϣ
 
ϱήϜδϟ΍νήϣϦϣΰϣϲπΘϘϳΔϳΎϋήϟ΍ΔϴΒτϟ΍ΔϴλΎμΘΧϻ΍Δϣ΍ΪΘδϤϟ΍ϦϣϞΒϗϲϣΪϘϣΔϳΎϋήϟ΍ΔϴΒτϟ΍ϒϴϘΜΘϟ΍ϭϲΤμϟ΍ΞϣήΒϤϟ΍
ήϤΘδϤϟ΍ξϳήϤϠϟϪΟϮϤϟ΍ϮΤϧϖϴϘΤΗΔϳΎϋήϟ΍ΔϴΗ΍άϟ΍ϑΪϬϟ΍ϭϦϣϚϟΫϪϠϛϮϫϖϴϘΤΗΔϳΎϗϮϟ΍ϦϣΕΎϔϋΎπϤϟ΍ΓΩΎΤϟ΍ϱήϜδϠϟ
ϒϴϔΨΘϟ΍ϭϦϣήτΧΕΎϔϋΎπϤϟ΍ΔϨϣΰϤϟ΍ΔϠϳϮσϯΪϤϟ΍ΔϤΟΎϨϟ΍΍ϭϪϨϋΔϤΟΎϨϟϦϋΐϠμΘϟ΍ϱΪϴμόϟ΍ωέΎδΘϤϟ΍Ϧϴϳ΍ήθϠϟ 
(accelerated atherosclerosis) 
ΔϴΠϬϨϣϖ΋΍ήσϭΚΤΒϟ΍
ϡΎϗΚΣΎΒϟ΍ΔϠΑΎϘϤΑϞϛξϳήϣϙέΎθϣϲϓΚΤΒϟ΍ϢΗ΃ϭϪδϔϨΑϢϴϘΘϟ΍ϱήϳήδϟ΍ΔϟΎΤϟξϳήϤϟ΍˱˯΍ΪΘΑ΍ΔμϘϟΎΑΔϴοήϤϟ΍ϒθϜϠϟ΍ϭ
ϱˬήϳήδϟ΍΍˱έϭήϣςϴτΨΘϟΎΑϲ΋ΎΑήϬϜϟ΍ΐϠϘϠϟϮϜϳ΍ϭΐˬϠϘϟ΍ΔϳΎϋήϟΎΑϭΔϴΒτϟ΍ϲϓΓΪΣϭΔϳΎϋήϟ΍ΔϴΒϠϘϟ΍ΓΩΪθϤϟ΍ϢΗ΍˯ήΟ΍ΓήτΜϘϟ΍
ΔϴΒϠϘϟ΍ΔϴμϴΨθΘϟ΍ΔϴΟϼόϟ΍ϭ΃ϦϣΚΣΎΒϟ΍ϞΒϗΔΣ΍ήΟϭϦϴϳ΍ήηΐϠϘϟ΍ϦϣϞΒϗϱέΎθΘγ΍ΔΣ΍ήΟΐϠϘϟ΍ϲϓΰϛήϣΐϠϘϟ΍ΐδΣ
ΔΟΎΤϟ΍ϚϟάϛϢΗϝΎΧΩ΍ΕΎϣϮϠόϤϟ΍ΔλΎΨϟ΍ϞϜΑξϳήϣϲϓΞϣΎϧήΑϲ΋ΎμΣ΍ιΎΧ  (SPSS Software Package)ϞϴϠΤΗ
ΕΎϧΎϴΒϟ΍Ύ˱ϴ΋ΎμΣ΍ΓΪϋΎδϤΑϲλΎμΘΧ΍ϲϓϢϠϋΎ˯μΣϻ΍
΍˯ήΟ΍ήϤΘγ΍ϩάϫΔγ΍έΪϟ΍ΙϼΛΕˬ΍ϮϨγϦϴΑΎϣήϬηήϳΎϨϳϡΎϋϮϬϬϳˬήϬηϭήΒϤδϳΩϮϬϭϬˬΖϨϤπΗϭϭϱϬξ˳ϳήϣϊ˳ΑΎΘϣϲϓ
ΙϭΪΣνήϤϟ΍ωϮοϮϣΔγ΍έΪϟ΍ϊϣΎ˯ϨΜΘγ΍ΕϻΎΤϟ΍ϲΘϟ΍κϧΎϬϴϠϋϝϮϜΗϭήΑΚΤΒϟ΍˶ϙέΎηϲϓϩάϫΔγ΍έΪϟ΍ϰοήϣϦϣ
ϦϴδϨΠϟ΍ϦϣϭΕΎΌϓΔϳήϤϋΔϔϠΘΨϣϥϮΑΎμϣΎ˯θΘΣϻΎΑϲΒϠϘϟ΍ΩΎΤϟ΍ϊϣϱήϜδϟ΍Δο΍ήϤϛΔϘϓ΍ήϣϭ΃ϪϧϭΪΑΖϠϤΘη΍Δγ΍έΪϟ΍ϰϠϋ
Δ΋ΎϣξϳήϣΏΎμϣρήϔΑήϜγϡΪϟ΍ϢΟΎϨϟ΍ϦϋϱήϜδϟ΍ςϤϧϮΔϋϮϤΠϣΔϟΎΤϟ΍ϦϴδϤΧϭξϳήϣήϴϏΏΎμϣρήϔΑήϜγϡΪϟ΍
ΔϋϮϤΠϤϟ΍ΔτΑΎπϟ΍ˬϢϬόϴϤΟϭϦϣϰοήϤϟ΍ϦϴΑΎμϤϟ΍Ύ˯θΘΣϻΎΑϲΒϠϘϟ΍ΩΎΤϟ΍ϢΗϭϢϴδϘΗϰοήϤϟ΍ϦϴΑΎμϤϟ΍ρήϔΑήϜγϡΪϟ΍
ΔϋϮϤΠϣΔϟΎΤϟ΍ϰϟ΍ϦϴϘϳήϓϝϭϷ΍ϥϮϜϣϦϣϦϴδϤΧξϳήϣΞϟϮ˵ϋϭΔϘϳήτΑΐϳήδΘϟ΍ϱΪϳέϮϟ΍ήϤΘδϤϟ΍έΎϘόϟϦϴϟϮδϧϻ΍
ϲϣΎψϨϟ΍(IIT)ˬϲϧΎΜϟ΍ϭϥϮϜϣϦϣϦϴδϤΧξϳήϣΞϟϮ˵ϋϭΔϘϳήτΑϢϠδϟ΍΍ϹϲϗϻΰϧϦϘΤΑϦϴϟϮδϧϻ΍ϲϣΎψϨϟ΍ΖΤΗΪϠΠϟ΍(SSI)
Ύϣ΃Γ΍ϭ΍ΪϣΎ˯θΘΣϻ΍ϲΒϠϘϟ΍ΖϧΎϜϓΓΪΣϮϣϲϓϲΘϋϮϤΠϣΔϟΎΤϟ΍ΔτΑΎπϟ΍ϭ
ϥΎϜϣΕΎΒϴΗήΗϭ΍˯ήΟ΍ΚΤΒϟ΍
ΖϳήΟ˵΃ϩάϫΔγ΍έΪϟ΍ϲϓΰϛήϣΪˬΣ΍ϭϮϫΰϛήϣΐϠϘϟ΍ϲϓϰϔθϣΓέϮΜϟ΍ϲϤϴϠόΘϟ΍ϲϓΎ˯όϨλΔϳέϮϬϤΠϟΎΑΔˬϴϨϤϴϟ΍ϲϫϭΔγ΍έΩ
ΔϴϗΎΒΘγ΍ΔϴϠΧ΍ΪΗϰϠϋϞϴΟϦϣϰοήϤϟ΍΍ϮϠΧΩ˵΃ϰϟ΍ΔϳΎϋήϟ΍ΔϴΒϠϘϟ΍ΓΩΪθϤϟ΍ϰϔθϤϟΎΑϲϓΔϟΎΣΎ˯θΘΣ΍ϲΒϠϗΩΎΣ΍ϮϘϠΗϭΔϳΎϋήϟ΍
ΔϴΒτϟ΍ΔϴλΎμΘΧϻ΍ϦϣϞΒϗΚΣΎΒϟ΍ϝϼΧΓήΘϔϟ΍ΓˬΩΎΤϟ΍΍ϮόπΧϭΔόΑΎΘϤϠϟΔΒϗ΍ήϤϟ΍ϭϦϣϪϠΒϗΎ˱πϳ΃ΪόΑϢϬΟϭήΧϦϣϰϔθϤϟ΍ϰϠϋ
ϯΪϣϲϨΛ΍ήθϋ΍˱ήϬη
ϑ΍Ϊϫ΃ΚΤΒϟ΍
 
ϑΪϬΗϩάϫΔγ΍έΪϟ΍ϲΘϟ΍ΎϬϨϤπΘΗϩάϫΔΣϭήσϷ΍ϰϟ΍ΔϓήόϣήϴΛ΄ΗΔϘϳήσΐϳήδΘϟ΍ϱΪϳέϮϟ΍ήϤΘδϤϟ΍έΎϘόϟϦϴϟϮδϧϻ΍(IIT)ϲϓ
ΝϼϋρήϓήϜγϡΪϟ΍ϝϼΧΔΑΎλϷ΍Ύ˯θΘΣϼΑϲΒϠϘϟ΍ΩΎΤϟ΍ΔϧέΎϘϣΔϘϳήτΑϦϘΣϦϴϟϮδϧϻ΍ΖΤΗΪϠΠϟ΍ϰϠϋϢϠδϟ΍΍Ϲϲϗϻΰϧ(SSI)
ϚϟΫϭϲϓέΎσ΍ΔϋϮϤΠϣΔϟΎΤϟ΍ϱ΃ΔϋϮϤΠϤϟ΍ϲΘϟ΍Ύϫ΍ήΘϋ΍ρήϓήϜγϡΪϟ΍(hyperglycemia)ΐΒδΑΔΑΎλ΍ΔϘΑΎγνήϤΑ
ϱήϜδϟ΍
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ϝΪΗΞ΋ΎΘϨϟ΍ϲΘϟ΍ΎϫήϬχ΃ΚΤΒϟ΍ϥ΃ιϢϟϦϜϳϙΎϨϫϕήϓϭΫΔϟϻΩΔϴ΋ΎμΣ΍ϦϴΑςγϮΘϣήϤόϟ΍ϦϴΑΔϋϮϤΠϣΔϟΎΤϟ΍ΔϋϮϤΠϤϟ΍ϭ
ΔˬτΑΎπϟ΍ϦϜϟϭξόΑΕ΍ήηΆϣΕΎγΎϴϘϟ΍ΔϳήθΒϟ΍(anthropometry)ϲϓΔϋϮϤΠϣΔϟΎΤϟ΍ΖϧΎϛϕϮϔΗΔϟϻΪΑΔϴ΋ΎμΣ΍ΔϣΎϫ
ΎϬΘϠϴΜϣϲϓΔϋϮϤΠϤϟ΍ΔˬτΑΎπϟ΍ςϴΤϤϛΓήλΎΨϟ΍ (ൌͲǤͲ͵ ሻʹΔΒδϧϭΓήλΎΨϟ΍ϰϟ΍ϝϮτϟ΍(WHtR)(ƉсϬ͘ϬϬϯϳ) ˬΎϣ΃
ΐδϨϣΔϠΘϛϢδΠϟ΍(BMI)ϢϠϓϦϜϳΎ˱ϔϠΘΨϣϦϴΑϦϴΘϋϮϤΠϤϟ΍ϱ΃Ϫϧ΃ϰϠϋϢϏήϟ΍ϦϣϡΪϋΩϮΟϭϑϼΘΧ΍ϱήϫϮΟϦϴΑϦϴΘϋϮϤΠϤϟ΍
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  Objectives of the study 
 
1. Assessment  of  the  acute  outcome  of  MI  in 
patients having hyperglycemia in comparison to 
non-hyperglycemic patients. 
2. Evaluation  of  the   impact  of  IV   continuous 
insulin infusion technique on the outcome of MI 
compared   to   the   sliding   scale   in   diabetic 
patients. 
3. Post MI  surveillance of patients over the next 
twelve months and monitoring remote 
complications in relation to the regimen of 
treatment of hyperglycemia. 
4. Clinical end points: 
Primary end points 
 
Myocardial infarction related fatal stroke, 
cardiogenic shock, sudden death, and arrhythmia 
Myocardial infarction related non-fatal heart failure, 
systolic hypertension, and recurrent chest pain. 
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Secondary end points: Non vascular causes of 
morbidity and mortality. 
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Diabetes mellitus is a chronic disease that requires continuing medical  
care  and  patient  self-management education  to  prevent acute 
complications and to reduce the risk of long-term complications. 
 
History 
 
The term  diabetes (Greek: SiaP^x^ , diabetes) was  coined by 
Aretaeus of  Cappadocia. It  was derived  from  the Greek  verb 
SiaPalvsiv, diabainein, itself formed from the prefix dia-,  "across, 
apart," and the verb bainein, "to walk, stand." The verb diabeinein 
meant  "to  stride,  walk,  or  stand  with  legs  asunder";  hence,  its 
derivative diabetes meant  "one that  straddles,"  or  specifically  "a 
compass,  siphon."  The  sense  "siphon"  gave  rise  to  the  use  of 
diabetes  as  the  name  for  a  disease involving  the  discharge  of 
excessive amounts of urine. Diabetes is first recorded in English, in  
the  form  diabete,  in  a  medical  text written  around  1425.  In 
1675, Thomas Willis added the word mellitus, from the Latin meaning 
"honey", a reference to the sweet taste of the urine. This sweet  taste  
had  been  noticed  in  urine  by  the  ancient  Greeks, Chinese,  
Egyptians,  Indians,  and  Persians.  In   1776,  Matthew Dobson 
confirmed that the sweet taste was because of an excess 
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of a kind of sugar in the urine and blood of people with diabetes 
(59). 
 
The ancient Indians tested for diabetes by observing whether ants 
were attracted to  a person's urine,  and called the  ailment  "sweet 
urine disease" (Madhumeha). The Korean, Chinese, and Japanese 
 
words  for  diabetes  are  based  on  the  same  ideographs  ( M M ^ ) 
which mean  "sugar urine disease".  In medieval Persia, Avicenna 
(980-1037)  provided  a  detailed  account  on  diabetes  mellitus  in 
The Canon of Medicine, "describing the abnormal appetite and the 
collapse of sexual functions and he documented the sweet taste of 
diabetic urine."  Like Aretaeus before  him,  Avicenna recognized 
primary   and   secondary   diabetes.   He   also   described   diabetic 
gangrene,   and   treated   diabetes   using   a   mixture   of   lupine, 
trigonella (fenugreek), and zedoary seed, which produces a 
considerable reduction in the excretion of sugar, a treatment which is  
still  prescribed  in  modern  times.  Avicenna  also   "described 
diabetes insipidus very precisely for the first time", though it was later 
Johann Peter Frank (1745-1821) who first differentiated between 
diabetes mellitus and diabetes insipidus (60). 
 
Although diabetes has been recognized since antiquity, and treatments 
of various efficacy have been known in various regions since   the   
Middle   Ages,   and   in   legend   for   much   longer, pathogenesis of 
diabetes has only been understood experimentally since about 1900 
(61). 
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The discovery of a role for the pancreas in diabetes is  generally 
ascribed  to  Joseph  von  Mering  and  Oskar  Minkowski,  who  in 
1889 found that dogs whose pancreas was removed developed all 
the  signs  and  symptoms of diabetes  and  died  shortly  afterwards 
(62). 
 
In 1910, Sir Edward Albert Sharpey-Schafer suggested that people 
with   diabetes   were   deficient  in   a   single   chemical   that  was 
normally produced by the pancreas—he proposed calling this 
substance   insulin,  from  the   Latin   insula,  meaning   island,   in 
reference to the insulin-producing islets of Langerhans in the 
pancreas (61). 
 
The endocrine role of the pancreas in metabolism, and indeed the 
existence of insulin, was not further clarified until 1921, when Sir 
Frederick  Grant Banting  and  Charles  Herbert  Best  repeated  the 
work of Von Mering and Minkowski, and went further to 
demonstrate that they could reverse  induced diabetes  in dogs by 
giving them an extract from the pancreatic islets of Langerhans of 
healthy dogs (63). 
 
 
Banting, Best, and colleagues (especially the chemist Collip) went 
on to  purify the hormone  insulin from bovine pancreases at the 
University of Toronto. This led to the availability of an effective 
treatment—insulin injections—and the first patient were treated in 
1922. For this, Banting and laboratory director MacLeod received 
the Nobel Prize in Physiology or Medicine in  1923;  both shared 
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their   Prize   money   with   others   in   the   team   who   were   not 
recognized, in particular Best and Collip. Banting and Best made 
the patent available without charge and did not attempt to control 
commercial production. Insulin production and therapy rapidly spread 
around the world, largely as a result of this decision. 
 
The distinction between what is now known as type 1 diabetes and 
type 2  diabetes  was  first  clearly  made  by  Sir  Harold  Percival 
(Harry) Himsworth, and published in January 1936 (64). 
 
Despite  the  availability  of  treatment,  diabetes  has  remained  a 
major cause of death. For instance, statistics reveal that the cause- 
specific  mortality rate  during  1927  amounted to  about 47.7  per 
100,000 populations in Malta (65). 
 
Other landmark discoveries include: (61) 
 
• identification of the first of the sulfonylureas in 1942 
• reintroduction of the use  of biguanides for Type 2  diabetes 
in  the  late 1950s.  The  initial  phenformin  was  withdrawn 
worldwide  (in  the  U.S. in 1977)  due  to  its  potential  for 
sometimes fatal lactic acidosis and metformin was first 
marketed in France in 1979, but not until 1994 in the US. 
• the determination of the amino acid sequence of insulin (by 
Sir Frederick Sanger, for which he received a Nobel Prize) 
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•   the radioimmunoassay for insulin, as discovered by Rosalyn 
Yalow and Solomon Berson (gaining Yalow the  1977 Nobel 
Prize in Physiology or Medicine)(66). 
• the three-dimensional structure of insulin (PDB 2INS) 
• Dr  Gerald  Reaven's identification of  the constellation of 
symptoms now called metabolic syndrome in 1988 
• demonstration that intensive glycemic control in type 1 
diabetes reduces chronic side effects more as glucose levels 
approach 'normal' in a large longitudinal study,(67) and also 
in type 2 diabetics in other large studies 
• identification  of the  first  thiazolidinedione  as  an  effective 
insulin sensitizer during the 1990s. 
 
In   1980,  U.S.   biotech  company  Genentech  developed  human 
insulin.  The  insulin  is  isolated  from  genetically-altered bacteria 
(the  bacteria  contain  the  human  gene  for  synthesizing  human 
insulin), which produce large quantities of insulin.  Scientists then 
purify  the  insulin  and  distribute  it  to  pharmacies  for  use  by 
diabetes patients. 
 
Social issues 
 
The  1989 Declaration of St Vincent was the result of international 
efforts to improve the care accorded to those with diabetes. Doing so 
is important both in terms of quality of life and life expectancy but 
also economically - expenses to diabetes have been shown to 
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be a major drain on health- and productivity-related resources for 
healthcare systems and governments. 
 
Several countries established more and less successful national 
diabetes programmes to improve treatment of the disease (68). 
 
A study shows that diabetic patients with neuropathic symptoms 
such  as  numbness  or  tingling  in  feet  or  hands  are  twice  more 
likely to be unemployed than those without the symptoms (69). 
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Definition and classification of diabetes. 
 
Definition 
It  is  a  metabolic  disorder  of multiple  etiology  characterized  by 
chronic hyperglycemia with disturbances of carbohydrate, fat, and 
protein metabolism resulting from defects of insulin secretion, 
insulin action, or a combination of both (1). 
 
 
Type 1 diabetes is due to a virtually complete lack of endogenous 
pancreatic insulin production. On contrary, in type 2diabetes, the 
rising blood glucose results from a combination of genetic 
predisposition, unhealthy diet, physical  inactivity, and increasing 
weight with a central adiposity resulting in complex 
pathophysiological  processes.  DM  is  defined  by  its  association 
with hyperglycemia and specific microvascular complications. 
However, it also imports a 2-4 folds risk of cardiovascular disease 
(CVD) (100). 
Microvascular  complications include  retinopathy  with  potential 
blindness, nephropathy with a risk of progression to renal failure, 
neuropathy  with  risk  for  foot  ulcers,  amputation,  and  Charcot 
joints and autonomic dysfunction such as sexual impairment. 
Patients  with  diabetes  also  are  at  a  particularly  great  risk  for 
cardiovascular, cerebrovascular, and peripheral artery disease. 
Although  microvascular complications  can  lead  to  a  significant 
morbidity  and  premature  mortality,  by  far the  greatest cause  of 
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death in people with diabetes is CVD. Moreover, persons without 
established coronary heart disease are considered to be at high risk of 
a  coronary  event  if they  have  diabetes  as  a  condition that  is 
equivalent to coronary heart disease (101). 
 
 
Since  the  first unified  classification of diabetes  by  the National 
Diabetes   Data   Group   in    1979   (2)   and   the   World   Health 
Organization (WHO) in  1980 (3), a few modification have been 
introduced by the WHO (4, 5) and the American Diabetes Association 
(ADA) (6, 7). Impaired glucose tolerance (IGT) is essentially 
asymptomatic and only can be recognized by the result of OGTT 
only:  2-h post-load plasma glucose (2h PG) level >7.8 and <  11.1  
mmol/l. A standardized OGTT test performed in the morning, after 
an overnight fast (8-14h); first blood sample should be taken before 
and the second sample 120 min after intake of 75 g  glucose 
dissolved in 250-300 mL water in a course of 5  min. 
Classification  (old)  of diabetes  includes  both  aetiological  types 
and  different clinical  stages  of hyperglycaemia as  suggested by 
Kuzuya and Matsuda (8). Four main aetiological categories of diabetes 
have been identified as diabetes type 1, type 2, and other specific 
types and gestational diabetes. 
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Classification 
 
 
 
 
 
The term diabetes, without qualification, usually refers to diabetes 
mellitus, which is  associated with excessive  sweet urine (known 
as "glycosuria") but there are several rarer conditions also named 
diabetes. The most common of these is diabetes insipidus in which 
the urine is not sweet (insipidus meaning "without taste" in Latin); it  
can  be  caused  by  either kidney  (nephrogenic DI)  or pituitary 
gland (central DI) damage. 
 
The principal two idiopathic forms of diabetes mellitus are known as  
types   1  and  2.  The  term  "type 1  diabetes"  has  universally 
replaced several former terms, including childhood-onset diabetes, 
juvenile  diabetes, and  insulin-dependent  diabetes  (IDDM). 
Likewise, the term "type 2  diabetes" has replaced several former 
terms, including adult-onset diabetes, obesity-related diabetes, and 
non-insulin-dependent diabetes  (NIDDM).  Beyond these two 
types,  there  is  no  agreed-upon  standard  nomenclature.  Various 
sources have defined  "type 3  diabetes"   as, among others, 
gestational  diabetes  (9),   insulin-resistant type 1 diabetes (or 
"double  diabetes"),  type 2 diabetes which   has   progressed to 
require injected insulin, and latent autoimmune diabetes of adults 
(or  LADA  or  "type 1.5" diabetes)  (10). is also  maturity  onset 
diabetes of the young (MODY) which is a group of several single 
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gene   (monogenic)  disorders  with   strong  family  histories  that 
present as type 2 diabetes before 30 years of age. 
 
 
 
 
 
 
Type 1 diabetes mellitus 
 
Characterized  by  loss  of the  insulin-producing beta  cells  of the 
islets  of Langerhans  in the  pancreas,  leading to  a  deficiency of 
insulin. The main cause of this beta cell loss is a T-cell mediated 
autoimmune attack  (70).  There  is no known preventive measure 
which  can  be  taken  against type 1  diabetes;  it  is  about  10% of 
diabetes mellitus cases in North America and Europe (though this 
varies  by  geographical  location),  and  is  a  higher  percentage  in 
some other areas. Most affected people are otherwise healthy and of 
a healthy weight when onset occurs. Sensitivity and responsiveness  
to  insulin  are  usually  normal,  especially  in  the early stages. Type 
1 diabetes can classified into 2 main subtypes: 
 
 
1-Autoimmne 
 
i- Rapidly progressive-autoimmune type1 
diabetes(in children and adolescent) 
ii- Slowly progressive type1 autoimmune diabetes 
(LADA). 
 
2- Idiopathic type1 diabetes. 
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The principal treatment of type 1  diabetes, even from its earliest 
stages,  is  replacement of   insulin  combined with  careful 
monitoring  of blood  glucose  levels  using  blood  glucose  meters. 
Without insulin, diabetic ketoacidosis often develops which may 
result in coma or death. Treatment emphasis is now also placed on 
lifestyle   adjustments  (diet and exercise) though  these  cannot 
reverse the progress of  the  disease. Apart from  the common 
subcutaneous injections, it is also possible to deliver insulin by a 
pump, which allows continuous infusion of insulin 24 hours a day at  
preset  levels,  and  the  ability  to  program  doses  (a  bolus)  of 
insulin  as  needed  at  meal  times. An   inhaled  form  of  insulin, 
Exubera,  was  approved  by  the  FDA  in  January  2006,  although 
Pfizer discontinued the  product for business  reasons  in  October 
2007 (11). 
 
Non-insulin treatments, such as monoclonal antibodies and stem- 
cell based therapies, are effective in animal models but have not 
yet completed clinical trials in humans (12). 
 
Type 1 treatment must be continued indefinitely in essentially all 
cases. Treatment need not significantly impair normal activities, if 
sufficient patient training, awareness, appropriate care, discipline in  
testing  and  dosing  of insulin  is  taken.  However,  treatment is 
burdensome for patients, insulin is replaced in a non-physiological 
manner, and this approach is therefore far from ideal. The average 
glucose level for the type 1  patient should be as close to normal 
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(80-120 mg/dl,    4- 6 mmol/l)    as    is    safely    possible.    Some 
physicians suggest up to  140-150 mg/dl (7-7.5 mmol/l) for those 
having trouble with lower values, such as frequent hypoglycemic 
events.   Values   above   400 mg/dl   (20 mmol/l)   are   sometimes 
accompanied by discomfort and frequent urination leading to 
dehydration. Values above 600 mg/dl (30 mmol/l) usually require 
urgent   medical   intervention   as   it   may   lead   to   ketoacidosis, 
although they are not immediately life-threatening. However, low 
levels of blood glucose, called hypoglycemia, may lead to seizures or  
episodes  of unconsciousness  and  absolutely  must  be  treated 
immediately (12). 
 
 
 
 
 
Type 2 diabetes mellitus 
 
 
 
 
Type 2 diabetes mellitus is characterized differently due to insulin 
resistance  or reduced  insulin  sensitivity,  combined with  reduced 
insulin secretion. The defective responsiveness of body tissues to 
insulin almost certainly involves the insulinreceptor  in cell 
membranes. In  the  early  stage  the  predominant  abnormality  is 
reduced  insulin  sensitivity,  characterized  by elevated  levels   of 
insulin in the blood. At this stage hyperglycemia can be reversed 
by  a  variety  of measures  and  medications  that  improve  insulin 
sensitivity or  reduce glucose production by  the liver. As  the 
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disease  progresses  the  impairment  of  insulin  secretion  worsens 
due to progressive decline of B-cell function and therapeutic 
replacement of insulin often becomes necessary. 
 
There are numerous theories as to the exact cause and mechanism in  
type 2  diabetes.  Central  obesity  (fat  concentrated  around  the waist 
in relation to abdominal organs, but not subcutaneous fat) is known to 
predispose individuals for insulin resistance. Abdominal fat is 
especially active hormonally, secreting a group of hormones called  
adipokines  that  may  possibly  impair  glucose  tolerance. Obesity is 
found in approximately 55% of patients diagnosed with type 2  
diabetes (10).  Other factors  include aging  (about 20% of elderly  
patients  in  North  America  have  diabetes)  and  family history (type 
2 is much more common in those with close relatives who   have   had   
it).   In   the   last   decade,   type 2   diabetes   has increasingly 
recognized among children and adolescents, likely in connection  with  
the  increased  prevalence  of  childhood  obesity seen in recent 
decades in many parts of the world (14). 
 
Type 2 diabetes may go unnoticed for  years because  visible 
symptoms are typically mild, non-existent or sporadic, and usually 
there  are  no  ketoacidotic  episodes.  However,  severe  long-term 
complications can result from unnoticed type 2 diabetes, including 
renal  impairment  due  to  diabetic  nephropathy,  vascular  disease 
(including  coronary  artery  disease),  visual impairment due  to 
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diabetic retinopathy, loss of sensation or pain due to diabetic 
neuropathy, and liver damage from non-alcoholic steatohepatitis. 
 
Lifestyle interventions: 
 
 
Type 2 diabetes is usually first treated by life style modifications, 
increasing  physical  activity,  decreasing  carbohydrate  intake,  and 
losing weight. These can restore insulin sensitivity even when the 
weight loss is modest, for example around 5 kg (10 to 15 lb), most 
especially when  it  is  in abdominal fat deposits.  It  is  sometimes 
possible  to  achieve  long-term,  satisfactory  glucose  control  with 
these measures alone. However, the  underlying tendency to 
insulin resistance is not lost, and so attention to diet, exercise, and 
weight loss must continue.  The major environmental factors that 
increase the risk of  type 2 diabetes are overnutrition and  a 
sedentary  lifestyle,  with  consequent overweight and  obesity  (86, 
87). 
 
 
 
Not   surprisingly,   interventions   that  reverse   or  improve  these 
factors  have  been  demonstrated  to  have  a  beneficial  effect  on 
control  of glycemia in  established type 2  diabetes  (88). 
Unfortunately, the high rate of weight regain has limited the role of 
lifestyle interventions as an effective means of controlling Glycemia 
in the  long term.  The most convincing long-term data indicating 
that weight loss effectively lowers glycemia have been generated  in 
the follow-up  of type 2  diabetic patients who have 
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had bariatric surgery. In this setting, with a mean sustained weight 
loss of _20 kg, diabetes is virtually eliminated (89-92). 
 
 
In  addition to the beneficial effects of weight loss  on  glycemia, 
weight  loss  and  exercise  improve  coincident  CVD  risk  factors, 
such   as   blood   pressure   and   atherogenic   lipid   profiles,   and 
ameliorate other consequences of obesity (88, 93, and 94). 
 
 
 
There  are  few  adverse  consequences  of such  life  style 
interventions other than difficulty in incorporating them into usual 
lifestyle  and  sustaining  them  and  the  usually  minor 
musculoskeletal injuries and potential problems associated with 
neuropathy, such  as  foot trauma and ulcers that may  occur as  a 
result  of increased  activity.  Theoretically,  effective  weight  loss, 
with its pleiotropic benefits, safety profile, and low cost, should be the 
most cost-effective means of controlling diabetes—if it could be 
achieved and maintained over the long term. Given these beneficial 
effects, which are usually  seen rapidly—within weeks to  months—
and  often  before  there  has  been  substantial  weight loss (94), a 
lifestyle intervention program to promote weight loss and  increase  
activity  levels   should,  with  rare   exceptions,  be included as part 
of diabetes management. 
 
 
 
Weight loss of as little as 4 kg will often ameliorate 
hyperglycemia.However, the limited long-term success of lifestyle 
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programs  to  maintain  glycemic  goals  in  patients  with  type  2 
diabetes  suggests  that the  large  majority  of patients  will  require 
the addition of medications over the course of their diabetes (95). 
 
 
 
Step 1: lifestyle intervention and metformin. 
 
 
Based   on   the   numerous   demonstrated   short-   and   long-term 
benefits  that  accrue  when  weight  loss  and  increased  levels  of 
activity are achieved and maintained, as well as the cost- effectiveness 
of lifestyle interventions when they succeed, the consensus is that 
lifestyle interventions should be initiated as the first step in treating 
new-onset type 2 diabetes . 
These interventions should be implemented by health care 
professionals  with appropriate training— usually registered 
dietitians   experienced   in   behavioral   modification—   and   be 
sensitive to ethnic and cultural differences among populations. 
Moreover,   lifestyle   interventions   to   improve   glucose,   blood 
pressure,  and lipid levels,  and to promote weight loss or at least 
avoid weight gain, should remain an underlying theme throughout 
the  management  of type  2  diabetes,  even  after  medications  are 
used. For the 10-20% of patients with type 2 diabetes who are not 
obese  or  overweight,  modification  of  dietary  composition  and 
activity levels may play a supporting role, but medications are still 
generally required early in the course of diabetes. 
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The  authors  recognize  that  for  most  individuals  with  type  2 
diabetes, lifestyle interventions fail to achieve or maintain the 
metabolic  goals  either because  of failure  to  lose  weight,  weight 
regain,  progressive  disease,  or  a  combination  of factors. Therefore, 
our consensus is that metformin therapy should be initiated 
concurrently with lifestyle intervention at diagnosis. Metformin    is   
recommended   as   the    initial   pharmacological therapy, in the 
absence of specific contraindications, for its effect on glycemia,  
absence  of weight gain or hypoglycemia,  generally low level  of 
side effects, high level  of acceptance, and relatively low cost. 
Metformin treatment should be titrated to its maximally effective  
dose  over  1- 2  months,  as  tolerated.  Rapid  addition of other  
glucose-lowering  medications  should be  considered  in  the setting 
of persistent symptomatic hyperglycemia. 
 
 
 
Step 2: addition of a second medication. 
 
 
If  lifestyle   intervention   and   the   maximal   tolerated   dose   of 
metformin fail to  achieve or sustain the glycemic  goals, another 
medication should be added within 2- 3 months of the initiation of 
therapy or at any time when the target A1C level is not achieved. 
Another medication may also be necessary if metformin is 
contraindicated or not tolerated. 
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The consensus regarding the  second medication added  to 
metformin  was  to  choose  either  insulin  or  a  sulfonylurea. As 
discussed above, the A1C level will determine in part which agent is  
selected next,  with  consideration  given  to  the  more  effective 
glycemia-lowering agent,  insulin, for patients with an A1C level of 
_8.5% or with symptoms secondary to hyperglycemia. Insulin can be 
initiated with a basal (intermediate- or long-acting) insulin regimens) 
(103). However, many newly diagnosed type 2 diabetic patients will
 usually respond to oral  medications,  even   if 
symptoms of hyperglycemia are present (103). 
 
 
 
Step 3: further adjustments. 
 
 
If lifestyle,  metformin,  and  sulfonylurea  or basal  insulin  do  not 
result in achievement of target glycemia, the next step should be to  
start,  or  intensify,  insulin  therapy.  Intensification  of insulin 
therapy usually consists of additional injections that might include a  
short-  or  rapid-acting  insulin  given  before  selected  meals  to 
reduce postprandial glucose excursions  . When insulin injections 
are started, insulin secretagogues (sulfonylurea or glinides) should be 
discontinued, or tapered and then discontinued, since they are not 
considered to be synergistic. Although addition of a third oral agent  
can  be  considered,  especially  if the A1C  level  is  close to target 
(A1C _8.0%), this approach is usually not preferred, as it is 
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no more effective in lowering glycemia, and is more costly, than 
initiating or intensifying insulin (103). 
 
Glycemic goals of therapy 
 
The most recent glycemic  goal recommended by ADA,  selected on 
the basis of practically and the projected reduction in complications   
over  time,   is   ,   in   general,   an   A1C   level   of 
<7%(12).The most recent  glycemic  goal  set by the  International 
Diabetes Federation is an A1C level of <6.5%. 
 
Gestational diabetes 
 
Defined  as  "glucose  intolerance  with  onset  or  first  recognition 
during  pregnancy,  has  been  the  subject  of considerable controversy 
(HAPO) (104,105). 
 
 
 
 
 
 
 
 
Screening for and diagnosis of GDM: 
 
 
Perform a 75-g OGTT, with plasma glucose measurement fasting 
and  at  1  and  2  h,  at  24-28  of weeks  gestation  in  women  not 
previously  diagnosed  with  overt  diabetes.  The  OGTT  should be 
performed in the morning after an overnight fast of at least 8 h. 
The diagnosis of GDM is made when any of the following plasma 
glucose values are exceeded: 
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•  Fasting: > 92 mg/dl (5.1 mmol/l) 
•  1 h: > 180 mg/dl (10.0 mmol/l) 
•  2 h: >153 mg/dl (8.5 mmol/l) 
 
Gestational diabetes mellitus (GDM) resembles type 2 diabetes in 
several respects, involving a combination of relatively inadequate 
insulin secretion and responsiveness. It occurs in about 2%-5 % of 
all pregnancies and may improve or disappear after delivery. 
Gestational diabetes is fully treatable but requires careful medical 
supervision   throughout   the   pregnancy.   About   20%-50 %   of 
affected women develop type 2 diabetes later in life. 
 
Even  though  it  may  be  transient,  untreated  gestational  diabetes 
can damage the health of the fetus or mother.  Risks to the baby 
include macrosomia (high birth weight), congenital cardiac and central 
nervous system anomalies, and skeletal muscle malformations. 
Increased fetal insulin may inhibit fetal surfactant production and 
cause respiratory distress syndrome. Hyperbilirubinemia may result 
from red blood cell destruction. In severe  cases,  perinatal  death  
may  occur,  most  commonly  as  a result  of poor  placental  
profusion  due  to  vascular  impairment. Induction may be  indicated 
with decreased placental function. A cesarean section may be 
performed if there is marked fetal distress or an increased risk of 
injury associated with macrosomia, such as shoulder dystocia. 
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A 2008  study  completed  in the  U.S.  found that more American 
women are entering pregnancy with preexisting  diabetes.  In fact 
the rate of diabetes in expectant mothers has more than doubled in 
the past 6 years (16). This is particularly problematic as diabetes raises 
the risk of complications during pregnancy, as well as increasing the 
potential that the children of diabetic mothers will also become 
diabetic in the future. 
 
Other types 
 
There  are  several rare  causes  of diabetes  mellitus that do  not fit 
into  type 1,  type 2,  or  gestational  diabetes;  attempts  to  classify 
them remain controversial.  Some cases of diabetes are caused by 
the body's tissue receptors  not responding to  insulin (even when 
insulin levels are normal, which is what separates it from type 2 
diabetes);   this  form   is  very uncommon.    Genetic  mutations 
(autosomal or  mitochondrial)  can  lead  to defects in  beta  cell 
function. Abnormal insulin action may also have been genetically 
determined  in some  cases. Any  disease  that  causes  extensive 
damage to the pancreas may lead to diabetes (for example, chronic 
alcoholic pancreatitis  and    cystic fibrosis).  Diseases associated 
with  excessive   secretion  of  insulin-antagonistic   hormones can 
cause   diabetes  (which  is  typically  resolved  once  the  hormone 
excess  is removed e.g  Cushing,s syndrome).  Many  drugs  impair 
insulin  secretion  and  some  toxins  damage  pancreatic  beta  cells 
e.g. (nicotinic  acid and glucocorticoids). The ICD-10 (1992) 
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diagnostic  entity,  malnutrition-related  diabetes  mellitus  (MRDM or  
MMDM,  ICD-10  code  E12),  was  deprecated  by  the  World Health  
Organization when the  current taxonomy was  introduced in 1999 
(4). 
Infections. 
Certain  viruses   have   been   associated  with   B-cell   destruction. 
Diabetes occurs in patients with congenital rubella, although most 
of these patients have HLA and immune markers characteristic of 
type  1  diabetes. In addition, coxsackievirus   B, cytomegalovirus, 
adenovirus, and mumps have been implicated in inducing certain 
cases of the disease (105). 
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Epidemiology of diabetes 
 
In 2000, according to the World Health Organization, at least 171 
million  people  worldwide  suffer  from  diabetes,  or  2.8%  of the 
population  (54).  Its  incidence  is  increasing  rapidly,  and  it  is 
estimated that by the year 2030, this number will  almost double 
(54). 
 
Diabetes  mellitus occurs throughout  the  world,  but is  more 
common (especially type 2) in developing  countries. The greatest 
increase in prevalence is, however, expected to occur in Asia and 
Africa, where most patients will likely be found by 2030 (54). The 
increase in incidence of diabetes in developing countries follows 
the  trend   of  urbanization  and  lifestyle changes,  perhaps   most 
importantly  a "Western-style" diet.  This has suggested  an 
environmental (i.e., dietary) effect, but there is little understanding of 
the mechanism(s) at present, though there is much speculation, 
some of it most compellingly presented. [ 5 4 ]      The National Diabetes 
Information  Clearinghouse  estimates that  diabetes costs  $132 
billion in the United States alone every year. About 5%—10% of 
diabetes  cases  in North America are type 1,  with the  rest being 
type 2.  The fraction of type 1  in other parts of the world differs; 
this  is  likely  due  to  both  differences  in  the  rate  of type 1  and 
differences  in  the  rate  of other types,  most  prominently type 2. 
Most of this difference is not currently understood. The American 
Diabetes  Association point  out  the  2003  assessment of the 
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National   Center   for   Chronic   Disease   Prevention   and   Health 
Promotion (Centers for Disease Control and Prevention) that 1  in 
3   Americans  born  after  2000  will  develop  diabetes   in  their 
lifetime (55, 56). 
 
According to  the American Diabetes Association, approximately 
18.3% (8.6 million) of Americans age 60 and older have diabetes 
(57). 
 
Diabetes mellitus prevalence increases with age, and the numbers of 
older persons with diabetes are expected to grow as the elderly 
population   increases   in   number.   The   National   Health   and 
Nutrition Examination Survey (NHANES  III)  demonstrated that, in 
the population over 65 years old,  18% to 20% have diabetes, with 
40% having either diabetes or its precursor form of impaired glucose 
tolerance (49). 
 
Indigenous populations in first world countries have a higher 
prevalence and increasing incidence of diabetes than their 
corresponding non-indigenous populations.  In  Australia the  age- 
standardised prevalence of self-reported diabetes in Indigenous 
Australians  is  almost 4  times that of non-indigenous Australians 
(58). Preventative community health programs such as Sugar Man 
(diabetes education) are showing some success in tackling this 
problem. 
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Signs and symptoms 
 
The  classical  triad  of diabetes  symptoms  is  polyuria,  polydipsia 
and polyphagia, which are, respectively, frequent urination; increased   
thirst   and   consequent   increased   fluid   intake;   and increased 
appetite. Symptoms may develop quite rapidly (days or weeks)  in 
type 1  diabetes, particularly in  children.  However,  in type 2  
diabetes the  symptoms develop much more  slowly(weeks to  
months)  and  may  be  subtle  or  completely  absent.  Type 1 diabetes   
may   also   cause   a  rapid  yet  significant  weight  loss (despite 
normal or even increased eating) and irreducible fatigue. All  of 
these  symptoms  except weight loss  can  also  manifest  in type 2   
diabetes  in  patients  whose  diabetes  is  associated  with severe B-
cell defect or is poorly controlled. 
 
When the glucose concentration in the blood is raised beyond the 
renal  threshold,  reabsorption  of  glucose  in  the  proximal  renal 
tubules is incomplete, and part of the glucose remains in the urine 
(glycosuria). This increases the osmotic pressure of the urine and 
inhibits the reabsorption of water by the kidney, resulting in 
increased  urine  production  (polyuria)  and  increased  fluid  loss. 
Lost blood volume will be replaced osmotically from water held in 
body cells, causing dehydration and increased thirst. 
 
Prolonged high blood glucose causes increase ocular   glucose 
absorption, which leads to changes in the  shape of the lenses of 
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the eyes, resulting in vision changes. Blurred vision is a common 
complaint leading to a diabetes diagnosis; type 1 should always be 
suspected  in  cases  of  rapid  vision  change  whereas  type 2   is 
generally more gradual, but should still be suspected. 
 
Patients  (usually  with  type 1   diabetes)  may  also  present  with 
diabetic ketoacidosis (DKA), an extreme state of metabolic 
dysregulation   characterized   by   the   smell   of  acetone   on   the 
patient's breath; a rapid, deep breathing known as Kussmaul 
breathing;  polyuria;  nausea;  vomiting  and  abdominal  pain;  and 
any  of many  altered  states  of consciousness  or  arousal  (such  as 
hostility and mania or, equally, confusion and lethargy). In severe 
DKA,  coma  may  follow,  progressing to  death.  Diabetic 
ketoacidosis   is   a   medical   emergency   and   requires   hospital 
admission. Increase B-OH Butyrate in the blood confirms the 
diagnosis. 
 
 
A rarer but equally severe possibility is hyperosmolar nonketotic 
state, which is more common in type 2 diabetes and is mainly the 
result of dehydration due to loss of body water. Often, the patient 
has  been  drinking  extreme  amounts  of sugar-containing  drinks, 
leading to a vicious circle in regard to the water loss. 
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Genetics 
 
Both  type 1   and  type 2  diabetes  are  at  least  partly  inherited. 
Type 1  diabetes  appears to  be triggered by  some  (mainly viral) 
infections, or in a less common group, by stress or environmental 
exposure (such as exposure to certain chemicals or drugs). There is 
a genetic element in individual susceptibility to  some of these 
triggers which has been traced to particular HLA genotypes (i.e., 
the genetic "self" identifiers relied upon by the immune system). 
However,  even  in  those  who  have  inherited  the  susceptibility, 
type 1 diabetes mellitus seems to require an environmental trigger. A  
small  proportion  of people  with  childhood  diabetes  carry  a 
mutated  gene  that  causes  maturity  onset  diabetes  of the  young 
(MODY). 
 
 
There is a stronger inheritance pattern for type 2 diabetes. Those 
with first-degree relatives with type 2 have a much higher risk of 
developing type 2,  increasing with the number of those relatives. 
Concordance  among  monozygotic  twins  is  close  to 100%,  and 
about  25%  of those  with  the  disease  have  a  family  history  of 
diabetes.   Candidate genes  causing  monogenic diabetes include 
KCNJ11  (potassium  inwardly rectifying  channel,  subfamily J, 
member  11),  which  encodes  the islet  ATP-sensitive  potassium 
channel Kir6.2 resulting in permanent neonatal diabetes, and 
genes encoding glucokinase (GCK) resulting in MODY2. On the 
other hand certain genotypes are associated with T2DM. Increase 
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expression  of     TCF7L2  (transcription  factor  7-lik e  2),  which 
regulates proglucagon gene expression and thus the production of 
glucagon-like peptide-1in pancreatic B-cell predispose to  type  2 
DM (70). Moreover, obesity (which is an independent risk factor 
for type 2 diabetes) is strongly inherited (71). 
 
Various hereditary conditions may feature diabetes,  for example 
myotonic dystrophy and Friedreich's ataxia. Wolfram's syndrome is 
an autosomal recessive neurodegenerative disorder that first becomes  
evident  in  childhood.  It  consists  of diabetes  insipidus, diabetes 
mellitus, optic atrophy, and deafness, hence the acronym DIDMOAD 
(15). 
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Pathophysiology 
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Most  of the  carbohydrates  in  food  are  converted  within  a  few 
hours to the  monosaccharide glucose, the principal carbohydrate 
found in blood and used by the body as fuel. Insulin is released 
into  the  blood  by  beta  cells  (p-cells),  found  in  the  Islets  of 
Langerhans in the pancreas, in response to rising levels of blood 
glucose  after  eating.  Insulin  is  used  by  about  two-thirds  of the 
body's cells to absorb glucose from the blood for use as fuel, for 
conversion to  other needed molecules,  or for  storage.  Insulin  is 
also  the  principal  control  signal  for  conversion  of  glucose  to 
glycogen for internal storage in liver and muscle cells.  Lowered 
glucose levels result both  in the  reduced release of insulin from 
the beta cells and in the reverse conversion of glycogen to glucose 
when glucose levels fall. This is mainly controlled by the hormone 
glucagon which  acts  in  an  opposite  manner to  insulin.  Glucose 
thus recovered by the liver re-enters the bloodstream; muscle cells 
lack the necessary export mechanism. 
 
Higher insulin levels increase some anabolic ("building up") processes  
such as  cell  growth and duplication, protein synthesis, and fat 
storage. Insulin (or its lack) is the principal signal in converting  many  
of  the  bidirectional  processes  of  metabolism from a catabolic to 
an anabolic direction, and vice versa. In particular, a low insulin level 
is the trigger for entering or leaving ketosis (the fat burning metabolic 
phase). 
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If the amount of insulin available  is  insufficient, if cells respond 
poorly to the effects of insulin (insulin insensitivity or resistance), or  
if  the  insulin  itself  is  defective,  then  glucose  will  not  be 
absorbed properly by those body cells that require it nor will it be 
stored appropriately in the liver and muscles. The net effect is 
persistent high levels of blood glucose, poor protein synthesis, and 
other metabolic derangements, such as acidosis (99). 
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Diagnosis 
 
The  diagnosis  of type 1  diabetes  and  many  cases  of type 2,  is 
usually  prompted  by  recent-onset  symptoms  of excessive urination 
(polyuria) and excessive thirst (polydipsia), often accompanied  by  
weight  loss.  These  symptoms  typically worsen over days  to  
weeks; about a quarter of people with new  type 1 diabetes have 
developed some degree of diabetic ketoacidosis by the time the 
diabetes is recognized. 
 
The diagnosis of other types of diabetes is usually made in other 
ways. These include ordinary health screening; detection of 
hyperglycemia during other medical investigations; and secondary 
symptoms   such   as   vision   changes   or   unexplainable   fatigue. 
Diabetes is often detected when a person suffers a problem that is 
frequently caused by diabetes, such as a heart attack, stroke, 
neuropathy,  poor  wound  healing  or  a  foot  ulcer,  certain  eye 
problems, certain fungal infections, or delivering a baby with 
macrosomia or hypoglycemia. 
 
Diabetes mellitus is characterized by recurrent or persistent 
hyperglycemia, and is diagnosed by demonstrating any one of the 
following: (4) 
 
•  fasting plasma glucose level at or above 126 mg/dL 
(7.0 mmol/l). 
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•   plasma  glucose  at  or  above  200 mg/dL  (11.1 mmol/l)  two 
hours after a 75 g oral glucose load as in a glucose tolerance 
test. 
•   random     plasma     glucose     at     or     above     200 mg/dL 
(11.1 mmol/l). 
 
A positive result, in the absence of clinical symptoms of diabetes, 
should be confirmed by another of the above-listed methods on a 
different day. Most physicians prefer to measure a fasting glucose 
level  because  of the  ease  of measurement  and  the  considerable 
time commitment of formal glucose tolerance testing, which takes 
two hours to  complete. According to the  current definition, two 
fasting glucose measurements above  126  mg/dL  (7.0  mmol/l) is 
considered diagnostic for diabetes mellitus. 
 
 
Hyperglycemia not  sufficient to  meet the  diagnostic criteria  for 
diabetes is categorized as either IFG or impaired glucose tolerance 
(IGT), depending on whether it is  identified through the FPG or 
the OGT: 
 
 
*IFG=  FPG  100  mg/dl  (5.6  mmol/l) to 125  mg/dl  (6.9 
mmol/l.    
 
*IGT = 2
mg/dl (11.0 mmol/l). 
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IFG  and  IGT  have  been  officially termed  "  pre-diabetes".  Both 
categories of pre-diabetes are risk factors for future diabetes and 
for cardiovascular disease. 
 
Of these two pre-diabetic states, the latter in particular is a major 
risk factor for progression to full-blown diabetes mellitus as well as 
cardiovascular disease (19). 
 
The A1C assay is the test of choice for the diagnosis and chronic 
management of diabetes, an elevated level of glucose  irreversibly 
bound to hemoglobin (termed glycosylated hemoglobin or HbAlc) of 
6.0% or higher (the 2003  revised U.S.  standard) is considered 
abnormal by most labs; HbA1c is primarily used as a treatment- 
tracking test reflecting average blood glucose levels over the 
preceding 90 days (approximately). 
 
 
 
However,  some  physicians  may  order  this  test  at  the  time  of 
diagnosis to track changes over time. The current, ADA 
recommended goal for HbA1c in patients with diabetes is <7.0%, 
which is considered good glycemic control, although some other 
guidelines, AACE are stricter (<6.5%). People with diabetes who have  
HbA1c  levels  within this  range  have  a  significantly lower 
incidence  of complications  from  diabetes,  including  retinopathy 
and diabetic nephropathy (20, 21). 
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In  order to  minimize the  risk  of diabetes  related  complications, 
the goal of therapy is to achieve a hemoglobin A1c (A1C) of 6.5% or  
less,  with  recognition  of  the  need  for  individualization  to 
minimize the risks of hypoglycemia AACE-ACE-Congress (22). 
 
Screening 
 
Diabetes  screening  is  recommended for many  people  at various 
stages of life, and for those with any of several risk factors.  The 
screening test varies according to circumstances and local policy, 
and may be a random blood glucose test, a fasting blood glucose 
test,  a blood glucose test two hours after 75 g  of glucose,  or an 
even   more   formal   glucose   tolerance   test.   Many   healthcare 
providers recommend universal screening for adults at age 40 or 
50, and often periodically thereafter. Earlier screening is typically 
recommended for those with risk factors such as obesity, family 
history  of  diabetes,  high-risk  ethnicity  (Hispanic,  Native 
American, Afro-Caribbean, Pacific Island, and South Asian ancestry) 
(22, 23). 
 
 
Many medical conditions are associated with diabetes and warrant 
screening. A partial list includes: high blood pressure, elevated 
cholesterol   levels,   coronary   artery   disease,   past   gestational 
diabetes,  polycystic  ovary  syndrome,  chronic  pancreatitis,  fatty 
liver, hemochromatosis, cystic fibrosis, several mitochondrial 
neuropathies  and  myopathies,  myotonic  dystrophy,  Friedreich's 
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ataxia,  some  of the  inherited  forms  of neonatal  hyperinsulinism. 
The   risk   of  diabetes   is   higher  with   chronic   use   of  several 
medications, including high-dose glucocorticoids, some 
chemotherapy agents (especially L-asparaginase), as well as some of  
the  antipsychotics  and  mood  stabilizers  (especially 
phenothiazines and some atypical antipsychotics). 
 
People with a confirmed diagnosis of diabetes are tested routinely 
for complications. This includes yearly urine testing for 
microalbuminuria and examination of the  eye  for retinopathy.  In 
the UK, systematic screening for diabetic retinopathy, which can 
be  effectively  treated  if detected  at  an  early  stage,  has  helped 
reduce visual impairment in people with diabetes since its 
implementation. 
 
Prevention 
 
Type 1   diabetes   risk   is   known   to   depend   upon   a   genetic 
predisposition based  on HLA types  (particularly types  DR3  and 
DR4), an unknown environmental trigger (suspected to be an 
infection, although none has proven definitive in all cases), and an 
uncontrolled autoimmune response that attacks the  insulin 
producing beta cells (21). 
 
 
Some research has suggested that breastfeeding decreased the risk in 
later life ;(25, 26) various other nutritional risk factors are being 
studied,   but  no   firm  evidence  has   been  found  (27).   Giving 
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children 2000  IU  of Vitamin D  during their first year  of life  is 
associated with reduced risk of type 1 diabetes, though the causal 
relationship is obscure (28). 
 
Children with antibodies to beta cell proteins (i.e., at early stages of 
an immune reaction to them) but no overt diabetes, and treated with 
vitamin B-3  (niacin),  had  less  than  half the  diabetes  onset 
incidence in a 7-year time span as did the general population, and an 
even lower incidence relative to those with antibodies as above, but 
who received no vitamin B3 (29). 
 
Type 2  diabetes  risks  can be  reduced  in  many cases  by  making 
changes in diet and increasing physical activity (27,28). The 
American Diabetes Association (ADA) recommends maintaining a 
healthy weight,  getting  at least 2^ hours  of exercise per week 
(several brisk sustained walks appears sufficient), having a modest 
fat  intake,  and  eating  a good  amount of fiber and whole  grains. 
There  is  inadequate  evidence that eating  foods  of low  glycemic 
index is clinically helpful despite recommendations and suggested 
diets in favor (29). 
 
There are numerous studies which suggest connections with some 
aspect of Type II  diabetes with ingestion of certain foods or with 
some drugs. Some studies have shown delayed progression to 
diabetes in predisposed patients through prophylactic use of 
metformin,(31) rosiglitazone,(33) or valsartan (34). In patients on 
hydroxychloroquine for rheumatoid arthritis, incidence of diabetes 
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was reduced by 77% though causal mechanisms are unclear (35). 
Breastfeeding  may  also  be  associated  with  the  prevention  of type 
2 of the disease in mothers (36). 
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Treatment and management 
 
 
 
 
 
Diabetes  mellitus  is  currently a  chronic  disease, without a cure, 
and medical emphasis must necessarily be on managing/avoiding 
possible  short-term  as  well  as  long-term  diabetes-related 
problems. 
 
There is  an  exceptionally important role for  patient  education, 
dietetic support, sensible exercise, self monitoring of blood 
glucose (SMBG), with the goal of keeping both short-term blood 
glucose  levels,  and  long  term  levels  as  well,  within  acceptable 
bounds. Careful control is needed to reduce the risk of long term 
complications. This is theoretically achievable with combinations 
of diet,  exercise  and  weight  loss  (type 2),  various  oral  diabetic 
drugs (type 2 only), and insulin use (type 1  and increasingly for 
type 2 not responding to oral medications). 
 
In  addition,  given  the  associated  higher  risks  of cardiovascular 
disease,  lifestyle  modifications  should  be  undertaken to  control 
blood pressure (37) and cholesterol by exercising more, smoking 
cessation, consuming an appropriate diet, wearing diabetic socks, 
and  if necessary, taking any  of several drugs to  reduce pressure. 
Many  Type 1   treatments  include  the  premixed  preparation  of 
regular  and  NPH  insulin,  biphasic  insulin  analogues  such  as 
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insulin Lispro and Aspart,and long acting insulin analogues such as 
insulin Glarine and Levemir. 
 
Another treatment  option  for  type  1  diabetes  is  the  use  of the 
insulin  pump.   An  alternative  approach   is   basal-bolus   insulin 
regimen using long  acting analogue  such as  Insulin Glargine as 
basal  insulin  and  rapid  acting  insulin  analogue  such  as  Insulin 
Aspart,  Lispro  or  Glusiline  as  bolus  or  prandial  insulin.  This 
multiple  doses  injection  has  proved too  effective  in  controlling 
blood glucose and reducing the risk of recurrent hypoglycemia in 
type 1 diabetes. 
 
 
In countries using  a  general  practitioner  system,  such   as the 
United Kingdom,  care  may  take  place  mainly  outside  hospitals, 
with hospital-based specialist  care  used only   in case   of 
complications, difficult blood sugar control, or research projects. In 
other circumstances, general practitioners and specialists share care
  of  a   patient   in  a    team   approach.   Optometrists, 
podiatrists/chiropodists, dietitians, physiotherapists, clinical nurse 
specialists (eg, Certified Diabetes Educators and DSNs (Diabetic 
Specialist  Nurse)),  or  nurse practitioners   may  jointly  provide 
multidisciplinary expertise.   In  countries  where patients must 
provide their  own health care  (i.e., the United  States   in the 
developed  world),  the  impact  of out-of-pocket  costs  of diabetic 
care  can  be  high.  In  addition  to  the  medications  and  supplies 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
45 
 
 
 
 
 
 
 
 
 
 
needed, patients are often advised to receive regular consultation 
from a physician (e.g., at least every three to six months). 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
46 
 
 
 
 
 
 
 
 
 
Windows of opportunity to cure of DM 
 
Cures for type 1 diabetes 
 
There is no practical cure now for type 1  diabetes. The fact that 
type 1  diabetes is due to the damage of one of the cell types of a 
single organ with a relatively simple function (i.e. the failure of 
the  islets of Langerhans) has led to the  study of several possible 
schemes  to  cure  this  form  of diabetes  mostly  by  replacing  the 
pancreas  or just the  beta cells  (38).  Only those type 1  diabetics 
who   have   received   either   a   pancreas   or   a   kidney-pancreas 
transplant  (often  when   they   have   developed   diabetic   kidney 
disease  (ie,  nephropathy)  and  become  insulin-independent)  may 
now be  considered  "cured"  from their diabetes.  A  simultaneous 
pancreas-kidney  transplant   is   a   promising   solution,   showing 
similar   or   improved   survival   rates   over   a   kidney   transplant 
alone. [ 3 9 ]                     Still,      they      generally      remain      on      long-term 
immunosuppressive  drugs   and  there   is   a  possibility  that  the 
immune  system will  mount a  host versus  graft response against 
the transplanted organ (38). 
 
Transplants of exogenous beta cells have been performed 
experimentally in both mice and humans, but this measure is not 
yet practical  in regular clinical practice partly due to the limited 
number of beta cell donors. Thus far, like any such transplant, it 
has      provoked      an      immune      reaction      and      long-term 
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immunosuppressive drugs have been needed to protect the 
transplanted   tissue   (40).   An   alternative   technique   has   been 
proposed to place transplanted beta cells in a semi-permeable 
container, isolating and protecting them from the immune system. 
Stem cell research has also been suggested as a potential avenue 
for a  cure  since  it may permit regrowth of Islet cells which are 
genetically part of the treated individual, thus perhaps eliminating 
the  need  for  immuno-suppressants (38).  This  has  been  done  in 
mice, and a 2007 trial of 15 newly diagnosed patients with type 1 
diabetes  treated  with  stem  cells  raised  from  their  own  bone 
marrow  after  immune  suppression  showed that the  majority  did 
not  require  any  insulin  treatment  for  prolonged  periods  of time 
(41). 
 
Microscopic or nanotechnological approaches are under investigation 
as well, in one proposed case with implanted stores of insulin 
metered out by a rapid response valve sensitive to blood glucose 
levels. At least two approaches have been demonstrated in vitro. 
These are, in some sense, closed-loop insulin pumps. 
 
Cures for type 2 diabetes 
 
Type 2 has had no cure. But, very recently, it has been shown that a  
type  of  gastric  bypass  surgery  can  normalize  blood  glucose 
levels in 80-100% of severely obese patients. The effect is not due to 
weight loss  because  it usually  occurs within days  of surgery, 
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which  is  before  significant weight loss  happens.  The  pattern  of 
secretion  of gastrointestinal  hormones  is  changed by  the  bypass 
and  removal   of  the  duodenum  and  proximal  jejunum,  which 
together form the upper (proximal) part of the small intestine. The 
precise causal mechanisms are being intensively researched. This 
approach may become a standard treatment for some people with 
type 2 diabetes in the near future (42). 
 
One  hypothesis  is  that  the  proximal  small  intestine  is 
dysfunctional in type 2 diabetes; its removal eliminates the source of 
an unknown hormone that contributes to insulin resistance (43). This   
surgery  has   been  widely  performed  on  morbidly  obese patients 
and has had the additional benefit of reducing the death rate from 
all causes by up to 40% (44). A small number of normal to    
moderately    obese    patients    with    type 2    diabetes    have 
successfully undergone similar operations (45, 46). 
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Prognosis 
 
Patient education,  understanding,  and  participation  is  vital  since 
the complications of diabetes are far less common and less severe in 
people who  have well-controlled blood  sugar levels  (47,  48). 
Wider   health   problems   accelerate   the   deleterious   effects   of 
diabetes.   These   include   smoking,   elevated  cholesterol  levels, 
obesity,   high   blood   pressure,   and   lack   of  regular   exercise. 
According  to  a  study,  women with  high  blood  pressure  have  a 
threefold risk of developing diabetes. 
 
Anecdotal   evidence   suggests  that  some   of  those  with  type 2 
diabetes who exercise regularly, lose weight, and eat healthy diets 
may be able to keep some of the disease or some of the effects of the  
disease  in  'remission.'  Certainly these  tips  can  help  prevent people  
predisposed to  type 2  diabetes  and  those  at  pre-diabetic stages  
from actually  developing the  disorder as  it  helps  restore insulin  
sensitivity.  However patients  should talk to  their doctors about this 
for real expectations before undertaking it (esp. to avoid 
hypoglycemia or other complications);  few people actually seem to 
go  into total 'remission,' but some may find they need less of their  
insulin  medications  since  the  body  tends  to  have  lower insulin 
requirements during and shortly following exercise. Regardless of 
whether it works that way or not for an individual, there are 
certainly other benefits to this healthy lifestyle for both diabetics and 
non diabetics. 
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The   way   diabetes   is   managed   changes   with   age.   Insulin 
production decreases because of age-related impairment of 
pancreatic beta cells. Additionally, insulin resistance increases 
because  of the  loss  of lean  tissue  and  the  accumulation  of fat, 
particularly  intra-abdominal  fat,  and  the  decreased  tissue 
sensitivity  to  insulin.  Glucose  tolerance  progressively  declines 
with  age,  leading  to  a  high  prevalence  of type 2  diabetes  and 
postchallenge hyperglycemia  in  the  older population  (49).  Age- 
related  glucose  intolerance  in  humans  is  often  accompanied by 
insulin resistance, but circulating insulin levels are similar to those of 
younger people  (50).  Treatment goals  for  older patients with 
diabetes  vary  with  the  individual,  and  take  into  account  health 
status, loss of therapeutic motivation by the patient ,as well as life 
expectancy, level  of dependence, and willingness to  adhere to  a 
treatment regimen (51). 
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Acute complications 
 
Diabetic ketoacidosis 
 
Diabetic  ketoacidosis  (DKA)  is  an  acute  and  dangerous 
complication that is always a medical emergency. Lack of insulin 
causes the liver to turn fat into ketone bodies for use as fuel. This is 
normal when periodic, but can become a serious problem if sustained.  
Elevated levels of ketone bodies in the blood decrease the blood's 
pH, leading to DKA. On presentation at hospital, the patient in DKA is 
typically dehydrated, and breathing rapidly and deeply. Abdominal 
pain is common and may be severe. The level of consciousness is 
typically normal until late in the process, when lethargy may progress 
to  coma.  Ketoacidosis  can become  severe enough  to  cause  
hypotension,  shock,  and  death.  Urine  analysis reveals significant 
levels of ketone bodies (which spill over from the   blood  when  
the   kidneys   filter  blood)  well   before   overt symptoms.   Prompt,   
proper   treatment   usually   results   in   full recovery, though death 
can result from inadequate or delayed treatment, or from 
complications. Nevertheless, DKA is always a medical emergency and 
requires medical attention. Ketoacidosis is much more common in 
type 1 diabetes than type 2 (99). 
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Nonketotic hyperosmolar coma 
 
Hyperosmolar nonketotic state (HNS) is an acute complication 
sharing many symptoms with DKA, but an entirely different cause 
and different treatment. In a person with very high blood glucose 
levels  (usually  considered to  be  above  300  mg/dl  (16  mmol/l)), 
water  is  drawn  out  of cells  into  the  blood  by  osmosis  and  the 
kidneys dump glucose into the urine. This results in loss of water 
and an  increase  in blood osmolarity.  If fluid  is  not replaced (by 
mouth or intravenously), the osmotic effect of high glucose levels 
combined   with   the   loss   of  water   will   eventually   lead   to 
dehydration. The body's cells become progressively dehydrated as 
water is taken from them and excreted. Electrolyte imbalances are 
also   common  and  dangerous.   As  with  DKA,  urgent  medical 
treatment  is  necessary,  especially volume  replacement.  Lethargy 
may  ultimately  progress  to  a  coma,  which  is  more  common  in 
type 2 diabetes than type 1 (99). 
 
 
 
 
 
 
Hypoglycemia 
 
Hypoglycemia, or abnormally low blood glucose, is an acute 
complication  of  several   diabetes  treatments.   The  patient  may 
become  agitated,  sweaty,  and  have  many  symptoms  of sympathetic 
activation of the autonomic nervous system resulting in feelings 
similar to dread and immobilized panic. Consciousness 
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can  be  altered  or  even  lost  in  extreme  cases,  leading  to  coma, 
seizures,   or  even  brain  damage   and   death.   In  patients  with 
diabetes, this may be caused by several factors, such as too much or   
incorrectly  timed   insulin,   too   much   or   incorrectly   timed 
exercise (exercise decreases  insulin requirements) or not enough 
food (specifically glucose-producing carbohydrates), but this is an 
over-simplification (99). 
 
It   is   more  accurate  to   note  that   iatrogenic  hypoglycemia  is 
typically the result of the interplay of absolute (or relative) insulin 
excess and compromised glucose counterregulation in type 1  and 
advanced type 2  diabetes.  Decrements  in  insulin,  increments  in 
glucagon, and, absent the latter, increments in epinephrine are the 
primary  glucose  counterregulatory factors  that  normally  prevent or 
rapidly correct hypoglycemia. In insulin-deficient diabetes 
(exogenous) insulin levels do not decrease as glucose levels fall, 
and   the   combination   of  deficient   glucagon   and   epinephrine 
responses causes defective glucose counterregulation. 
 
 
Furthermore, reduced sympathoadrenal responses can cause 
hypoglycemia unawareness. The concept of hypoglycemia- 
associated autonomic failure (HAAF) in diabetes posits that recent 
incidents of hypoglycemia causes both defective glucose 
counterregulation and hypoglycemia unawareness. By shifting 
glycemic  thresholds  for  the  sympathoadrenal  (including 
epinephrine)  and  the  resulting  neurogenic  responses  to  lower 
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plasma glucose concentrations, antecedent hypoglycemia leads to a 
vicious cycle of recurrent hypoglycemia and further impairment of 
glucose  counterregulation.  In  many  cases  (but not all),  short- term 
avoidance of hypoglycemia reverses hypoglycemia unawareness in 
most affected patients, although this  is  easier in theory than it is in 
practice.In most cases, hypoglycemia is treated with sugary drinks or 
food. In severe cases of type 1 diabetes, an injection  of glucagon  (a  
hormone  with  the  opposite  effects  of insulin)   or   an   intravenous   
infusion   of  dextrose   is   used   for treatment,  but  usually  only   if  
the  person   is  unconscious.  In hospitals, intravenous dextrose is 
often used (99). 
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Chronic complications 
 
Vascular disease 
 
Chronic elevation of blood glucose level leads to damage of blood 
vessels (angiopathy). The endothelial cells lining the blood vessels 
take  in  more  glucose  than  normal,  since  they  don't  depend  on 
insulin. They then form more surface glycoproteins than normal, 
and cause the basement membrane to grow thicker and weaker. In 
diabetes, the resulting problems are grouped under "microvascular 
disease"  (due  to  damage  to  small  blood  vessels)  and 
"macrovascular disease" (due to damage to the arteries) (99). 
 
 
 
 
 
Microvascular disease: 
 
The  damage to  small  blood vessels  leads to  a  microangiopathy, 
which can cause one or more of the following: 
 
•   Diabetic retinopathy, growth of friable and poor-quality new 
blood  vessels   in  the   retina  as  well   as   macular  edema 
(swelling  of the  macula),  which  can  lead  to  severe  vision 
loss or blindness. Retinal damage (from microangiopathy) 
makes  it the  most common cause of blindness among non- 
elderly adults in the US. 
•   Diabetic   neuropathy,   abnormal   and   decreased   sensation, 
usually in a 'glove and stocking' distribution starting with the 
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feet but potentially  in other nerves,  later often  fingers  and 
hands. When combined with damaged blood vessels this can 
lead  to  diabetic foot  (see  below).  Other  forms  of diabetic 
neuropathy may present as mononeuritis or autonomic 
neuropathy. Diabetic amyotrophy is muscle weakness due to 
neuropathy. 
•   Diabetic nephropathy, damage to the kidney which can lead to   
chronic   renal   failure,   eventually   requiring   dialysis. 
Diabetes mellitus is the most common cause of adult kidney 
failure worldwide in the developed world. 
• Diabetic  cardiomyopathy,  damage  to  the  heart, leading  to 
Systolic and diastolic dysfunction and eventually 
heart failure. 
 
 
 
 
 
Macrovascular disease : 
 
Leads to cardiovascular disease, to which accelerated 
atherosclerosis is a contributor: 
 
•  Coronary artery disease, leading to angina or myocardial 
infarction ("heart attack") 
• Stroke (mainly the ischemic type) 
• Peripheral vascular disease, which contributes to intermittent 
claudication (exertion-related leg  and  foot pain)  as well  as 
diabetic foot. 
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• Diabetic myonecrosis ('muscle wasting') 
Diabetic  foot,  often  due  to  a  combination  of neuropathy  and 
arterial disease, may cause skin ulcer and infection and, in serious 
cases, necrosis and gangrene. It is why diabetics are prone to leg 
and foot infections and why it takes longer for them to heal from 
leg and foot wounds. It is the most common cause of adult 
amputation, usually of toes and or feet, in the developed world. 
 
Carotid artery stenosis does not occur more often in diabetes, and 
there   appears  to   be  a  lower  prevalence  of  abdominal  aortic 
aneurysm.   However,   diabetes   does   cause   higher   morbidity, 
mortality and operative risks with these conditions (49). 
 
Diabetic  encephalopathy  is  the  increased  cognitive  decline  and 
risk  of dementia  observed  in  diabetes.  Various  mechanisms  are 
proposed, including alterations to the vascular supply of the brain 
and the interaction of insulin with the brain itself (53). 
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Myocardial Infarction 
 
 
 
 
 
I. Concept and definition of myocardial 
infarction: 
 
 
Myocardial infarction (MI) can be defined from a number of different 
perspectives related to clinical, electrocardiographic (ECG), 
biochemical and pathologic characteristics.  The term MI also   has   
social   and   psychological   implications,   both   as   an indicator of a 
major health problem and as  a measure of disease prevalence in 
population statistics and outcomes of clinical trials 
In  the  distant  past,  a  general  consensus  existed  for the  clinical 
entity designated as MI. 
 
 
 
In studies of disease prevalence by the World Health Organization 
(WHO), MI was defined by a combination of two of three 
characteristics: typical symptoms (i.e., chest discomfort), enzyme rise  
and  a typical  ECG pattern  involving the  development of Q waves. 
However, current clinical practice, health care delivery systems,  as  
well  as  epidemiologic studies  and  clinical trials,  all require a more 
precise definition of MI. 
 
 
 
Furthermore, the advent of sensitive and specific serologic 
biomarkers     and     precise     imaging     techniques     necessitate 
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reevaluation  of established  definitions  of MI.  The  latter 
technologic  advances  have  high  sensitivity to  detect very  small 
infarcts that would not have been considered an MI  in an earlier 
era.  Current technology can identify patients with small areas of 
myocardial necrosis weighing < 1 0 g. 
Thus,  if we  accept  the  concept  that  any  amount  of myocardial 
necrosis  caused by  ischemia  should be  labeled as  an  infarct (as 
proposed by this  consensus conference), then an  individual who 
was   formerly  diagnosed  as  having  severe,  stable  or  unstable 
angina pectoris might be diagnosed today as having had a  small 
MI. The resulting increase in the sensitivity of the defining criteria 
for MI would mean more cases identified; in contrast, an increase in 
specificity would lessen the number of false positive MIs. Such 
changes   in   definition  might  have   a   profound  effect  on  the 
traditional monitoring of disease rates and outcomes. 
 
 
In response to the  issues posed by an alteration in our ability to 
identify   MI,   the   ESC   and   the   ACC   convened   a   consensus 
conference during July 1999 to reexamine jointly the definition of 
MI. The scientific and societal implications of a new definition for 
MI were examined from seven points of view:  pathology, 
biochemistry, electrocardiography, imaging, clinical trials, 
epidemiology and public policy. 
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It becomes apparent from the deliberations of the consensus 
committee that the  term MI  should not  be  used without  further 
qualifications, whether  in  clinical  practice,  in the  description of 
patient cohorts or in population studies. Such qualifications should 
refer to  the  amount of myocardial cell  loss  (infarct size), to  the 
circumstances leading to the infarct (spontaneous or in the setting of 
a  coronary artery  diagnostic  or therapeutic procedure)  and  to the 
timing  of the  myocardial necrosis relative to  the time  of the 
observation (evolving, healing or healed MI) (106-119). 
 
 
 
 
II. Clinical presentation 
 
 
It is accepted that the term MI reflects a loss of cardiac myocytes 
(necrosis) caused by prolonged ischemia. Ischemia is the result of a 
perfusion-dependent imbalance between supply and demand. 
 
 
 
Ischemia in a clinical setting can be identified from the patient's 
history and from the ECG.  Possible  ischemic  symptoms  include 
chest, epigastric, arm, and wrist or ja w discomfort with exertion or at 
rest.  The discomfort associated with acute MI usually lasts at least 
20 min, but may be shorter in duration. The discomfort may develop  
in the  central  or left chest and then radiate to  the  arm, jaw,  back  
or  shoulder.  The  discomfort  is  usually  not  sharp  or highly 
localized and may be associated with dyspnea, diaphoresis, nausea, 
vomiting or light-headedness. 
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The  discomfort can  develop  in  the  epigastrium (often  confused 
with indigestion), arm, shoulder, wrist, jaw or back, without 
occurring   in  the   chest,   but   such   a   pattern   is   atypical.   The 
discomfort is  not affected by  moving the  muscles  of the  region 
where the discomfort is not localized, nor is it worsened by deep 
inspiration. The discomfort is not positional in nature. Symptoms 
can also include unexplained nausea and vomiting, persistent 
shortness of breath secondary to left ventricular failure and 
unexplained weakness, dizziness, lightheadedness or syncope, or a 
combination of these. 
 
 
These   symptoms   may   be   noted   in   association   with   chest 
discomfort or they may occur in the absence of chest symptoms. 
Although   many   patients   have   symptoms   such   as   those  just 
described, these complaints may go unrecognized or may be 
erroneously labeled as another disease entity, such as  indigestion or 
a viral syndrome. Myocardial necrosis may also occur without 
symptoms; it may be detected only by the ECG, cardiac imaging or 
other studies (106-119). 
 
 
 
 
III. Detection of necrosis of myocardial cells 
 
 
The  presence  or absence  and the  amount of myocardial  damage 
resulting from prolonged ischemia can be assessed by a number of 
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different means,  including pathologic examination, measurement of  
myocardial  proteins   in  the   blood,   ECG  recordings   (ST-T 
segment wave changes, Q waves), imaging modalities such as 
myocardial perfusion imaging, echocardiography and contrast 
ventriculography. For each of these techniques, a gradient can be 
distinguished   from   minimal   to   small   to   large   amounts   of 
myocardial necrosis. Some clinicians classify myocardial necrosis as 
microscopic, small, moderate and large on the basis of the peak level 
of a particular biomarker.  The sensitivity and specificity of each of 
these techniques used to detect myocardial cell loss, quantitate  this  
loss  and  recognize  the  sequence  of events  over time, differ 
markedly (106-119). 
 
 
 
 
1. Pathology 
 
Myocardial infarction  is  defined  as  myocardial  cell  death  due  to 
prolonged  ischemia.  Cell  death  is  categorized  pathologically  as 
either coagulation or contraction band necrosis, or both, which usually 
evolves through oncosis, but can result to a lesser degree from 
apoptosis. Careful analysis of histologic sections by an experienced 
observer is essential to distinguish these entities. 
 
 
 
After   the   onset   of  myocardial   ischemia,   cell   death   is   not 
immediate but takes a finite period to develop (as little as  15 min in 
some animal models, but even this may be an overestimate). It 
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takes 6 h before myocardial necrosis can be identified by standard 
macroscopic  or  microscopic  postmortem examination.  Complete 
necrosis of all myocardial cells at risk requires at least 4 h to 6 h or 
longer, depending on the presence of collateral blood flow into the   
ischemic   zone,   persistent  or   intermittent  coronary   artery 
occlusion and the sensitivity of the myocytes. 
 
 
Infarcts   are   usually   classified   by   size—   microscopic   (focal 
necrosis),  small  (<10%  of the  left  ventricle),  medium  (10%  to 
30% of the left ventricle) or large (>30% of the left ventricle)— as 
well as by location (anterior, lateral, inferior, posterior or septal or a 
combination of locations). The pathologic identification of 
myocardial necrosis is made without reference to morphologic 
changes  in the  epicardial  coronary  artery  tree  or to  the  clinical 
history. The term MI  in a pathologic context should be preceded 
by the words 'acute, healing or healed'. An acute or evolving 
infarction is characterized by the presence of polymorphonuclear 
leukocytes.  If the  interval  between  the  onset  of  infarction  and 
death is brief (e.g., 6 h), minimal or no polymorphonuclear 
leukocytes may be  seen.  The presence of mononuclear cells  and 
fibroblasts and the absence of polymorphonuclear leukocytes 
characterize a healing infarction. 
 
 
 
A healed  infarction  is  manifested as  scar tissue without cellular 
infiltration.  The  entire  process  leading  to  a  healed  infarction 
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usually   requires   five   to   six   weeks   or   more.   Furthermore, 
reperfusion  alters  the  gross  and  microscopic  appearance  of the 
necrotic zone by producing myocytes with contraction bands and large 
quantities of extravasated erythrocytes. Infarcts are classified 
temporally  according  to  the  pathologic  appearance  as  follows: 
acute (6 h to 7 days); healing (7 to 28 days), healed (29 days or 
more). It should be emphasized that the clinical and ECG timing of 
an acute ischemic event may not be the same as the pathologic 
timing  of an  acute  infarction.  For  example,  the  ECG  may  still 
demonstrate   evolving    ST-T    segment   changes,    and    cardiac 
troponin may still be elevated (implying a recent infarct) at a time 
when, pathologically, the infarct is in the healing phase (106-119). 
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2.   Biochemical markers  of myocardial necrosis 
 
 
 
 
Myocardial necrosis results in and can be recognized by the 
appearance  in  the  blood  of different  proteins  released  into  the 
circulation due to the damaged myocytes: myoglobin, cardiac 
troponins T and I, creatine kinase, lactate dehydrogenase, as well as 
many others. 
Myocardial infarction is diagnosed when blood levels of sensitive 
and specific biomarkers, such as cardiac troponin and the MB fraction 
of creatine kinase (CK-MB), are increased in the clinical setting  of 
acute  ischemia.  These  biomarkers  reflect  myocardial damage  but  
do  not  indicate  its  mechanism.  Thus,  an  elevated value  in  the  
absence  of  clinical  evidence  of  ischemia  should prompt a search 
for other causes of cardiac damage, such as myocarditis. The most 
recently described and preferred biomarker for  myocardial  damage  
is  cardiac  troponin  (I  or  T),  which  has nearly absolute myocardial 
tissue specificity, as well as high sensitivity,  thereby  reflecting  
evenmicroscopic  zones  of myocardial necrosis. 
 
 
 
An  increased value  for cardiac troponin  should be  defined as  a 
measurement exceeding the 99th percentile of a reference control 
group. Reference values must be determined in each laboratory by 
studies using  specific assays with appropriate quality control, as 
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reported in peer-reviewed journals. Acceptable imprecision 
(coefficient  of variation)  at  the  99th  percentile  for  each  assay 
should be defined as _10%. Each individual laboratory should confirm 
the range of reference values in their specific setting. In addition, 
meticulous laboratory practice must be maintained. 
 
 
Because cardiac troponin values may remain elevated for 7 to  10 
days or longer after myocardial necrosis, care should be exercised in  
attribution  of elevated  cardiac  troponin  levels  to  very  recent 
clinical events  .  If cardiac troponin assays  are not available, the 
best alternative is CK-MB (measured by mass assay). This is less 
tissue-specific than cardiac troponin, but the data documenting its 
clinical specificity for irreversible injury are more robust. As with 
cardiac  troponin,  an  increased  CK-MB  value  (i.e.,  above  the 
decision limit for MI) is defined as one that exceeds the 99th 
percentile of CK-MB values in a reference control group. In most 
situations, elevated values for biomarkers should be recorded from 
two successive blood samples to diagnose MI. 
 
 
 
Measurement  of total  CK  is  not  recommended  for  the  routine 
diagnosis of acute MI, because of the wide tissue  distribution of 
this enzyme. Nevertheless, total CK has a long history, and some 
physicians may opt to continue to employ it for epidemiologic or 
scientific   purposes.   In   such   a   setting,   total   CK   should   be 
combined  with   a  more   sensitive  biomarker,   such   as   cardiac 
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troponin or CKMB, for more accurate clinical diagnosis of acute 
MI.  The  cut-off limits  for  total  CK  should  be  relatively  higher 
than those for cardiac troponin or CK-MB (at least twice the upper 
reference limit for CK). Glutamicoxaloacetic transaminase (ASAT 
[aspartate  amino transferase]),  lactate  dehydrogenase and  lactate 
dehydrogenase isoenzymes should not be used to diagnose cardiac 
damage. Along with other clinical factors (e.g., residual left 
ventricular function), the degree of biomarker elevation is related to 
clinical risk. 
 
 
 
A  classification  for  the  extent  of  myocardial  damage 
(microscopic,   small,   medium  or   large)   should   be   employed, 
although  no  generally  accepted  grading  system  of  infarct  size 
exists. For most patients, blood should be obtained for testing on 
hospital admission, at 6 to 9 h and again at 12 to 24 h if the earlier 
samples are negative and the  clinical  index of suspicion is high. 
For  patients  in  need  of an  early  diagnosis,  a  rapidly  appearing 
biomarker (such as CK-MB isoforms or myoglobin), plus a biomarker 
that rises later (e.g., cardiac troponin), is recommended for 
confirmation of the diagnosis. 
 
 
 
Detection of reinfarction is  clinically important because  it carries 
incremental risk for the patient. Reinfarction may present special 
diagnostic difficulties, because an increase of cardiac troponin can be 
longlasting, and when cardiac troponin is persistently high, the 
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timing of the initial myocardial damage is difficult to ascertain. If 
the first sample on presentation has a high cardiac troponin value, 
then sequential samples of a biomarker with a shorter time course, 
such as CK-MB or myoglobin, could be employed to clarify the 
timing of the infarct (119-125). 
 
3.   Electrocardiography 
 
The ECG may show signs of myocardial ischemia, specifically ST 
segment  and  T  wave  changes,  as  well  as  signs  of myocardial 
necrosis, specifically changes in the QRS pattern. A working 
definition for acute or evolving MI in the presence of a clinically 
appropriate syndrome, as demonstrated by standard  12-lead ECG, 
has  been  established  by  using  data  from  clinical  and 
pathoanatomic correlative studies. 
 
 
 
The following ECG criteria (in the absence of QRS  confounders 
[i.e., bundle branch block, left ventricular hypertrophy, Wolff- 
Parkinson-White   syndrome])  have   emerged   as   robust 
determinants for the diagnosis of myocardial ischemia. Such 
ischemic   changes   may   be   associated  with   evolving   MI,   as 
discussed subsequently. The ECG criteria reflect myocardial ischemia 
and are not sufficient by themselves to define MI. 
 
 
 
The   final   diagnosis   of  myocardial   necrosis   depends   on   the 
detection of elevated levels of cardiac biomarkers in the blood, as 
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discussed earlier. ST segment elevation in patients with suspected 
acute MI can resolve rapidly either spontaneously or after therapy. 
The effect of reperfusion therapy on ST segment changes should be 
taken into consideration when using the ECG to diagnose MI. Some  
patients  with  rapid  reversal  of ST  segment elevation will not  
develop  myocardial  necrosis.  Moreover,  ST  segment depression, 
which is maximal in leads V1 through V3, without ST segment   
elevation   in   other   leads,   should   be   considered   as indicative of 
posterior ischemia or infarction, or both, but imaging studies are 
usually needed to confirm the presence of ischemia or infarction  in  
an  individual  patient.  In  the  presence  of new  or presumed new left 
bundle branch block, ST segment elevation can accompany the bundle 
branch block, making it difficult or impossible to recognize an acute 
infarction, and criteria indicative of acute  MI  need  to  be  defined  
by  further  research.  Tall  and peaked T waves (hyperacute T waves) 
have been noted during the very early phases of acute MI. New or 
presumed new ST segment depression or T wave abnormalities , or 
both, should be observed in two or more contiguous leads on two 
consecutive ECGs at least several hours apart.  Myocardial necrosis 
or clinically established MI  may  be  defined  from  standard  12-lead  
ECG  criteria  in  the absence of QRS confounders (e.g., bundle 
branch block, left ventricular hypertrophy, Wolff-Parkinson-White 
syndrome) or immediately after coronary artery bypass  graft 
surgery, utilizing the QRS changes presented in. 
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A  single  ECG that  meets  the  Q  wave  criteria  is  indicative  of a 
previous MI.  Q waves <30 ms  in duration associated with  ST-T 
segment  depression may  represent  infarction,  but these  findings 
require more research and confirmation. When three or more ECG 
recordings  are  obtained,  then  at  least  two  consecutive  ECGs 
should  demonstrate  the  abnormality  in  question.  Criteria  for  Q 
wave depth require more research, as do QRS criteria to establish 
the diagnosis of posterior MI. 
 
 
Bundle branch block with additional Q waves is included in these 
descriptions. Right bundle branch block will not interfere with the 
ability to diagnose Q waves; left bundle branch block usually obscures  
Q waves;  new Q waves  in the presence of left bundle branch 
block should be considered as pathologic. Not all patients who  
develop myocardial necrosis exhibit ECG changes.  Thus, a normal  
ECG  does  not  rule  out the  diagnosis  of MI.  Since  new sensitive 
biochemical markers enable detection of myocardial necrosis too 
small to be associated with QRS abnormalities, some patients will 
have their peak values in the sub range of any QRS changes. Such 
patients might be considered to have only a micro- infarction, but 
these aspects need further clarification (106-119). 
 
4.  Imaging 
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Imaging techniques have been used to  assist in (1) ruling out or 
confirming  the  presence  of acute  infarction  or  ischemia  in  the 
Emergency Department;  (2)  identifying non-ischemic conditions 
causing chest pain;  (3) defining short-  and long-term prognoses; 
and (4) identifying mechanical complications of acute infarction. 
 
 
The rationale of acute imaging using echocardiographic or nuclear 
techniques in patients  suspected of having acute  ischemia is that 
ischemia results in regional myocardial hypoperfusion, leading to a 
cascade of events that can include myocardial dysfunction and 
ultimately cell death. Only conventional methods such as 
crosssectional echocardiography, radionuclide angiography and 
myocardial  single-photon  emission  computed  tomographic 
(SPECT) perfusion imaging are discussed in this document, and 
not  those  that  are  presently  being  tested  in  clinical  research 
studies. 
 
 
 
One of the major advantages of echocardiography is that it allows 
assessment of most non-ischemic causes of acute chest pain, such as 
perimyocarditis, valvular heart disease (aortic stenosis), pulmonary 
embolism and aortopathies (aortic dissection). Radionuclide 
techniques enable the physician to assess perfusion at  the  time  of 
patient  presentation;  this  can  be  performed with immediate  tracer  
injection,  because  image  acquisition  can  be 
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delayed for 60 to 90 min. Quantitative analysis is an advantage of 
this technique. 
 
 
The  accuracy  of the  studies  is  high when  interpreted by  skilled 
observers. These studies also provide simultaneous information on 
myocardial perfusion  and  function.  Biomarkers  are  more sensitive, 
more  specific and less  costly than  imaging techniques for the 
diagnosis of myocardial necrosis.  Injury  involving >20% of 
myocardial wall thickness is required before a segmental wall 
motion  abnormality  can  be  detected  by  echocardiography.  In 
general,  >10  g  of myocardial  tissue  must  be  injured  before  a 
radionuclide perfusion defect can be resolved. Neither technique 
can distinguish  ischemia  from  infarction.  (a) Acute ischemia and 
acute or evolving MI. By its ability to detect regional wall motion 
abnormalities within minutes of an ischemic injury, two- 
dimensional echocardiography may be useful  in the diagnosis of 
acute MI. 
 
 
 
Both the localization and extent of infarction can be determined. 
An echocardiographic or radionuclide image early after the onset of 
symptoms  is  of great help  in the  assessment of patients with 
suspected  acute  MI  and  a  non-diagnostic  or  non-interpretable 
ECG.  With  acute  imaging  in  such  patients,  a  normal 
echocardiogram or  a  normal  rest  gated  technetium-99m  SPECT 
study is useful for excluding acute infarction, because of a 95% to 
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98% negative predictive value when CK-MB is used as the gold 
standard. However, it is unknown whether these techniques have 
the   same  negative  predictive  value   in  patients  with  elevated 
troponin and a normal CK-MB value. 
 
 
A wall motion abnormality on echocardiographic or radionuclide 
imaging may be caused by acute MI or one of a number of several 
myocardial   ischemic   conditions,   including   an   old   MI,   acute 
ischemia, stunning or hibernation, or a combination. The positive 
predictive value of echocardiography is _50% for the diagnosis of 
acute  MI,  because  of the  aforementioned  conditions  and  other 
non-infarct-related etiologies  of wall  motion  abnormalities  (e.g., 
dilated cardiomyopathy). 
 
 
 
The positive predictive value for gated SPECT is also limited, 
because abnormal regional perfusion and/or an old MI, acute 
ischemia, stunning and/or hibernation may cause regional 
dysfunction.  Attenuation  artifacts  and  inexperienced  interpreters 
may also lead to false positive scan interpretation. (b) Established 
MI. 
Echocardiography is  useful  after a  sudden event for analysis  of 
residual left ventricular function. Determination of left ventricular 
function  has  prognostic value.  Left  ventricular  function  can  be 
evaluated during exercise or dobutamine stress; the results of such 
testing conveys information on myocardial  viability. The number 
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of segments involved allows one to calculate a wall motion score as 
a measure of residual left ventricular function, which has early and 
late prognostic value in predicting complications and survival. 
 
 
Co-existing mitral valve dysfunction, infarct expansion, mural 
thrombus  and  mechanical  complications  of infarction  are  easily 
identified. Echocardiography is the diagnostic procedure of choice 
for identification of mechanical complications of MI. 
 
 
 
Radionuclide techniques can also be used in the healing or healed 
phases   of  infarction  for  prognostication.  In   conjunction  with 
exercise or vasodilator stress, measuring the extent of defect 
reversibility can identify the extent of ischemia. Detecting defects in 
more than one coronary artery zone can identify multivessel disease.  
A variety  of prognostic findings  can be  identified (e.g., lung  
uptake  of the  tracer thallium-201,  ischemic  left ventricular cavity   
dilation,   defect  size  that  corresponds  to   infarct  size). Finally,  
the  extent  of myocardial  viability  can  be  estimated  by quantitative 
perfusion imaging with either thallium-201 or technetium-99m 
perfusion tracers (106-119). 
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Definition  of MI 
 
 
Criteria   for   acute,   evolving   or   recent   MI  Either   one   of  the 
following criteria satisfies the diagnosis for an acute, evolving or 
recent MI: 
(1) Typical rise and gradual fall (troponin) or more rapid rise and 
fall (CK-MB) of biochemical markers of myocardial necrosis with at 
least one of the following: 
(a) ischemic symptoms; 
(b) development of pathologic Q waves on the ECG; 
(c) ECG changes indicative of ischemia (ST segment elevation or 
depression); or 
(d) coronary artery intervention (e.g., coronary angioplasty). 
(2) Pathologic findings of an acute MI. 
 
 
Criteria  for  established MI 
Any one of the following criteria satisfies the diagnosis 
forestablished MI: 
(1) Development of new pathologic Q waves on serial ECGs. The 
patient    may    or    may    not    remember    previous    symptoms. 
Biochemical    markers    of    myocardial    necrosis    may    have 
normalized, depending on the length of time that has passed since 
the infarct developed. 
(2) Pathologic findings of a healed or healing MI. 
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Diabetes and the heart 
 
Scope of the problem: 
 
Patient with type 2 DM have a two to four fold increase incidence of 
disease related to atheroma. And those who present in their 40s and 
50s have a twofold increase total mortality.In the United Kingdom   
the    incidence   of   macrovascular   complications   in patients  with  
type  2  DM  is  twice  that  of microvascular disease (72). 
 
 
 
Stress  hyperglycaemia  with  myocardial  infarction  is  associated 
with an  increase risk  of in-hospital mortality  in patient with and 
without   diabetes;   the   risk   of   congestive   heart   failure    or 
cardiogenic  shock  is  also  increased  in  patients without diabetes 
(73). 
 
 
In DIGAMI study, it was found that mortality in diabetic patients with 
AMI is predicted by age, previous heart failure, and severity of the 
glycometabolic state at admission but not by conventional risk 
factors or sex.  Intensive insulin treatment reduced long-term 
mortality despite high admission blood glucose and HbAa1c (74). 
 
 
 
Infusion of GIK provided no  benefit and  may  cause  early  harm 
following STEMI. Avoidance of infusion-related hyperglycaemia, 
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hyperkalemia,  and  net  fluid  gain  may  be  advisable  in  future 
studies of metabolic modulation in patients with STEMI (75). 
 
 
 
Despite   modern   therapies    for   ACS,    diabetes    conferred   a 
significant independent excess mortality risk at 30 days and 1 year 
following ACS (76). 
 
 
 
Type 2 DM is associated with a high rate of complications related to  
cardiovascular  disease  and  diabetic  nephropathy,  retinopathy and 
neuropathy. The rate of death among patients with type 2 DM is 
approximately twice as high as that among persons without the 
disorder (77). 
 
 
 
CVD is the major cause of mortality for individuals with diabetes. It 
is also a major contributor to morbidity and direct and indirect coasts 
of diabetes.  Type 2  diabetes is  an independent risk factor for 
macrovascular disease, and its common coexisting conditions (e.g. 
hypertension and dyslipidemia) are also risk factors (78). 
 
 
 
The practice of sliding-scale insulin management persists even 
though it has been called a relic from the past that should be left in 
the medical history books.  Given the knowledge we have today, 
however, this practice  is  not acceptable. It  is  not safe.  It is  not 
evidence based (79). 
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Numerous recently reviewed clinical and epidemiological 
investigations, including prospective studies in unselected 
populations-based surveys, provide unequivocal evidence for 
cardiovascular and cerebrovascular diseases as the leading causes of 
mortality in type 2 DM. Coronary heart diseases represents the most 
prominent cause of death in Type 2  diabetes.  The coronary excess  
risk  is  due  to  a higher incidence of MI.  There  is  strong evidence 
that congestive heart failure without significant atherosclerosis occurs 
more frequently in diabetic patients than in the general population 
(80). 
 
 
In HI-5  study, they did not find a reduction in mortality among 
patients who received insulin/dextrose infusion therapy. However, it 
remains possible that glycemic control with insulin therapy following 
AMI improved outcomes (81). 
 
 
 
Type   2   and   its   associated  metabolic  abnormalities   favor  an 
imbalance in the coagulation/fibrinolytic system that support clot 
formation and stability. Diabetic patients have increased level of 
fibrinogen  and  plasminogen activator inhibitor type  1(PAI-1)  in 
the  plasma  and  lesions.   They  also  appear  to  have  abnormal 
platelet function.  These various  abnormalities may  contribute to 
heightened susceptibility to the thrombotic complications of 
atherosclerosis (82). 
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People  with  diabetes  have  an  increased  prevalence  of 
atherosclerosis and coronary heart disease (CHD) and experience 
higher morbidity and mortality after ACS and MI than people without 
diabetes (83). 
 
 
Diabetes has dramatic impact on outcomes following UA or MI. 
Analyzing data collected for the Organization to Assess Strategies for 
Ischemic Syndromes (OASIS) Registry, Malmberg and colleagues  
showed that diabetes  significantly  increased all-cause death  and  
the  incidence  of new  MI,  stroke,  and  heart  failure during a 2 
year follow-up  in patients who were hospitalized for UA or non-Q- 
wave MI (84). 
 
 
 
Tight  glycemic  control  can  reverse  hyperglycemia-induced platelet   
reactivity   and   reduced   the   typically   elevated   PAI-1 activity in 
patients with diabetes. Part of the benefit derived from the use of 
insulin in the tight control arm may have resulted from the removal 
of any potential cardiac risk associated with the use of sulfonylureas 
(85). 
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Study designs and Methods 
 
Sample size and sampling procedure: 
 
Our  study   is   a  hospital  based  cohort  prospective  study.   We 
recruited all patients admitted to the intensive care units (cardiac 
and   non-   cardiac)   at  Al-Thawra   Teaching   Hospital   (Cardiac 
centre) in Sana'a over 12 months (Jan 2007-Dec2010). A total of 
150  consecutive  Yemeni  patients  were  included  in  this  study. 
Patients of both sexes, and various age groups with AMI and with 
and without DM were included in this study. 
 
 
 
 
 
 
Inclusion criteria: 
 
Cases: First attack of AMI in patients with a previously diagnosed 
DM or those who developed stress hyperglycemia. 
 
 
Control:  First  attack  of AMI  in  patients  having  no  previously 
diagnosed diabetes or current stress hyperglycemia. 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
81 
 
 
 
 
 
 
 
 
 
Exclusion criteria: 
 
Patients  with  known   impaired  fasting  plasma  glucose   (IFG): 
FPG= 5.6-6.9 mmol/l or known impaired glucose tolerance: IGT= 
7.8-11 mmol/l. (ADA 2010, 2011) (96,97). 
Previous attack of AMI. 
Patients with chronic complications of DM. 
Patients with severe peripheral neuropathy. 
 
Clinical assessment 
 
 
 
 
Demographic, cardiovascular risk and history of the patients were 
collected as soon as the patients admitted. All the patients reported in 
this study were examined and followed up according to unified 
clinical protocol of data base consisting of questionnaire, clinical 
examination, and investigation. 
 
 
 
The clinical examination included, height, weight, waist, and hip 
measurement and  calculation of,  waist to  hip  ratio  (WHR),  and 
waist to  height ratio  (WHtR)  in  addition to  the  detailed clinical 
assessment. 
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Then ECG (Sheller machine model 2005), cardiac enzymes (CK, CK-
MB, Troponin, AST and LDH), ESR, CRP, and Echocardiography  
(HP  5500),  all  were  done.  Coronary angiography was planned for 
each patient during hospital stay by using  Phillips  machine  model  
2001.Admission  plasma  glucose and HbA1c were measured at 
time  of admission.  Then  capillary whole blood glucose (CBG) 
concentration was measured every 4 hours daily during the period of 
stay in the CCU.  The follow-up was scheduled as outpatient visits 
at 3, 6, and 12 months after the index myocardial infarction. 
 
Social Classification: 
 
The  study groups were  categorized into  5  social  classes: 
professionals   (I),   managerial   (II),   non-manual   skilled 
(IIIN), manual skilled (IIIM), partially skilled (IV), and 
unskilled (V) (98). 
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Definitions: 
Diagnost
 
 
Myocardial infarction (MI): 
 
MI was defined according to the joint recommendation of the ESC 
and  ACC.  It  was  diagnosed  if markers  of myocardial  ischemia 
exceeded the  upper reference  limit  on  two  occasions,  (troponin 
>0.05  g/l,  or  CK-MB  >10  micg/l)  in  the  presence  of typical 
symptoms (chest pain > 5  min, pulmonary edema in the absence of  
valvular  heart  disease,  cardiogenic  shock,  ventricular tachycardia 
or ventricular fibrillation) or new Q-waves in at least two  of the   
12  slandered  ECG  leads  or  ECG  indicating  acute ischemia  (ST-  
segment  elevation,  ST-segment  depression  or  T- wave inversion) 
and new LBBB (102). 
 
Hyperglycemia 
 
Defined as fasting  plasma  glucose  > 7.0 mmol/l or  2-h  post 
prandial or random plasma glucose >11.1 mmol/l, according to the 
WHO criteria and ADA (2011) (96) for classification of glucose 
metabolism. Fasting is defined as no caloric intake for at least 8h. 
Glycohemoglobin (HbA1c) is considered as an index of glycemic 
control. HbA1c status, non-diabetic range: 4.0-5.6%, pre-diabetic 
5.7-6.4%, and diabetes >6.5% (ADA 2011) (96). 
The machine used is Hitachi-Roche 912. 
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Outcome measures 
 
Cardiovascular death; 
 
(ICD-10 code 121.o-code 121.9) is defined according to WHO as 
death  from  MI,  stroke,  and  sudden  cardiac  death  without  any 
obvious reason (119). 
 
Stroke; 
 
(ICD  10  code  160-code  166)  is  defined according to the WHO 
criteria  as   neurological   deficit   observed  by   a   physician  and 
persisting   >   24h   without   any   other   disease   explaining   the 
symptoms (119). 
 
Cardiogenic shock 
 
(ICD-10 code R57.0) is defined as  systolic blood pressure < 90 
mmHg, persisting > 1h despite fluid challenge, associated with 
clinical signs of hypo perfusion (119). 
 
 
 
 
 
 
Heart failure; 
 
(ICD-10 code) is diagnosed according to the criteria established in   
the   ESC   Guidelines.   Grading   of  HF   will   be   performed 
according   to   criteria   established   by   the   New   York   Heart 
Association (119). 
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Treatment Protocol 
 
The patients were randomized into 3 groups: 
 
Group 1- Continuous 
 
Intravenous  insulin  infusion therapy  (IIT)  group.  These  are  the 
patients with hyperglycemia due to previously diagnosed DM, 
undiagnosed DM, or stress hyperglycemia. This group is divided 
into two categories according to their hemodynamic status (99). 
 
Category A: 
 
1. Patients without HF (Killip class I). 
2. Patients with mild HF, e.g., elevated jagular venous 
pressure, third heart sound, basal rales (Killip class II). 
 
 
 
 
 
Category B 
 
1. Patients in severe left ventricular failure with clinical or 
radiological evidence of pulmonary edema(Killip class III) 
2. Patients in cardiogenic shock with systolic blood pressure < 
90 mmHg, oligouria , cold clammy periphery (Killip class 
IV). 
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Group  1  patients will receive insulin regimen therapy beside the 
usual anti-ischemic drugs  such as, thrombolytic therapy,  aspirin, 
beta blockers (BB), angiotensin converting enzymes inhibitors 
(ACEI),  nitrate  and  statins.  Insulin  in  this  group  will  be  given 
through an infusion pump by means of  diluting 50u human 
soluble  insulin in 50  ml  isotonic  saline (1u/1ml).  Blood glucose 
level  will  be  checked hourly  by  means  of a  bedside  reflectance 
meter until stable at 4-6 mmol/l for 3  consecutive hours, then 2- 
hourly for 4 hours and 4- hourly for 12 hours. 
Validity  of bedside  whole  blood  glucose  measurements  will  be 
ensured by comparing the result against laboratory sample every 4 
hours (99). 
The infusion rate (IIT) will be selected as shown in (Table 1): 
Blood glucose Insulin infusion rate 
(mmol/l) (U/h) 
Group A Group B 
< 4 0 0 
4-6.9 1 2 
7-10.9 2 3 
11-12.9 3 5 
>13 6 9 
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Group 2- conventional insulin therapy. 
 
Patients with hyperglycemia in this  group will receive the  usual 
protocol of insulin therapy in the Cardiac Care Unit (CCU) at Al 
Thawra Teaching hospital (sliding scale) (SSI) as shown in (Table 
2). Human insulin therapy in this group was as subcutaneous 
injections (SC) according to blood glucose measurements several 
times per day. 
 
 
 
 
RBS                                       Dose of crystalline insulin 
140-180                                              4 units 
180-250                                              6 units 
250-320                                              8 units 
320-390                                              10 units 
390                                             12 units 
 
 
 
 
 
 
 
 
 
Group 3, control group. 
 
This  group  will   include  the  non-diabetic  patients  with  AMI, 
defined as fasting blood glucose <6.0 mmol/l and random or post 
prandial blood glucose concentration < 7.8 mmol/l. 
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Statistical Methods 
 
 
 
 
The data were processed and analyzed by SPSS (Statistical 
Package for Social Science, Ver. 15). 
Data were collected in a personal computer and statistical analysis 
was conducted using statistical package for Social Science (SPSS 
Inc.,  Chicago, Illinois; version  15  2006);  Epi-Info version 6.02, 
1994(CDC, Atlanta, Georgia and World Health Organization, 
Geneva); and Confidence Interval Analysis (CIA) software 
package; version 1.0,  1989(Grander MJ, Winter PD, Grander SB). 
Continuous variables were expressed as mean (±SD) and 2-tailed 
t-test was  used  for  calculating  statistical  significance.  Chi-squar 
test was used to analyze categorical variables and for trend 
analysis. Two  by  two  tables  were  used  to  calculate  univariate 
relative risk.  Multivariate analysis was computed using statistical 
package for social science. Ninety-five percent confidence interval 
(CI) were computed to  indicate precision of sample estimate, the 
variability of the  characteristics being  studied, and the  degree of 
confidence required.  A p-value of <0.05  was taken as  statistical 
significant. 
Significance was considered when P- value is just < 0.05. 
P= <0.0001 highly significant. 
P= <0.05 significant. 
P= >0.05 non significant. 
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This study included  150 patients presented with acute myocardial 
infarction  to  the  cardiac  centre  at  Al-Thawra  teaching  hospital 
Sana'a.  100 patients were type 2 diabetic (cases) and 50 patients 
were non diabetic (control). 
 
Demographic data 
 
The clinical data of the patients are illustrated in Tables (1-3) and 
figures (1-8), in the text. 
 
Table (1): Baseline characteristics of diabetic and non diabetic 
groups at entry to the study: 
 
 
Variables Diabetes 
 
;ŶсϭϬϬ) 
Control   group(non 
diabetes) 
;ŶсϱϬ) 
P-value 
Gender :Male ϳϯ ;ϳϯй) ϯϴ ;ϳϲй) Ϭ͘ϲϵϯ 
Age Mean  (SD) year ϱϴ͘ϱ ;ϭϬ͘ϰ) ϱϵ ;ϴ.Ϭ ) Ϭ͘ϲϲϰ 
BMI ŬŐͬŵϮ Mean (SD) ϯϬ͘ϳ ;ϳ͘ϰ) ϯϯ ;ϭϰ͘ϲ) Ϭ͘ϭϵϵ 
WC (cm)Mean  (SD) ϵϱ͘ϰ ;ϭϱ͘Ϯ) ϴϵ͘ϵ ;ϭϯ͘ϯ) Ϭ͘ϬϯϮ 
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Table (1) continued 
 
SBP mmHg Mean (SD) ϭϯϵ͘ϰ ;ϯϰ͘Ϯ) ϭϰϲ͘Ϭ ;Ϯϴ͘ϱ) Ϭ͘Ϯϰϱ 
DBP mmHg Mean (SD) ϴϰ.ϯ ;ϭϴ͘ϳ) ϴϲ͘Ϭ ;ϭϯ͘Ϯ) Ϭ͘ϱϳϱ 
Mean arterial blood 
pressure (MAP)Mean 
(SD) 
ϭϬϮ͘ϳϭ ;ϮϮ͘ϲ) ϭϬϲ͘Ϭ ;ϭϴ͘Ϭ) Ϭ͘ϯϳϬ 
Admission plasma 
Glucose 
(mmol/l)Mean (SD) 
ϭϳ͘Ϯ ;ϱ͘ϲ) ϲ͘ϵ ;ϭ͘ϯͿ фϬ͘ϬϬϬϭ 
,ďϭĐ% Mean (SD) ϭϭ͘ϰ ;ϭ͘ϰϮ) ϱ͘ϴ ;Ϭ͘ϲϰ) Ϭ͘ϬϬϲ 
CK_MB iu/l  Mean (SD) Ϯϱϭ͘Ϯ ;ϭϱϳ͘ϲ) ϯϰϲ͘ϱ ;ϭϱϭ͘ϰ) Ϭ͘ϬϬϭ 
Troponin iu/l 
 
Mean  (SD) 
 
 
ϰ͘ϯ ;Ϯϯ͘ϰ) 
 
 
ϯ͘ϱ;ϭϯ͘ϭ) 
 
 
Ϭ͘ϴϱϭ 
Typical chest pain (%) ϵϵ;ϵϵй) ϰϴ;ϵϲй) Ϭ͘Ϯϭϲ 
 
 
Kllip,s class(%) 
 
I II 
III 
IV 
 
 
 
 
64(64%) 
26(26%) 
08(8%) 
02(2%) 
 
 
 
 
40(80%) 
10(20%) 
0.0 
0.0 
 
 
 
 
0.019 
0.008 
 
 
 
 
ECG changes 
 
STEMI(%) 
 
                     NSTEMI %o) 
 
 
 
 
 
 
87(87%) 
13(13%) 
 
 
 
 
 
 
47(94%) 
3(6%) 
 
 
 
 
 
 
0.190 
0.102 
 
 
Smoking status 
 
Current smoker 
Ex-smoker 
Non-smoker 
 
 
 
 
57(57%) 
16(16%) 
27(27%) 
 
 
 
 
24(48%) 
14(28%) 
12 (24%) 
 
 
 
 
0.715 
0.016 
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Table (1) continued 
 
Current khat chewer 83(83%) 37(74%) <0.0001 
Occupation : 
i- Admnistrator 
/Professional 
 
 
ii-Business 
 
 
iii-NM+Mskilled 
 
 
iv-Partially skilled 
v- Unemployed 
vi- retired 
 
 
 
 
15 
 
 
15 
 
 
13 
 
 
11 
 
 
26 
 
 
2 
 
 
 
 
3 
 
 
5 
 
 
4 
 
 
14 
 
 
16 
 
 
0 
 
 
 
 
0.005 
 
 
0.025 
 
 
0.549 
 
 
0.123 
 
 
 
 
 
 
0 
 
 
Lipids: Mean  (SD) 
TC 
HDL-C 
LDL-C 
TG 
TC/HDL 
 
 
 
 
 
 
5.8± (1.1) 
 
 
1.7± (0.9) 
 
 
5.9± (11.8) 
 
 
2.7 ± (1.6) 
 
 
4.4 ± (3.2) 
 
 
 
 
 
 
5.4± (1.4) 
 
 
1.2± (0.4) 
 
 
3.6± (0.8) 
 
 
2.2± (1.1) 
 
 
5.7 ± (6.2) 
 
 
 
 
 
 
0.037 
 
 
<0.0001 
 
 
0.049 
 
 
0.030 
 
 
0.105 
 
 
 
 
As  shown in  Table  (1), there  is  no  significant difference  in the 
mean (±SD) age of both diabetic and control patients (58.5±10.4) 
year  and  (59±8.0)  year  respectively).  Male  predominance  was 
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evident in the study, 73/27 male to female in cases and 38/12 in 
control.  Mean (±SD) Waist circumference (WC)  is  significantly 
higher in diabetic patients (95.4±15.2 cm) than in the control (90±13.3 
cm) (p= 0.032). There is no significant difference in the mean (±SD) 
BMI (kg/m2) between the diabetic (30.7±7.4) and the control group, 
(33±14.6). Both groups presented with typical chest pain  99%  in  
diabetic  patients  and  96%  in  the  control  patients. Also there was 
no significant difference in the mean(±SD) value of  mean arterial 
blood pressure (MAP) between the two groups, (102.7 ±22.6) mmHg 
and (106±18.0) mmHg, p=0.4. 
 
 
The mean (±SD) admission blood glucose (ABG) level was 
significantly higher in the diabetic group (17.2±5.6 mmol/l) than in 
the control group, (6.9±1.3 mmol/l), p<0.0001.  Also the mean (±SD) 
HbA1c% showed significantly higher value in the diabetic group  
(11.4±1.42  %)  compared to  the  control  group,  (5.8±0.64 
%), p=0.006. The mean (±SD) CK-MB was significantly higher in the  
control  group  (346.5±151.4  iu/l) than  in the  diabetic  group, 
(51.2±157.6 iu/l), p=0.001. 
 
 
 
Regarding   troponin,   the   mean   (±SD)   value,   there   was   no 
significant difference between the diabetic group (4.3±23.4 iu/l), 
and the control group, (3.5±13.1 iu/l), p=0.85. Most of the control 
group  and  many  of the  diabetic    group  presented with  Killip s 
class I, (80% vs.  64%) with a significant difference between the 
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two  groups, p=0.019.It was  also  noted that,  26% of the  diabetic 
group  presented  with  Kllip s  class  II  compared  to  20%  of the 
control group, p=0.008. Only 8% of the diabetic group presented 
with Kllip s class III and 2% with Kllip s class IV with none of 
these classes (III and IV) were seen in the control group. 
 
 
ST  segment elevation myocardial  infarction (STEMI)  was  more 
prevalent  in the  control  group than the  diabetic  group,  94% vs. 
87%    yet  the  difference  was  not  significant  (p=0.19),    but  the 
reverse   was   true   regarding   the   non   ST   segment   elevation 
(NSTEMI),  13%  in  the  diabetic  group  and  6%  in  the  control 
group.  .Most of the diabetic group were smoker (57%) in relation 
to the control group (48%). Ex smokers are highly more frequent in 
the diabetic group than in the control group (16% vs.14%, p=0.016). 
On the other hand, 27% of the diabetic group was non smoker 
compared to 24% of the control group. Also most of the diabetic 
group found to be Khat chewers (83%) compared to the control group 
(37%), p< 0.0001. 
 
 
 
Admnistrator/professonal  social  class  people  were  found  to  be 
more  among the  diabetic  group  (15%)  compared to  the  control 
group (6%).p=0.005. On contrary, the business social class people 
showed similar values  between the two  groups,  (15% vs.  16%), 
p=0.03.  On  the  other  hand,  non  manual+  manual  skilled social 
class people were 15% in the diabetic group and 8% in the control 
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group, while the partially skilled social class people were noted to 
be more frequent 28% in the control group compared to the  11% in 
the diabetic group. The unemployed patients were found to be less  
frequent 26% in the diabetic group compared to the control group 
(32%). 
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Table ;Ϯ); Prevalence of cardiovascular risk factors at the time of 
 
admission among diabetic and non-diabetic (control) patients. 
 
 
Variables Diabetic 
patients 
;ŶсϭϬϬ) 
Non-diabetic 
patients 
;ŶсϱϬ) 
p-value 
ŐĞхϱϬ year ϴϯ ;ϴϯй) ϰϳ ;ϵϰй) Ϭ͘ϭ 
Obesity 
 
;D/хϯϬ 
 
Kg/mϮ 
ϯϵ ;ϯϵй) Ϯϰ;ϰϴй) Ϭ͘ϯϴ 
Abdominal 
adiposity 
;Ύt,ƚZхϬ͘ϲ) 
ϳϬ ;ϳϬй) ϮϮ ;ϰϰй) Ϭ͘ϬϬϯϳ 
Current 
smoking% 
ϱϳ ;ϱϳй) Ϯϰ;ϰϴй) Ϭ͘ϯϴ 
Hypertension, 
(systolic BP> 
ϭϰϬ mmHg) 
ϲϰ ;ϲϰй) ϯϰ;ϲϴ%) Ϭ͘ϳϲ 
Atherogenic 
lipid profile 
(LDL-C хϰ͘Ϯ
mmol/l 
and/or 
TC/HDL-C хϰ͘Ϭ) 
ϴϰ ;ϴϰй) ϯϴ ;ϳϲй) Ϭ͘ϯϰ 
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(*): WHtR : Waist-to-Height Ratio. 
 
 
Table (2);  presented the prevalence of cardiovascular risk factors at 
the time of admission among diabetic and non-diabetic patients. 
Abdominal adiposity measured as , waist to height ratio (WHtR) 
was found to be more prevalent among diabetic patient (70%) 
compared to the control patients (44%), p= 0.0037. There was no 
significant difference between diabetic and non diabetic patients in 
regards to other cardiovascular risk factors. 
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Table ;ϯ): Initial presentation: Clinical features of AMI in 
 
diabetic and non-diabetic control patients: 
 
 
Features D M ( n=100) Non-DM(n=50 ) P-value 
Character of chest 
pain: 
Constricting (%) 
 
Crushing (%) 
Burning (%) 
Others (%) 
 
 
 
 
19 (19%) 
18 (18%) 
32 (32%) 
31 (31%) 
 
 
 
 
7 (14%) 
10 (20%) 
19 (38%) 
14 (28%) 
 
 
 
 
0.019 
0.131 
0.043 
 
 
Arrhythmia 
 
Heart block (%) 
PVC (%) 
 
 
 
 
18 (18%) 
10 (10%) 
 
 
 
 
6 (12%) 
4 (8%) 
 
 
 
 
0.345 
0.691 
CK-MB iu/l Mean (SD) 251.2  (1576) 346.5 (151.4) 0.001 
Troponin iu/l Mean 
 
(SD) 
4.3 (23.4) 3.6  (13.1) 0.851 
STEMI(%) 87 (87%) 47 (94%) 0.190 
NSTEMI(%) 13 (13.0%) 3 (6.0%) 0.102 
 
 
Killips(%) 
 
I II 
III 
IV 
 
 
 
 
64 (64%) 
26 (26%) 
8 (8%) 
2 (2%) 
 
 
 
 
40 (80%) 
10 (20%) 
0 (0%) 
0 (0%) 
 
 
 
 
0.019 
0.008 
N S 
N S 
SBP(mmHg)-MEAN 
(SD) 
139.4  (34.2) 146.0 (28.5) 0.245 
DBP(mmHgϬ -MEAN 
(SD) 
84.3  (18.7) 86.0  (13.2) 0.575 
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Table (25) continued 
 
 
MAB(mmHg)-MEAN 
(SD) 
102.71 (22.6) 106.0 (18.0) 0.370 
HR bpm-MEAN (SD) 93.04  (2.951) 94.38 (2.884) 0.774 
Categories of HR bpm 
 
хϭϬϬ 
 
ϲϬ-ϭϬϬ 
 
фϲϬ 
 
 
34(34.0%) 
53(53.0%) 
13(13.0%) 
 
 
12(24.0%) 
34(68.0%) 
4(8.0%) 
 
 
0.001 
0.042 
0.029 
TC(mmol/l)-Mean 
 
(SD) 
5.8  (1.1) 5.4 (1.4) 0.037 
HDL(mmol/l)-Mean 
 
(SD) 
1.7  (0.9) 1.2  (0.4) <0.0001 
LDL(mmol/l)-Mean( 
SD) 
5.9 (11.8) 3.6  (0.8) 0.049 
TG(mmol/l)-Mean 
 
(SD) 
2.7  (1.6) 2.2 (1.1) 0.030 
TC/HDL(mmol/l)- 
Mean (SD) 
4.4  (3.2) 5.6  (6.2) 0.105 
 
Table (3); showed that both groups were having the same 
characteristics  of pain  such  as,  constricting 19%  in  the  diabetic 
group  14% in the control group, (p=0.019), crushing  18% in the 
diabetic group and 20% in the control group with non significant 
differences, (p=0.13) and burning 32% in the diabetic group and 
38% in the control group, (p=0.04). 
 
 
It also showed that the heart block was more frequent among the 
diabetic group (18%) compared to the control group (12%) with 
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non significant differences (p=0.34). Premature ventricular 
contractions  (PVC)  found  to  be  more  frequent  among  diabetic 
group (10%) compared to the control group (8%). Regarding the 
systolic, diastolic and mean arterial blood   pressure (MAP) there 
were no significant differences between the two groups. 
 
 
Mean (±SD) systolic (SBP) blood pressure in the diabetic group 
was  (139.4±34.2 mmHg)  and  in the  control  group was 
(146.0±28.5  mmHg)  with  non  significant  difference  (p=0.24). 
Mean (±SD) diastolic (DBP) blood pressure in the diabetic group 
was (84.3±18.7 mmHg) and in the control group was (86.0±13.2 
mmhg) with non significant difference (p=0.57). 
 
 
 
The mean (±SD) value of the mean arterial blood pressure (MAP) in 
the diabetic group was (102.7±22.6 mmhg) and in the control group 
was (106.0±18.00 mmHg) with non significant differences (p=0.37). 
A heart rate (HR) > 100 beats / minute (bpm) was found to be 
significantly more frequent among the diabetic group (34%) than 
among the control group (24%), p=0.001. 
 
 
 
HR  60-100  bpm  was  less  frequent  among  the  diabetic  group 
(53%) compared to the control group (68%) with significant 
difference (p=0.04). On the other hand, a HR <60 bpm was noted to 
be more frequent among the diabetic group (13%) compared to the 
control group (8%) with significant difference (p=0.02). 
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Total cholesterol (TC) was significant higher in the diabetic group 
(5.8±1.1) mmol/l compared to the control group (5.4±1.4) mmol/l, 
(p=0.03.  The  mean  (±SD) value  of the  High  density  lipoprotein 
(HDL-C)  was  shown  to  be  significantly  higher  in  the  diabetic 
group  (1.7±0.9) mmol/l compared to  the  control group was  (1.2 
±0.4) mmol/l,(p<0.0001). Mean (±SD) value  of the Low density 
lipoprotein (LDL-C) was also found to be highly significant in the 
diabetic  group  (5.9±1.8)  mmol/l  compared to  the  control  group 
(3.6±0.8) mmol/l,(p=0.04). The mean (±SD) value of the 
triglyceride (TG)  in the  diabetic group was  (2.7±1.6) mmol/l  in 
contrast to (2.2±1.1) mmol/l of the control group with significant 
differences, (p=0.03). TC/HDL mean  (±SD)  value showed  no 
significant differences, which was in the diabetic group (4.4±3.2) 
mmol/l compared to the control group (5.6±6.2) mmol/l, (p=0.10). 
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Table ;ϰ): Echocardiography characterization of AMI in DM and 
 
Non-DM: 
 
 
Variables D;ŶсϭϬϬ) EϬE-DM ;ŶсϱϬ) P-value 
Akinesia ϯϮ ;ϯϮй) ϭϭ ;ϮϮй) Ϭ͘ϭϲϱ 
Hypokinesia ϴϰ ;ϴϰй) ϰϵ ;ϵϴй) Ϭ͘Ϯϲ 
Dyskinesia ϭϯ ;ϭϯй) ϰ ;ϴй) Ϭ͘ϯϯϮ 
Aneurismal changes ϴ ;ϴй) Ϭ͘Ϭ Ϭ͘Ϭϯϳ 
Mitral regurge Ϯϰ;Ϯϰ͘ϳй) Ϭ;Ϭ͘Ϭй) Non 
VSD Ϯ ;Ϯй) ϭ͘Ϭ ;ϮйͿ Ϭ͘ϱϲϰ 
 
 
 
 
 
Table  (4)  and  figures  (9,9A,26-27);  presents  the 
Echocardiographic findings.  More  akinesia was  seen  among the 
diabetic group (32%) than in the control group (22%), p=0.16, but 
hypokinetic was  significantly more  prevalent among  the  control 
group (98%) than in the diabetic group (84%), p=0.02. 8% of the 
diabetic group was having aneurismal changes with no similar 
changes in the control group (0.0%). Dyskinesia was shown to be 
more  frequent  in  the  diabetic  group  (13%)  than  in  the  control 
group (8%), p=0.33.   Mitral regurge was note among 24% of the 
diabetic  group  but  not  in  the  control  group.  Ventricular  septal 
defect (VSD) was found to be similar in both groups (2%). 
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Table ;ϱ): In hospital course of AMI in DM and Non- DM ;ϳĚĂǇƐ): 
 
 
Variables DM ;ŶсϭϬϬ) Non-DM 
;ŶсϱϬ ) 
P- value 
Heart Failure Ϯϲ ;Ϯϲй) ϵ ;ϭϴ %) Ϭ͘Ϯϯϱ 
Arrhythmia ϭϲ ;ϭϲй) ϳ ;ϭϰй) Ϭ͘ϳϭϮ 
Recurrent 
chest pain 
Ϯϴ ;Ϯϴй) ϵ ;ϭϴй) Ϭ͘ϭϰϮ 
Stroke ϭϬ ;ϭϬй) ϰ ;ϴй) Ϭ͘ϲϰϲ 
Mortality in 
hospital 
ϭϯ ;ϭϯй) ϰ ;ϴй) Ϭ͘ϯϲϮ 
 
 
 
 
 
Table (5); this table represented the in hospital course of AMI in 
diabetic  and  non  diabetic  (control)  over  7  days.  26%  of  the 
diabetic  patients  developed  heart  failure  compared to  the    non- 
diabetic patients (18%). Arrhythmia was recognized slightly more 
frequent among the diabetic group (16%) than among the control 
group  (14%).  In diabetic patients, 28% had recurrent chest pain, 
10% had stroke and 13% died in hospital. On the other hand, 18% 
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of the  non  diabetic  patients  had  recurrent  chest  pain, 8%  had 
stroke and 8% died in hospital. 
 
Table ;ϲ): In hospital course of AMI in diabetic patients treated 
either with insulin infusion protocol (group ϭ) or with sliding 
scale protocol (group Ϯ) over (ϳ days): 
 
 
Variables Insulin infusion 
group ϭ ;ŶсϱϬ) 
Sliding scale 
group Ϯ ;ŶсϱϬ) 
P- value 
Heart Failure% ϵ ;ϭϵ͘ϭй) ϭϳ ;ϯϰй) Ϭ͘Ϭϵϵ 
Arrhythmia% ϲ ;ϭϮ͘Ϭй) ϭϬ ;ϮϬ͘Ϭй) Ϭ͘ϯϭϱ 
Recurrent 
chest pain% 
ϭϵ ;ϯϴ͘Ϭй) ϵ ;ϭϴ͘Ϭй) Ϭ͘Ϭϰϰ 
Stroke% Ϭ ;Ϭй) ϭϬ ;ϮϬ͘Ϭй) фϬ͘ϬϬϬϭ 
Mortality in 
hospital% 
ϯ ;ϲ͘Ϭй) ϭϬ ;ϮϬ͘Ϭй) Ϭ͘Ϭϯϳ 
 
 
 
 
Table  (6);  showed  the  in  hospital  course  of  AMI  in  diabetic 
patients  treated  by  either    insulin  infusion  protocol  or    sliding 
scale  protocol over 7  days.  Heart failure was  noted to  be  more 
frequent among  group  2,  (34%) than  group  1  (19.1%),  p=0.01. 
Arrhythmia was less frequent among group 1 (12%) than group 2 
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(20%),  p=0.31.Recurrent chest  pain  found  to  be  more  frequent 
among  group  1(38%)  than  group  2  (18%),  p=0.04.  In  contrast, 
stroke was found to be more frequent among group 2 (20%) than 
group  1  (0%),  p<0.0001.  Also  mortality was  noted to  be  more 
among group 2 (20%) than group 1(6%), p=0.04. 
 
 
Table ;ϳͿ͗ Coronary Angiography of the study 
groups: 
 
 
Variables GrouƉϭ (patients 
treated by insulin 
infusion ;ŶсϱϬ) 
GrouƉϮ (patients 
treated by sliding 
scale) ;ŶсϱϬ) 
Group ϯ (control 
ƉĂƟĞŶƚƐͿ;ŶсϱϬ) 
Normal ϭ ;Ϯй) Ϭ͘Ϭ ϯ ;ϲй) 
Single vessel Ϯϲ ;ϱϮй) Ϯϲ ;ϱϮй) ϭϵ ;ϯϴй) 
Ϯ-vessel ϭϮ ;Ϯϰй) ϭϭ ;ϮϮй) ϭϲ ;ϯϮй) 
Multivessel ϴ ;ϭϲй) ϯ ;ϲй) ϴ ;ϭϲй) 
Left system ϭϵ ;ϯϴй) ϭϳ ;ϯϰй) ϭϴ ;ϯϲй) 
Right system ϵ ;ϭϴй) ϭϮ ;Ϯϰй) ϲ ;ϭϮй) 
Right+Left 
system 
ϭϵ ;ϯϴй) ϭϭ ;ϮϮй) ϮϮ ;ϰϰй) 
PCI ϰϬ ;ϴϬй) ϯϲ ;ϳϮй) ϯϳ ;ϳϰй) 
CABG ϳ ;ϭϰй) ϰ ;ϴй) ϴ ;ϭϲй) 
 
 
 
 
Table (7) and figures (10-20); is showing the angiographic 
results  of the  group  1(diabetic  patients  using  insulin  by 
infusion pump), group 2 (diabetic patients using insulin by 
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sliding scale protocol) and group 3 (the control patients). 
Normal  coronary  artery  found to  be  less  frequent in the 
diabetic group (1%) compared to the control group (6%). 
Single vessel lesion was noted to be more frequent among 
the diabetic group (52%) than the control group (38%). 
 
 
 
On the other hand, two vessel diseases were noticed to be 
more frequent among the control group (32%) than among the 
diabetic group (23%). Multivessel diseases were shown to be 
more frequent among the control group (16%) than the 
diabetic group (11%).  Left system affection found to 
similar in both groups (36% for each), while right system 
was   more   frequent   among   the   diabetic   group   (21%) 
compared  to  the  control  group  (12%).  Involvements  of 
both systems (right and left) were noted to be more among 
the control group (44%) than among the diabetic group 
(30%).  In group  1  (diabetic patient on insulin infusion), 
52%  had   single   vessel   disease,   24%  had  two   vessel 
diseases, and 16% had multi vessel involvement. 
 
 
 
On contrast, in group 2 (diabetic patients on sliding scale), 
single vessel affection had similar result to group 1 (52%) 
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Table ;ϴ): Baseline clinical characteristics of diabetic patients 
 
treated with both insulin infusion (group ϭ) and sliding scale 
 
(group ϮͿ: 
 
 
Variables IV-insulin infusion  
;ŶсϱϬ) Group ϭ 
Sliding scale ;ŶсϱϬ) 
Group Ϯ 
P-value 
Duration of diabetic 
 
Mean(SD) 
ϭϯ ;ϴ͘ϲ) ϭϯ͘Ϭϯ ;ϴ͘ϲͿ Ϭ͘ϬϬϰ 
Age: MEAN(SD) ϱϴ͘ϰ ;ϭϭ͘ϯ) ϱϴ͘ϱ ;ϵ͘ϲ) Ϭ͘ϵϲϮ 
 
 
Gender(M/F)% 
 
Male 
 
Female 
 
 
 
 
ϯϱ ;ϳϬ͘Ϭй) 
 
ϭϱ ;ϯϬ͘Ϭй) 
 
 
 
 
ϯϴ ;ϳϲ͘Ϭй) 
 
ϭϮ ;Ϯϰ͘Ϭй) 
 
 
 
 
Ϭ͘ϳϮϱ 
 
Ϭ͘ϱϲϰ 
 
 
Killip's % 
 
I 
II 
III 
IV 
 
 
 
 
ϯϭ ;ϲϮй) 
 
ϭϬ ;ϮϬй) 
 
ϳ ;ϭϰй) 
 
Ϯ ;ϰй) 
 
 
 
 
ϯϯ ;ϲϲй) 
 
ϭϲ ;ϯϮй) 
 
ϭ ;Ϯй) 
 
Ϭ͘Ϭ ;ϬйͿ 
 
 
 
 
Ϭ͘ϴϬϯ 
 
Ϭ͘Ϯϯϵ 
 
Ϭ͘Ϭϯϰ 
 
Nil 
D/;ŬŐͬŵϮͿ;ŵŵ,ŐͿ- 
Mean (SD) 
ϯϬ͘ϳ ;ϴ͘ϱ) ϯϬ͘ϳ ;ϲ͘Ϯ) Ϭ͘ϵϵϴ 
SBP(mmHg)- 
Mean(SD) 
ϭϰϮ͘ϲ ;ϯϰ͘ϴ) ϭϯϲ͘ϯ ;ϯϯ͘ϴ) Ϭ͘ϯϲϮ 
DBP(mmHg)- 
Mean(SD) 
ϴϰ͘ϰ ;ϭϴ͘ϭ) ϴϰ.ϯ ;ϭϵ͘ϱ) Ϭ͘ϵϴϯ 
HR b/m-Mean(SD) ϵϰ͘ϳϲ ;Ϯϳ͘ϵ) ϵϭ͘ϯϮ ;ϯϭ͘ϯ) Ϭ͘ϱϲϯ 
Troponin iu/l- 
Mean(SD) 
ϲ͘ϯ ;ϯ͘ϯ) Ϯ͘Ϯ ;Ϯ͘ϯͿ Ϭ͘ϯϴϵ 
CK-MB iu/l- 
Mean(SD) 
ϮϬϱ͘ϯ ;ϭϰϰ͘Ϯ) Ϯϵϳ ;ϭϱϴ͘ϰ) Ϭ͘ϬϬϯ 
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Table (25) continued 
 
PG(mmol/l)- 
Mean(SD) 
ϭϳ͘Ϯ ;ϱ͘ϲ) ϭϳ͘Ϯ ;ϱ͘ϲ) Ϭ͘ϵ 
 
 
HbAc% Mean(SD) 
 
 
ϭϬ͘ϯ;ϭ͘ϭϭ) 
 
 
ϭϮ͘ϲ;ϭ͘ϲϳ) 
 
 
Ϭ͘ϲ 
 
 
Chest pain(%) 
 
 
ϰϵ ;ϵϴ͘Ϭй) 
 
 
ϱϬ ;ϭϬϬ͘Ϭй) 
 
 
Ϭ͘ϵϮϬ 
STEMI (%) ϰϯ ;ϴϲй) ϰϰ ;ϴϴй) Ϭ͘ϵϭϱ 
NSTEMI (%) ϳ ;ϭϰй) Ϯ ;ϰй) Ϭ͘Ϭϵϲ 
Arrhythmia (%) ϲ ;ϭϮ͘ϱй) ϭϬ ;ϮϬ͘Ϭй) ϭ͘ϬϬϬ 
Stress 
hyperglycemia (%) 
ϭϬ ;ϮϬ͘Ϭй) Ϯ ;ϰй) Ϭ͘ϬϮϭ 
 
 
 
 
Table (8) and figure (21), is showing the baseline clinical 
characteristics  of diabetic  patients  treated  with  either  IV-insulin 
infusion (group 1) or sliding scale (group 2).  The mean±SD value of  
the   duration  of  diabetic   at  the   time   of  acute   myocardial 
infarction in group 1(13±8.6 year) is highly significant than that in 
group 2 (13.03±8.6 year), (p= 0.004). 
 
 
Mean±SD value of the age is nearly similar in both groups, 
(58.4±11.3  year)  vs.  (58.5±9.6  year).  Male  predominance  was 
found less frequently in group 1(70%) than in group 2 (76%), while 
female  fond to  be  slightly  more  frequent among  group  1(30%) 
than among group 2 (24%).  There is a similarity in both groups 
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regarding  the  mean±SD  value  of the  Body  Mass  Index  (BMI 
kg/m2) (30.7±8.5) in each group. 
 
 
Typical chest pain presentation was found to  be nearly  similar in 
both groups, (98.0%) in group 1 and (100%) in group 2. Killip's II 
presentation was noted to be more frequent among  group 2 (32%) 
than  group 1 (20%),  while  Killips  III  presentation  was   more 
frequent among group 1 (14%) than group 2 (2%) 
p=0.03. Mean±SD of the SBPand DBP showed no significant 
differences in both groups, in group  1  SBP was (142.6±34.8) 
mmHg, and in group 2, (136.3±33.8) mmHg, while DBP in  
group 1 was 84.4(18.1)  mmHg  and  in  group  2  was  84.3(19.5)  
mmhg.  The mean   value   of  the   HR   also   found   to   have   non-
significant differences in both groups, in group 1 was (94.7±27.9) 
bpm and in group 2 was (91.3±31.3) bpm. Mean±SD of the 
admission plasma glucose value was found to be similar in both 
groups,  (17.2 ±5.6) mmol/l. 
The mean troponin was more common in group  1, (6.3±3.3) iu/l 
than in group 2, (2.2±2.3) iu/l. CK-MB was highly significant in 
group2, (297±158) iu/l than in group  1, (205.3±144.2), p=0.003. 
STEMI  showed  to  be  nearly  similar  in  both  groups,  (86%)  in 
group  1  and (88%) in group 2  and NSTEMIN was  noted to be 
more frequent among group 1 (14%) than group 2(4%). 
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Arrhythmia was found to be more frequent among group 2 (20%) 
than among group  1  (12.5%).  Stress hyperglycemia seems to be 
more frequent in group 1 (10%) than in group 2 (4%), p=0.02. 
 
Table ;ϵͿ: Comparison of mean blood glucose concentration between 
diabetic patients treated with insulin infusion and sliding scale methods, 
at admission and during in hospital treatment of AMI: 
 
 
 
 
Variables Insulin ŝŶĨƵƐŝŽŶ;ŶсϱϬ) Sliding scale(«=50) P-value 
 
 
Admission 
(pretreatment) 
plasma glucose 
concentration 
(mmol/l): 
Mean  (SD) 
 
 
 
ϵϱ% CI of mean 
 
 
 
 
 
 
 
 
 
 
 
 
ϭϳ͘Ϯ;ϱ͘ϲ) 
 
 
 
ϭϱ͘ϲ-ϭϴ͘ϴ 
 
 
 
 
 
 
 
 
 
 
 
 
17.3(5.6) 
 
 
15.7-18.9 
 
 
 
 
 
 
 
 
 
 
 
 
0.942 
Average plasma 
glucose concentration 
during treatment 
;ϭ-ϯ days)(mmol/l): 
Mean (SD) 
 
 
ϵϱ% CI of mean 
 
 
 
 
 
 
 
 
ϱ͘ϭ;Ž͘ϳ) 
 
 
 
ϰ͘ϵ-ϱ.ϰ 
 
 
 
 
 
 
 
 
8.0 (1.5) 
 
 
7.8-8.4 
 
 
 
 
 
 
 
 
<0.0001 
 
 
 
 
Table (9) and figures (22-23); is  showing a comparison of mean 
blood glucose concentration between diabetic patients treated with 
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insulin  infusion  and  those  treated with  sliding  scale  methods  at 
admission  and  during  in  hospital  treatment  (1-3days)  of AMI. 
There was no difference in admission blood glucose concentration in 
both groups, in group  1  it was (17.2±5.6) mmol/l with 95%CI of 
mean  is  15.6-18.8,  and  in  group  2  it was  (17.3±5.6) mmol/l with  
95%  CI  of mean  is  15.7-18.9.  The  average  blood  glucose 
concentration during treatment mean was  (5.1±0.7) mmol/l with 
95% CI of mean is 4.9-5.4 in group1, and (8.0±1.5) mmol/l with 
95%CI  of mean  is  7.8-8.4  in  group  2  with  highly  significant 
differences, p <0.0001. 
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Variables Group  ϭ;ŶсϱϬͿ Group  Ϯ;ŶсϱϬͿ Group  ϯ;ŶсϱϬͿ p-value 
Recurrent chest pain- 
 
% 
ϰϬ% Ϯϭ% ϮϬ% Ϭ͘ϬϮ 
FPG(mmol/l)- 
Mean(SD) 
ϱ͘ϴ ;Ϭ͘ϰϱ) ϲ͘ϯ ;Ϭ͘ϳϰ) ϱ.ϳ ;Ϭ͘ϵ) <0.0001 ) 
,ďϭĐй-Mean(SD) ϲ͘Ϭ ;Ϭ͘ϭϳ) ɭŜɩ ſɥŜɩɥ) ϱ͘ϯ ;Ϭ͘ϯϭ) <0.0001 ) 
Echo-complications  
 
ϲ ;ϭϮ͘Ϭй) 
 
ϱ ;ϭϬ͘Ϭй) 
 
ϭϬ ;ϮϬ͘Ϭй) 
 
 
ϭϯ ;Ϯϲ͘Ϭй) 
 
ϭϯ ;Ϯϲ͘Ϭй) 
 
ϭϰ ;Ϯϴ͘Ϭй) 
 
 
ϳ ;ϭϰй) 
 
ϳ ;ϭϰй) 
 
ϳ ;ϭϰйϬ 
 
 
Ϭ͘ϭϱ 
 
Ϭ͘Ϭϵ 
 
Ϭ͘Ϯϳ 
Aneurysm  (%) 
Scaring (%) 
Rupture  papillary 
muscles (%) 
Lipid profiles  
 
ϱ͘ϰ ;Ϭ͘ϱ) 
 
ϭ͘ϯ ;Ϭ͘ϮϬ) 
 
 
 
ϯ͘ϰ ;Ϭ͘ϯ) 
 
 
 
ϭ͘ϲϱ ;Ϭ͘Ϯ) 
 
 
ϱ͘ϲ ;Ϭ͘ϰ) 
 
ϭ͘ϯ ;Ϭ͘Ϯ) 
 
 
 
ϯ͘ϰ ;Ϭ͘ϯϰ) 
 
 
 
ϭ͘ϲ ;Ϭ͘Ϯϰ) 
 
 
ϱ͘ϯ ;Ϭ͘ϱ) 
 
ϭ͘ϯ ;Ϭ͘ϭϰ) 
 
 
 
ϯ.ϳ ;Ϭ͘ϯϮ) 
 
 
 
ϭ͘ϲϱ ;Ϭ͘ϮϬ) 
 
 
Ϭ͘Ϭϭϭ 
 
Ϭ͘ϭ 
 
 
 
фϬ͘ϬϬϬϭ 
 
 
 
Ϭ͘ϲ 
TC(mmol/l)-Mean(SD) 
HDL(mmol/l)- 
Table ;ϭϬ) continued 
Mean(SD) 
LDL(mmol/l)- 
Mean(SD) 
TG(mmol/l)-Mean(SD) 
Need for readmission ϱ ;ϭϬ͘Ϭй) ϭϱ ;ϯϬй) ϲ ;ϭϮй) *0. 8 
CV-mortality ϯ ;ϲ͘Ϭй) ϵ ;ϭϴй) ϯ ;ϲ͘Ϭй) *1. 0 
Heart failure ϱ ;ϭϬй) ϭϮ ;Ϯϰй) ϲ;ϭϮй) *0. 8 
Stroke  ;Ϯ͘Ϭй) ϭϯ ;Ϯϲй) ϰ ;ϴ͘Ϭй) ΎϬ͘ϯϲ 
 
 
 
 
 
 
 
 
 
Table ;ϭϬ): Post MI Outcome at ϯ months: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Chi-square for trend' 
ϭ 
(xϮ—) 
 
 
 
Table (10); presented the post MI outcome at 3  months between 
group 1, group 2, and group 3. Regarding the recurrent chest pain, it 
was found to be more frequent among diabetic patients treated by  
insulin  infusion  therapy  (IIT)  (group   1)  40%,  than  those 
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patients treated by insulin sliding scale (SSI) (group 2)21%, compared 
to control group (group 3) 20% , p=0.02. . 
 
 
The  mean  value  of fasting  plasma  glucose  was  much  better  in 
group1 (5.8±0.45) mmol/l than in group 2 (6.3±0.74) mmol/l 
compared  to   that   in   group   3   (5.7±0.9)   mmol/l  with   highly 
significant differences, p<0.0001. 
 
 
 
HbA1c% mean value is nearly similar in group  1 (6.0±0.2)% and in  
group  2  (6.2±0.2)%    compared  to  group  3  (5.3±0.9)% with 
highly significant differences, p <0.0001. 
 
 
 
Echocardiographic manifestations were found to be more frequent in 
group 2 than group 1 compared to group 3. Aneurismal changes was 
found to be more frequent among group2 (26%) than group 
1(12%) compared to group 3, (14%). Scaring was found to be less 
frequent in group 1 (10%) than group 2 (26%) compared to group 
3(14%). 
 
 
Also rupture papillary muscles was found to  be less frequent in 
group1  (20%)  than  group  2(28%)  compared to  group  3  (14%). 
The mean (±) value of the TC in group  1  is (5.4±0.5) mmol/l, in 
group  2,   (5.6  ±0.4)  mmol/l,  and  group  3   is   (5.3±0.5)  with 
significant differences, p=0.01.  The  mean (±) value of the HDL 
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having  the  same  result  in  the  three  groups  which  is  (1.3±0.2) 
mmol/l with non-significant differences, p=0.1. 
 
 
Also  the  mean  (±SD)  of  the  LDL  was   found  to  be  highly 
significant differences,  in  group1  (3.4±0.3)  mmol/l,  in    group2 
(3.4±0.3) mmol/l, and in group 3, (3.7 ±0.3) mmol/l, p<0.0001.TG 
was  noted to  have the  same result in the three groups with non 
significant differences,  which  is  (1.65±0.2)  mmol/l,  p=0.6.  The 
need for readmission in the first three months follow up was not 
significantly more frequent in group 2 patients (30%) compared to 
group 1 patients (10%), p-value=0.8. 
 
 
 
Cardiovascular mortality was also not significantly more frequent in 
group2 (18%) than in group 1 (6%), p=1.0. Heart failure occurrence 
found to be not significantly more frequent in group 2 (24%) than in 
group 1 (10%), p= 0.8. Stroke frequency in group 2 (26%) compared 
to group 1 (2%), and group 3, (8%). 
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Table ;ϭϭ): Post MI Outcome at ϲ months: 
 
 
 
Variables Group  ϭ;ŶсϱϬͿ Group  Ϯ;ŶсϱϬͿ Group  ϯ;ŶсϱϬͿ p-value 
Recurrent chest pain-% Ϭ Ϭ Ϭ Ϭ 
FPG(mmol/l)-Mean(SD) ϱ͘ϱ ;Ϭ͘ϱ) ϲ͘Ϭ ;Ϭ͘ϯ) ϱ͘ϰ ;Ϭ͘ϳ) фϬ͘ϬϬϬϭ) 
,ďϭĐй-Mean(SD) ϲ͘ϭ ;Ϭ͘ϵ) ϲ͘Ϯ ;Ϭ͘Ϯϭ) ϱ͘ϯ ;Ϭ͘ϰ) фϬ͘ϬϬϬϭ) 
Echo-complications  
 
ϲ ;ϭϮ͘Ϭй) 
 
ϱ ;ϭϬ͘Ϭй) 
 
ϭϬ ;ϮϬ͘Ϭй) 
 
 
ϭϯ ;Ϯϲ͘Ϭй) 
 
ϭϯ ;Ϯϲ͘Ϭй) 
 
ϭϰ ;Ϯϴ͘Ϭй) 
 
 
ϳ ;ϭϰ%) 
 
ϳ ;ϭϰ%) 
 
ϳ ;ϭϰ%) 
 
 
Ϭ͘ϭϱ 
 
Ϭ͘Ϭϵ 
 
Ϭ͘Ϯϳ 
Aneurysm (%) 
Scaring (%) 
Rupture  papillary 
 
muscles (%) 
Lipid profiles  
 
ϱ͘ϰ ;Ϭ͘ϯ) 
 
 
ϱ͘ϰ ;Ϭ͘ϯ) 
 
 
ϱ͘ϯ ;Ϭ͘ϱ) 
 
 
Ϭ͘Ϭϰϱ TC(mmol/l)-Mean(SD) 
HDL(mmol/l)-Mean(SD) ϭ͘ϯ ;Ϭ͘ϭ) ϭ͘Ϯ ;Ϭ͘ϭ) ϭ͘Ϯ ;Ϭ͘ϭ) Ϭ͘Ϭϱϭ 
LDL(mmol/l)-Mean(SD) ϯ͘ϰ ;Ϭ͘Ϯ) ϯ͘ϯ ;Ϭ͘Ϯ) ϯ͘ϳ ;Ϭ͘ϯ) фϬ͘ϬϬϬϭ 
TG(mmol/l)-Mean(SD) ϭ͘ϱ ;Ϭ͘ϭ) ϭ͘ϱ ;Ϭ͘Ϯ) ϭ͘ϲ;Ϭ͘ϮϬ) Ϭ͘ϬϬϭ 
Need for readmission 0 Ϭ Ϭ Ϭ 
CV-mortality Ϭ Ϭ Ϭ Ϭ 
Heart failure Ϭ Ϭ Ϭ Ϭ 
Stroke Ϭ Ϭ Ϭ Ϭ 
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Table ;ϭϮ): Post MI Outcome at ϭϮ months: 
 
 
 
Variables Group  ϭ;ŶсϱϬͿ Group  Ϯ;ŶсϱϬͿ Group  ϯ;ŶсϱϬͿ p-value 
Recurrent chest pain-% Ϭ Ϭ Ϭ Ϭ 
FPG(mmol/l)-Mean(SD) ϱ͘ϱ ;Ϭ͘ϱ) ϱ͘ϳ ;Ϭ͘ϲ) ϱ͘Ϭ ;Ϭ͘ϲ) фϬ͘ϬϬϬϭ) 
,ďϭĐй-Mean(SD) ϲ͘ϭ ;Ϭ͘ϭϮ) ϲ͘ϭ ;Ϭ͘Ϯϭ) ϱ͘ϯ ;Ϭ͘ϰ) фϬ͘ϬϬϬϭ) 
Echo-complications  
 
ϲ ;ϭϮ͘Ϭй) 
 
ϱ ;ϭϬ͘Ϭй) 
 
ϭϬ ;ϮϬ͘ϬйϬ 
 
 
ϭϯ ;Ϯϲ͘Ϭй) 
 
ϭϯ ;Ϯϲ͘Ϭй) 
 
ϭϰ ;Ϯϴ͘Ϭй) 
 
 
ϳ ;ϭϰ%) 
 
ϳ ;ϭϰ%) 
 
ϳ ;ϭϰ%) 
 
 
Ϭ͘ϭϱ 
 
Ϭ͘Ϭϵ 
 
Ϭ͘Ϯϳ 
Aneurysm (%) 
Scaring (%) 
Rupture  papillary 
 
muscles (%) 
Lipid profiles  
 
ϱ͘ϰ ;Ϭ͘ϯϭ) 
 
 
ϱ͘ϰ ;Ϭ͘ϯ) 
 
 
ϱ͘ϯ ;Ϭ͘ϱ) 
 
 
Ϭ͘Ϭϯ TC(mmol/l)-Mean(SD) 
HDL(mmol/l)-Mean(SD) ϭ͘Ϯ ;Ϭ͘ϭϭ) ϭ͘Ϯ ;Ϭ͘ϭ) ϭ͘ϯ ;Ϭ͘ϭϰ) Ϭ͘ϬϬϳ 
M  e  T  O  'cͬϰn-MMneuaenc(SD) ϯ͘ϯ ;Ϭ͘Ϯ)  
ϭ͘ϰ ;Ϭ͘ϭϮ) 
ϯ͘ϯ ;Ϭ͘Ϯ) 
 
ϭ͘ϱ ;Ϭ͘Ϯ) 
ϯ͘ϳ ;Ϭ͘ϯϮ) 
 
ϭ͘ϲϰ ;Ϭ͘ϮϬ) 
фϬ͘ϬϬϬϭ 
 
фϬ͘ϬϬϬϭ 
TG(mmol/l)-Mean( SD) 
Need for readmission Ϭ Ϭ Ϭ Ϭ 
CV-mortality Ϭ Ϭ Ϭ Ϭ 
Heart failure Ϭ Ϭ Ϭ Ϭ 
Stroke Ϭ Ϭ Ϭ Ϭ 
 
 
 
 
 
Post  MI  outcome  at  6  and  12  months  in  the  three  groups  are 
shown in Tables (11) and (12). There was no recurrent chest pain 
between the three groups. 
 
 
Fasting  plasma  glucose  mean±SD  values  was  found  to  have 
highly  significant differences  in  group1  (IIT)  (5.5±0.5) than  in 
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group   2   (SSI)   (6.0±0.3),   compared   to   group   3   (5.4±0.7), 
p<0.0001. HbA1c% mean±SD value showed highly significant 
differences in both diabetic patients using insulin infusion therapy 
(IIT)  (6.1±0.9)  and  in  those  using  sliding  scale  insulin  (SSI) 
(6.2±0.2) compared to control group (5.3±0.7), p<0.0001. 
 
 
At this time of follow up, lipid profile results were found to have 
highly significant differences in the study groups, for total 
cholesterol  mean±SD  value  was   (5.4±0.3)  in  IIT   group  and 
(5.4±0.3) in SSI group, compared to control group (5.3±0.5), p= 
0.04. Regarding the mean ±SD value of HDL, it was (1.2±0.1) in 
IIT group and (1.2±0.1) in the SSI group compared to (1.3±0.1) of 
the control group, p=0.007. For mean±SD LDL value was found as 
follow (3.3±0.2) in the IIT treated patients and (3.3±0.2) in the SSI  
treated patients  group  compared to  (3.7±0.3)  in the  control 
patients  group, p<0.0001.  TG mean±SD value was  found to  be, 
(1.5±0.1) in the IIT group, (1.5±0.2) in the SSI group compared to 
(1.6±0.2)  in  the  control  group,  p<0.0001.  Also  at  this  time  of 
follow-up,  there was  no  re-hospital need  for the  patients  in the 
study  as  well  as  no  more  mortality. No  patients  found to  have 
heart failure or stroke during this time of follow up. 
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Category Insulin 
ŝŶĨƵƐŝŽŶ;ŶсϱϬ) 
Sliding 
Scale 
;ŶсϱϬ) 
RR ;ϵϱ% CI) P-value 
Recurrent chest pain ϭ ϴ Ϭ͘Ϯ ;Ϭ͘Ϭϯ-ϭ͘ϯϮ) ΎϬ͘Ϭϯϲ 
Heart  failure ϱ ϭϬ Ϭ͘ϲϯ ;Ϭ͘ϯ-ϭ͘ϯϮ) Ϭ͘Ϯϲ 
Arrhythmia ϲ ϵ Ϭ͘ϳϳ ;Ϭ͘ϰ-ϭ͘ϰϴ) Ϭ͘ϱϳ 
Stroke ϭ ϭϭ Ϭ͘ϭϱ ;Ϭ͘ϬϮ-Ϭ͘ϵϵ) Ϭ͘ϬϬϱ 
CV-mortality ϯ ϵ Ϭ͘ϰϳ ;Ϭ͘ϭϳ-ϭ͘Ϯϳ) Ϭ͘ϭϮ 
 
 
 
 
 
 
 
 
 
 
Table ;ϭϯͿ: Univariate analysis and Univariate Relative Risk 
(RR) 
for poor outcome of AMI in diabetic patients treated 
with insulin infusion vs. sliding scale: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Fisher exact 
p=0.016. 
 
 
Table   (13);   is   showing   a   univariate   analysis   and   
univariate Relative Risk (RR) for poor outcome of AMI in 
diabetic patients treated  with  insulin  infusion  vs.  sliding  
scale.  RR  for  diabetic patients treated by sliding scale =1.93  
and Fisher Exact p=0.017. Regarding to  heart  failure,  
arrhythmia and  cardiovascular mortality,  there  are  no  more  
differences  between  both  groups. Stroke found to be more in 
patients treated by  sliding scale and less  in patients treated by  
infusion protocol with RR= 2.07  and p=0.005. 
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Table ;ϭϰͿ: Univariate analysis and Univariate Relative Risk 
(RR) 
for poor outcome of AMI in diabetic patient's vs. non-
diabetic patients: 
 
 
Category Diabetic 
 
;ŶсϭϬϬ) 
Non-diabetic 
 
;ŶсϱϬ) 
RR ;ϵϱ% CI) P-value 
Recurrent chest pain ϵ ϵ Ϭ͘ϳϯ ;Ϭ͘ϰϱ-ϭ͘ϭϳ) Ϭ͘ϭϴ 
Heart  failure ϭϱ ϵ Ϭ͘ϵϯ ;Ϭ͘ϲϲ-ϭ͘Ϯϵ) Ϭ͘ϴ 
Arrhythmia ϭϱ ϳ ϭ͘Ϭϯ ;Ϭ͘ϳϱ-ϭ͘ϰ) Ϭ͘ϵϯ 
Stroke ϭϮ ϰ ϭ͘ϭϰ ;Ϭ͘ϴϰ-ϭ͘ϱϱ) Ϭ͘ϲϰ 
CV-mortality ϭϮ ϰ ϭ͘ϭϰ ;Ϭ͘ϴϰ-ϭ͘ϱϱ) Ϭ͘ϲϰ 
 
 
 
 
Table (14), is presenting the univariate analysis and univariate 
RR for poor outcome  of AMI  in  diabetic  and  non  diabetic  
patients. This  table  showed  no   differences  between  the  two  
types  of patients    in   regards   to   recurrent   chest   pain,   
heart   failure, arrhythmia, stroke and cardiovascular mortality. 
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Table ;ϭϱͿ: Multivariate Logistic Regression Analysis of poor 
outcome of AMI in diabetic patients treated with insulin 
infusion vs. sliding scale: 
 
 
Category Insulin 
ŝŶĨƵƐŝŽŶ;ŶсϱϬ) 
Sliding scale 
 
;ŶсϱϬ) 
RR ;ϵϱ% CI) P-value 
Recurrent chest pain ϭ ϴ Ϭ͘ϭϮϰ;Ϭ͘ϭϰ-ϭ͘ϭϳϳ) Ϭ͘Ϭϳ 
Heart  failure ϱ ϭϬ Ϭ͘ϰϲϭ;Ϭ͘ϭϮϳ-ϭ͘ϲϳ) Ϭ͘Ϯϰ 
Arrhythmia ϲ ϵ Ϭ͘ϵϱϮ;Ϭ͘ϮϮϱ-ϰ͘Ϭϯ) Ϭ͘ϵϱ 
Stroke ϭ ϭϭ Ϭ͘ϬϵϮ;Ϭ͘Ϭϭϭ-Ϭ͘ϳϵϴ) Ϭ͘Ϭϯ 
CV-mortality ϯ ϵ Ϭ͘ϬϬϬ ϭ͘ϬϬ 
 
 
 
 
Table (15); showed the Multivariate logistic regression analysis of 
poor  outcome  of AMI  in  diabetic  patients  treated  with  insulin 
infusion vs. sliding  scale. Insulin infusion therapy (Intervention) 
was  effective  in reducing  stroke  as  compared to  insulin sliding 
scale therapy. 
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Table ;ϭϲͿ: Multivariate Logistic Regression Analysis of poor 
 
outcome of AMI in diabetic patients vs. non-diabetic patients: 
 
 
Category Diabetic 
 
;ŶсϭϬϬ) 
Non-diabetic 
 
;ŶсϱϬ) 
RR ;ϵϱ% CI) P-value 
Recurrent chest pain ϵ ϵ Ϭ͘ϯϰϵ;Ϭ͘ϭϭϲ-Ϭ͘ϵϵϴ) Ϭ͘Ϭϱ 
Heart  failure ϭϱ ϵ ϭ͘Ϯϱϱ;Ϭ͘ϰϯϴ-ϯ͘ϱϵϰ) Ϭ͘ϲϳϮ 
Arrhythmia ϭϱ ϳ Ϭ͘ϳϵ;Ϭ͘Ϯϳϲ-Ϯ͘Ϯϱϴ) Ϭ͘ϲϲ 
Stroke ϭϮ ϰ ϭ͘ϲϰϭ;Ϭ͘ϰϲϲ-ϱ͘ϳϳ) Ϭ͘ϰϰϭ 
CV-mortality ϭϮ ϰ Ϭ͘ϬϬϬ ϭ͘ϬϬϬ 
 
 
 
 
Table  (16);  presented  the  Multivariate  logistic  analysis  of poor 
outcome  of AMI  in  diabetic  patients  vs.  non-diabetic  patients. 
Recurrent chest pain noted to be similarly associated between both 
groups of patients, p=0.05. 
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Table ;ϭϳ) Baseline biochemical characteristics of 
diabetic 
patients treated either with insulin infusion method or 
with sliding scale method: 
 
 
Variables Insulin infusion Group 
 
;ŶсϱϬ) (IIT) 
Sliding Scale Group 
 
;ŶсϱϬ) (SSI) 
p-value 
Mean(SD) ϵϱйI of mean Mean(SD) ϵϱйI of mean  
Admission BG ϭϳ͘Ϯ ;ϱ͘ϲ) ϭϱ͘ϲ to ϭϴ͘ϴ ϭϳ͘ϯ ;ϱ͘ϲ) ϭϱ.ϳ to ϭϴ͘ϴ Ϭ͘ϵϰ 
,ďϭĐ% ϴ͘ϳ ;ϭ͘ϳ) ϴ͘Ϯ to ϵ͘Ϯ ϵ͘Ϯϳ ;ϭ͘ϱ) ϴ͘ϴϲ to ϵ͘ϲϵ Ϭ͘ϴϲ 
 
 
TC(mmol/l) 
ϱ͘ϲ ;ϭ͘ϭ) ϱ͘ϯ to ϲ ϲ͘Ϭ ;ϭ͘Ϭ) ϱ͘ϳ to ϲ͘ϯ Ϭ͘Ϭϵ 
 
 
HDL(mmol/l) 
Ϯ͘ϭ ;ϭ͘Ϭ) ϭ͘ϴ to Ϯ͘ϰ ϭ͘ϰ ;Ϭ͘ϱϮ) ϭ͘Ϯ to ϭ͘ϱ фϬ͘ϬϬϬϭ 
LDL(mmol/l) ϯ͘ϵ ;ϭ͘ϯ ) ϯ͘ϲ to ϰ͘ϯ ϰ͘ϯ ;ϭ͘ϬϮ) ϰ͘Ϭϭ to ϰ͘ϳ Ž͘ϭϮϬ 
TG(mmol/l) Ϯ͘Ϭ ;ϭ͘ϭ) ϭ͘ϳ to Ϯ͘ϯ ϯ͘ϯ ;ϭ͘ϴ) Ϯ͘ϴ to ϯ͘ϴ фϬ͘ϬϬϬϭ 
 
 
Table (17), showing the baseline biochemical characteristics of 
diabetic  patients  treated  with  either  insulin  infusion  method  
or sliding  scale  method.  There  is  similarity  between  group  1  
and group 2 in the admission blood glucose (p=0.9) and HbA1c% 
(p=0.8). 
 
 
In contrast, lipid profile showing significant differences, the 
mean value of total cholesterol (TC) in group 1 (5.6 ±1.1), and 
in group 
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2,  (6.0±1.0), p =0.09.  HDL  mean value  is  noted to  have 
highly 
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significant differences, in group 1 was (2.1±1.0), and in group 2, 
(1.4±0.5), p<0.0001. 
 
 
On  the  other  hand,  there  was  no  significant  differences  in  the 
mean value of the LDL in both groups (p=0.12). Regarding 
triglyceride mean value was found to have highly significant 
differences,  in  group   1   was  (2.0±1.1),  and  in  group  2  was 
(3.3±1.8), p<0.0001. 
 
 
Table ;ϭϴ) Follow-up of biochemical characteristics of diabetic 
patients treated either with insulin infusion or with sliding scale 
at ϯŵŽŶƚŚƐ: 
 
Variables Infusion group ;ŶсϱϬͿ;/dͿ Sliding scale group 
 
;ŶсϱϬͿ;^^/Ϳ 
p-value 
Mean (SD) ϵϱ% CI of 
mean 
Mean (SD) ϵϱ% CI of mean 
FPG(mmol/l) ϲ ;Ϭ͘ϲͿ ϱ͘ϴ to ϲ͘Ϯ ϲ͘Ϯ ;Ϭ͘ϳϰ) ϲ to ϲ͘ϰ Ϭ͘ϮϮ 
,ďϭĐ% ϲ͘ϭ ;Ϭ͘Ϯϯ) ϲ to ϲ͘Ϯ ϲ͘ϭ ;Ϭ͘Ϯ) ϲ to ϲ͘Ϯ Ϭ͘ϱϳ 
TC (mmol/l) ϱ͘ϯ ;Ϭ͘ϱ) ϱ͘Ϯ to ϱ͘ϰ ϱ͘ϲ ;Ϭ͘ϯϱ) ϱ͘ϱ to ϱ͘ϳ фϬ͘ϬϬϬϭ 
HDL(mmol/l) ϭ͘Ϯϱ ;Ϭ͘Ϯ) ϭ͘Ϯ to ϭ͘ϯ ϭ͘ϯ ;Ϭ͘Ϯ) ϭ͘Ϯ to ϭ͘ϯ Ϭ͘ϴϰ 
LDL 
(mmol/l) 
ϯ͘ϯ ;Ϭ͘Ϯϲ) ϯ͘Ϯ to ϯ͘ϰ ϯ͘ϱ ;Ϭ͘ϯϯ) ϯ͘ϰ to ϯ͘ϲ Ϭ͘ϬϬϴ 
TG (mmol/l) ϭ͘ϲϰ ;Ϭ͘Ϯϭ) ϭ͘ϲ to ϭ͘ϳ ϭ͘ϲ ϯ;Ϭ͘Ϯϯ) ϭ͘ϱϲ to ϭ͘ϳ Ϭ͘ϵ 
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Table (18); present the follow-up of biochemical characteristics of 
both  groups at  3  months. It  shows no  significant differences in 
fasting blood glucose (FBG), p=0.2 and HbA1c%, p=0.5 in both 
groups. On the contrary, mean value of the TC showed significant 
differences between group 1, (5.3±0.5), and group 2 (5.6±0.3), 
p<0.0001. In contrast, HDL mean value showed no significant 
difference between group  1 and group 2  (p=0.8), but LDL  mean 
value found to have highly significant differences, in group 1 
(3.3±0.3), and in group 2 (3.5±0.3), p=0.008. There is also no 
significant difference in TG mean value in both groups, p=0.9. 
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Table ;ϭϵ) Follow-up of biochemical characteristics of diabetic 
patients treated either with insulin infusion or with sliding scale 
at ϲ months: 
 
 
Variables Infusion group ;ŶсϱϬͿ;/dͿ Sliding scale group 
 
;ŶсϱϬͿ;^^/Ϳ 
p-value 
Mean (SD) ϵϱ% CI of 
mean 
Mean (SD) ϵϱ% CI of mean 
FPG(mmol/l) ϱ͘ϴ ;Ϭ͘ϱͿ ϱ͘ϲ to ϲ͘Ϭ ϱ͘ϴ ;Ϭ͘ϰϯ) ϱ͘ϲϴ to ϱ͘ϵ Ϭ͘ϲϱ 
,ďϭĐ% ϲ͘ϭ ;Ϭ͘ϭϯ) ϲ͘Ϭ to ϲ͘Ϯ ϲ͘ϭ ;Ϭ͘ϭͿ ϲ to ϲ͘Ϯ Ϭ͘ϰϵ 
TC(mmol/l) ϱ͘ϯϲ ;Ϭ͘Ϯϵ) ϱ͘ϯ to ϱ͘ϰ ϱ͘ϰ ;Ϭ͘Ϯϳ) ϱ͘ϯ to ϱ͘ϱ Ϭ͘ϭϰ 
HDL(mmol/l) ϭ͘Ϯϳ ;Ϭ͘ϭϯ) ϭ͘Ϯϯ to ϭ͘ϯ ϭ͘ϯ ;Ϭ͘ϭͿ ϭ͘Ϯϱ to ϭ͘ϯϭ Ϭ͘ϲϳ 
LDL(mmol/l) ϯ͘ϯ ;Ϭ͘ϭϳ) ϯ͘Ϯϱ to ϯ͘ϱϱ ϯ͘ϰ ;Ϭ͘Ϯϯ) ϯ͘ϯ to ϯ͘ϱ Ϭ͘Ϭϲ 
TG(mmol/l) ϭ͘ϱ ;Ϭ͘ϭϰ) ϭ͘ϰϴ to ϭ͘ϱϲ ϭ͘ϱ ;Ϭ͘ϮͿ ϭ͘ϰϳ to ϭ͘ϲ Ϭ͘ϴϱ 
 
 
 
 
 
Table  (19);  showing  the  follow-up  at  6  months  of biochemical 
characteristics  in  both  groups  with  only  significant  differences 
found to  be  in the  result in the  LDL  mean value which was  in 
group 1 (3.3±0.2), and in group 2 was (3.4±0.2), p=0.06. 
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Table ;ϮϬ) Follow-up of biochemical characteristics of diabetic 
patients treated either with insulin infusion or with sliding scale 
at ϭϮ months: 
 
 
Variables Infusion group ;ŶсϱϬͿ;/dͿ Sliding scale group 
 
;ŶсϱϬͿ;^^/Ϳ 
p-value 
Mean (SD) ϵϱ% CI of 
mean 
Mean (SD) ϵϱ% CI of 
mean 
FPG(mmol/l) ϱ͘ϱϲ ;Ϭ͘ϱ) ϱ͘ϰ to ϱ͘ϳ ϱ͘ϳϰ ;Ϭ͘ϰϴ) ϱ͘ϲ to ϱ͘ϴϳ Ϭ͘Ϭϳϴ 
,ďϭĐ;ŵŵŽůͬů) ϲ͘ϭϯ ;Ϭ͘ϭϱ) ϲ͘ϭ to ϲ͘Ϯ ϲ͘ϭϯ ;Ϭ͘ϭͿ ϲ͘ϭ to ϲ͘ϭϲ Ϭ͘ϵϰ 
TC(mmol/l) ϱ͘ϯϴ ;Ϭ͘Ϯϰ) ϱ͘ϯ to ϱ͘ϰϱ ϱ͘ϰ ;Ϭ͘Ϯϲ) ϱ͘ϯϲ to ϱ͘ϱ Ϭ͘Ϯϰ 
HDL(mmol/l) ϭ͘Ϯ ;Ϭ͘ϭϮ) ϭ͘ϭϲ to 
 
ϭ͘Ϯϯ 
ϭ͘Ϯ ;Ϭ͘ϵϲ) ϭ͘ϭϲ to ϭ͘Ϯ Ϭ͘ϳϴ 
LDL(mmol/l) ϯ͘ϯ ;ϭ͘ϰͿ ϯ͘Ϯ to ϯ͘ϯϰ ϯ͘ϯϰ ;Ž͘ϭϳ) ϯ͘Ϯϵ to ϯ͘ϯϵ Ϭ͘Ϯϯ 
TG(mmol/l) ϭ͘ϰ ;Ϭ͘ϭϱ) ϭ͘ϯϲ to 
 
ϭ͘ϰϱ 
ϭ͘ϰ ;Ϭ͘ϭϲ) ϭ͘ϯϱ to ϭ͘ϰϱ Ϭ͘ϴ 
 
 
 
 
 
 
 
Table (20);  in this table biochemical characteristics follow-up at 
12  months  showing  significant  value  in  the  FBG  which  is  as 
follow, the mean value in group 1 was (5.6±0.5), and in group 2 
was (5.7±0.5), p=0.08. 
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Table ;Ϯϭ) One way analysis of variance (ANOVA) of the mean 
values of Glycemia and lipid profile between baseline, ϯ
months, ϲ months and ϭϮ months for insulin infusion group. 
 
 
Variables Baselines ϯ months ϲ months ϭϮ months ANOVA 
 
p-value 
FPG 
(mmol/l)Mean(SD) 
 
 
ϭϳ͘Ϯ ;ϱ͘ϲ) 
 
 
ϱ͘ϭ ;Ϭ͘ϲ) 
 
 
ϱ͘ϴ ;Ϭ͘ϱͿ 
 
 
ϱ͘ϲ ;Ϭ͘ϱϭ) 
 
 
фϬ͘ϬϬϬϭ 
,ďϭĐ% 
Mean (SD) 
 
 
ϴ͘ϳ ;ϭ͘ϳͿ 
 
 
ϲ͘ϭ ;Ϭ͘Ϯϯ) 
 
 
ϲ͘ϭ ;Ϭ͘ϭϮ) 
 
 
ϲ͘ϭ ;Ϭ͘ϭϱ) 
 
 
фϬ͘ϬϬϬϭ 
TC(mmol/l) 
Mean (SD) 
 
 
ϱ͘ϲ ;ϭ͘ϭͿ 
 
 
ϱ͘ϯ ;Ϭ͘ϱ) 
 
 
ϱ͘ϰ ;Ϭ͘ϯͿ 
 
 
ϱ͘ϰ ;Ϭ͘Ϯϰ) 
 
 
Ϭ͘Ϭϰϴ 
HDL(mmol/l) 
Mean (SD) 
 
 
Ϯ͘ϭ ;Ϭ͘ϭͿ 
 
 
ϭ͘Ϯ ;Ϭ͘Ϯ) 
 
 
ϭ͘ϯ ;Ϭ͘ϭϯ) 
 
 
ϭ͘Ϯ ;Ϭ͘ϭϮ) 
 
 
фϬ͘ϬϬϬϭ 
LDL(mmol/l) 
Mean (SD) 
 
 
ϯ͘ϵ ;ϭ͘ϯͿ 
 
 
ϯ͘ϯ ;Ϭ͘ϯ) 
 
 
ϯ͘ϯ ;Ϭ͘ϮͿ 
 
 
ϯ͘ϯ ;Ϭ͘ϭϰ) 
 
 
Ϭ͘ϭϵ 
TG(mmol/l) 
Mean (SD) 
 
 
Ϯ͘Ϭ ;ϭ͘ϭͿ 
 
 
ϭ͘ϲ ;Ϭ͘Ϯ) 
 
 
ϭ͘ϱ ;Ϭ͘ϭϰ) 
 
 
ϭ͘ϰ ;Ϭ͘ϭϱ) 
 
 
<Ϭ͘ϬϬϬϭ 
 
 
 
 
Table (21); represent the one way analysis of variance (ANOVA) 
of  the   mean  values   of  Glycemia   and   lipid   profile   between 
baseline, 3 months, 6 months, and 12 months for insulin infusion 
group. 
 
 
 
The mean values of  the Fasting Blood Glucose (FBG) (mmol/l) 
from baseline to 3 months, 6 months and 12 months are as follow, 
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(17.2±5.6),  (5.1±0.6),  (5.8±0.5),  and  (5.6±0.5)  respectively  and are 
showing increasing significant trend , p <0.0001. 
The mean value of HbA1c% from baseline to  12 months period 
are, (8.7% ±1.7) at baseline, (6.1% ±0.2) at 3 months, (6.1% ±0.1) at 
6 months, and (6.1% ±0.2), and at 12 months (6.1%±0.2) with 
increasing significant trend, p<0.0001. 
 
 
Mean value  of total cholesterol (TC)  (mmol/l) through the  same 
period are as follows, (5.6±1.1) at baseline,(5.3±0.5) at 3 months, 
(5.4±0.30)  at  6  months,  and  (5.4±0.2)  at   12  months  with  a 
borderline significance p=0.05. Regarding to High Density 
Lipoprotein (HDL-C) (mmol/l) mean values are, (2.1±0.1) at baseline,  
(1.2±0.2)  at  3   months,  (1.3±0.1)  at  6  months,  and (1.2±0.1)   at   
12   months,   and   found   to   have   an   increasing significant trend, 
p<0.0001. 
 
 
 
Mean  value  of the  Low  Density  Lipoprotein  (LDL-C)  mmol/l, 
showed no significant changes and decrease trend, p =0.19. Mean 
values   of   Triglyceride   (TG-C)   (mmol/l)   presentation   were, 
(2.0±1.1)  at  baseline,  (1.6±0.2)  at  3   months,  (1.5±0.1)  at  6 
months,   and   (1.4±0.2)   at   12   months,   and   showed  increased 
significant trend, p<0.0001. 
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Table ;ϮϮ) One way analysis of variance (ANOVA) of the mean 
values of Glycemia and lipid profile between ϯ months, ϲ
months and ϭϮ months for insulin infusion group. 
 
 
Variables ϯ months ϲ months ϭϮ months ANOVA 
 
p-value 
FPG(mmol/l) 
Mean(SD) 
 
 
ϲ͘Ϭ ;Ϭ͘ϲ) 
 
 
ϱ͘ϴ ;Ϭ͘ϱ) 
 
 
ϱ͘ϲ ;Ϭ͘ϱϭ) 
 
 
фϬ͘ϬϬϬϭ 
,ďϭĐ% 
Mean (SD) 
 
 
ϲ͘ϭ ;Ϭ͘Ϯ) 
 
 
ϲ͘ϭ ;Ϭ͘ϭϮ) 
 
 
ϲ͘ϭ ;Ϭ͘ϮͿ 
 
 
Ϭ͘ϱϮ 
TC(mmol/l) 
Mean (SD) 
 
 
ϱ͘ϯ ;Ϭ͘ϱ) 
 
 
ϱ͘ϰ ;Ϭ͘ϯ) 
 
 
ϱ͘ϰ ;Ϭ͘Ϯϰ) 
 
 
Ϭ͘ϱ 
HDL(mmol/l) 
Mean (SD) 
 
 
ϭ͘Ϯ ;Ϭ͘Ϯ) 
 
 
ϭ͘Ϯ ;Ϭ͘ϭ) 
 
 
ϭ͘Ϯ ;Ϭ͘ϭͿ 
 
 
Ϭ͘ϰϴ 
LDL(mmol/l) 
Mean (SD) 
 
 
ϯ͘ϯ ;Ϭ͘ϯ) 
 
 
ϯ͘ϯ ;Ϭ͘Ϯ) 
 
 
ϯ͘ϯ ;Ϭ͘ϭϰ) 
 
 
Ϭ͘ϴ 
TG(mmol/l) 
Mean (SD) 
 
 
ϭ͘ϲ ;Ϭ͘Ϯϭ) 
 
 
ϭ͘ϱ ;Ϭ͘ϭϰ) 
 
 
ϭ͘ϰ ;Ϭ͘ϭϱ) 
 
 
фϬ͘ϬϬϬϭ 
 
 
 
 
Table  (22);  showing one way  analysis of variance (ANOVA) of 
the mean values of Glycemia and lipid profile between 3 months, 
6 months, and 12 months for insulin infusion group. Mean Value 
of FPG (mmol/l) concentration having increasing significant trend 
which  is,  (6.0±0.6)  at  3  months,  (5.8±0.5)  at  6  months,  and 
(5.6±0.5) at 12 months and p<0.0001. HbA1c%, TC, HDL, LDL, 
showed  decreasing  trend.  Mean  value  of TG  (mmol/l)  showing 
increasing significant trend as follow, (1.6±0.2) at 3 months, 
(1.5±0.1) at 6 months and (1.4±0.2) at 12 months and p<0.0001. 
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Table ;Ϯϯ) One way analysis of variance (ANOVA) of the mean 
values of Glycemia and lipid profile between baseline, ϯ
months, ϲ months and ϭϮ months for sliding scale group. 
 
 
Variables Baseline ϯ months ϲ months ϭϮ months ANOVA 
 
p-value 
FPG(mmol/l) 
Mean (SD) 
 
 
ϭϳ͘ϯ ;ϱ͘ϲ) 
 
 
ϱ͘ϴ ;Ϭ͘ϰϮ) 
 
 
ϱ͘ϴ ;Ϭ͘ϰϯ) 
 
 
ϱ͘ϳϰ( Ϭ͘ϰϴ) 
 
 
фϬ͘ϬϬϬϭ 
,ďϭĐ% 
Mean (SD) 
 
 
ϵ͘ϯ ;ϭ͘ϱͿ 
 
 
ϲ͘ϭ ;Ϭ͘ϮͿ 
 
 
ϲ͘ϭ ;Ϭ͘ϭ) 
 
 
ϲ͘ϭϯ ;Ϭ͘Ϭϭ) 
 
 
фϬ͘ϬϬϬϭ 
TC(mmol/l) 
Mean (SD) 
 
 
ϲ͘Ϭ ;ϭ͘ϬϮ) 
 
 
ϱ͘ϲ ;Ϭ͘ϯϱ) 
 
 
ϱ͘ϰϱ ;Ϭ͘Ϯϳ) 
 
 
ϱ͘ϰ ;Ϭ͘Ϯϲ) 
 
 
фϬ͘ϬϬϬϭ 
HDL(mmol/l) 
Mean (SD) 
 
 
ϭ͘ϰ ;Ϭ͘ϱϮ) 
 
 
ϭ͘Ϯϱ ;Ϭ͘ϭϴ) 
 
 
ϭ͘Ϯϴ ;Ϭ͘Ϭϭ) 
 
 
ϭ͘Ϯ ;Ϭ͘ϭͿ 
 
 
Ϭ͘ϬϮ 
LDL(mmol/l) 
Mean (SD) 
 
 
ϰ͘ϯ ;ϭ͘ϬϮ) 
 
 
ϯ͘ϰϭ;Ϭ͘Ϭϯ) 
 
 
ϯ͘ϯϲ ;Ϭ͘ϬϮ) 
 
 
ϯ͘ϯϮ ;Ϭ͘ϬϮ) 
 
 
фϬ͘ϬϬϬϭ 
TG(mmol/l) 
Mean (SD) 
 
 
ϯ͘ϯ ;ϭ͘ϴͿ 
 
 
ϭ͘ϲϯ ;Ϭ͘Ϯϯ) 
 
 
ϭ͘ϱϯ ;Ϭ͘ϭϴ) 
 
 
ϭ͘ϰ ;Ϭ͘ϭϲ) 
 
 
фϬ͘ϬϬϬϭ 
 
 
 
 
Table (23); represents one way analysis of variance (ANOVA) of 
the  mean  value  of Glycemia and lipid profile  between  baseline, 
3months, 6 months, and 12 months for sliding scale group. 
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Mean concentration FPG (mmol/l), was (17.3±3.6) at baseline, 
(5.8±0.4) at 3 months, (5.8±0.4) at 6 months, (5.7±0.5) and at 12 
months with significant increasing trend, p<0.0001. 
 
 
 
Mean value of HbA1c% also has significant increasing trend. (9.3 
%±  1.5) at baseline, (6.1% ±0.2) at 3  months, (6.1% ±0.1) at 6 
months, and (6.1 %± 0.1) at 12 months and p<0.0001. 
Mean  value  of  the  TC   (mmol/l)  was,  (6.0±1.2)  at  baseline, 
(5.6±0.4) at 3  months, (5.5±0.3) at 6 months, and (5.4±0.3) at12 
months with increasing significant trend, p<0.0001. 
On  the  other  hand  mean  value  of HDL  (mmol/l)  also  having 
significant  increasing  trend   as   follow,   (1.4±0.5)   at   baseline, 
(1.3±0.2) at 3 months, (1.3±0.2) at 6 months, and (1.2±0.1) at 12 
months with p=0.02. Mean value of LDL  (mmol/l) in this group 
also  showing significant increasing trend,  (4.3±1.02) at baseline, 
(3.4±0.03) at 3 months, (3.4±0.03) at 6 months, and (3.3±0.02) at 
12 months and p<0.0001. The mean value of the TG (mmol/l) as 
well  having  significant  increasing  trend,  (3.3±1.80)  at  baseline, 
(1.6±0.2) at 3  months, (1.5±0.2) at 6 months, and (1.4±0.2) at12 
months, and the p<0.0001. 
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Table ;Ϯϰ) One way analysis of variance (ANOVA) of the mean 
values of Glycemia and lipid profile between ϯ months, ϲ
months and ϭϮ months for sliding scale group. 
 
 
Variables ϯ months ϲ months ϭϮ months ANOVA 
 
p-value 
FPG(mmol/l) 
Mean(SD) 
 
 
ϱ͘ϴ ;Ϭ͘ϰϮ) 
 
 
ϱ͘ϴ ;Ϭ͘ϰϯ) 
 
 
ϱ͘ϳϰ( Ϭ͘ϰϴ) 
 
 
фϬ͘ϬϬϬϭ 
,ďϭĐ% 
Mean (SD) 
 
 
ϲ͘ϭ ;Ϭ͘ϮͿ 
 
 
ϲ͘ϭ ;Ϭ͘ϭͿ 
 
 
ϲ͘ϭϯ ;Ϭ͘ϭͿ 
 
 
Ϭ͘ϲϰ 
TC(mmol/l) 
Mean (SD) 
 
 
ϱ͘ϲ ;Ϭ͘ϯϱ) 
 
 
ϱ͘ϰϱ ;Ϭ͘Ϯϳ) 
 
 
ϱ͘ϰ ;Ϭ͘Ϯϲ) 
 
 
Ϭ͘ϬϬϭ 
HDL(mmol/l) 
Mean (SD) 
 
 
ϭ͘Ϯϱ ;Ϭ͘ϭϴ) 
 
 
ϭ͘Ϯϴ ;Ϭ͘Ϭϭ) 
 
 
ϭ͘Ϯ ;Ϭ͘ϭ) 
 
 
Ϭ͘ϬϬϱ 
LDL(mmol/l) 
Mean (SD) 
 
 
ϯ͘ϱ ;Ϭ͘ϯϯ) 
 
 
ϯ͘ϱ ;Ϭ͘Ϯϯ) 
 
 
ϯ͘ϯϰ ;Ϭ͘ϭϳ) 
 
 
Ϭ͘ϬϭϮ 
TG(mmol/l) 
Mean (SD) 
 
 
ϭ͘ϲϯ ;Ϭ͘Ϯϯ) 
 
 
ϭ͘ϱϯ ;Ϭ͘ϭϴ) 
 
 
ϭ͘ϰ ;Ϭ͘ϭϲ) 
 
 
фϬ͘ϬϬϬϭ 
 
 
 
 
Table (24) presenting one way analysis of variance (ANOVA) of 
the mean value of Glycemia and lipid profile between 3 months, 6 
months,  and  12  months  for  sliding  scale  group.  Mean 
concentrations of  FPG (mmol/l) was, (5.8±0.4) at 3 months, 
(5.8±0.4) at 6months, and (5.7±0.5) at 12 months, and p<0.0001. 
 
 
The mean value of the HbA1c% showed decreased non significant 
trend, with p=0.6. Mean value of TC (mmol/l) was, (5.6±0.4) at 3 
months,  (5.5±0.3)  at  6  months,  and  (5.4±0.3)  at   12   months 
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increasing  significant  trend  and  p=0.001.  Mean  value  of HDL 
(mmol/l), was (1.3±0.2) at 3  months,(1.3±0.01) at 6 months, and 
(1.2±0.1)  at   12  months  with  significant  increasing  trend  and 
p=0.005.   Mean  value  of  LDL   (mmol/l)  was,   (3.5±0.3)  at  3 
months, (3.5±0.2) at 6 months, and (3.3±0.2) at  12 months with 
increasing   significant  trend   and   p=0.01.   Mean   value   of  TG 
(mmol/l) was, (1.6±0.2) at 3  months, (1.5±0.2) at 6 months, and 
(1.4±0.2)   at    12   months   with   increasing   significant   trend, 
p<0.0001. 
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Table (25) Comparison of 3 days mean plasma glucose (MPG) 
between the two groups: Group1, patients treated with insulin 
infusion protocol and group 2, patients treated with sliding 
scale protocol. 
 
 
Serial Insulin infusion Group ;ϭ) ŶсϱϬ Sliding scale Group ;ϮͿ ŶсϱϬ 
  
 
 
MPG 
 
 
 
SD 
ϵϱ% CI 
for 
mean 
Lower 
bound 
ϵϱ% CI 
for 
mean 
Upper 
bound 
 
 
 
CV 
 
 
 
MPG 
 
 
 
SD 
ϵϱйI 
for 
mean 
Lower 
bound 
ϵϱ% CI 
for 
mean 
Upper 
bound. 
 
 
 
CV 
ϭ ϲ͘ϭϬ ϭ͘ϱϬ ϱ͘ϮϬ ϲ͘ϭϬ Ϯ͘ϱ ϳ͘ϬϬ ϱ͘ϯϬ ϱ͘Ϭϰ ϭϮ͘ϰϬ ϳ͘Ϭ 
Ϯ ϱ͘ϯϬ Ϯ͘ϮϬ ϯ͘ϵϬ ϲ͘ϳϬ ϰ͘Ϭ ϳ͘ϰϬ ϰ͘ϮϬ ϰ͘ϳϬ ϭϬ͘ϬϬ ϲ͘Ϭ 
ϯ ϱ͘ϱϬ ϭ͘ϵϬ ϰ͘ϯϬ ϲ͘ϳϬ ϯ͘Ϭ ϳ͘ϬϬ ϯ͘ϵϬ ϰ͘ϴϬ ϵ͘ϯϬ ϲ͘Ϭ 
ϰ ϱ͘ϴϬ Ϯ͘ϲϬ ϰ͘ϮϬ ϳ͘ϱϬ ϰ͘Ϭ ϲ͘ϬϬ ϭ͘ϱϬ ϱ͘ϮϬ ϲ͘ϵϬ ϯ͘Ϭ 
ϱ ϲ͘ϳϬ ϯ͘ϰϬ ϰ͘ϲϬ ϴ͘ϳϬ ϱ͘Ϭ ϴ͘ϲϬ ϰ͘ϱϬ ϲ͘ϭϬ ϭϭ͘ϮϬ ϱ͘Ϭ 
ϲ ϲ͘ϰϬ ϭ͘ϵϬ ϱ͘ϯϬ ϳ͘ϱϬ ϯ͘Ϭ ϵ͘ϰϬ ϰ͘ϵϬ ϲ͘ϱϬ ϭϮ͘ϮϬ ϱ͘Ϭ 
ϳ ϲ͘ϴϬ ϯ͘ϳϬ ϰ͘ϳϬ ϵ͘ϭϬ ϱ͘Ϭ ϴ͘ϯϬ ϯ͘ϭϬ ϲ͘ϱϬ ϭϬ͘ϭϬ ϰ͘Ϭ 
ϴ ϱ͘ϰϬ Ϯ͘ϬϬ ϯ͘ϱϬ ϲ͘ϳϬ ϯ͘Ϭ ϵ͘ϳϬ ϲ͘ϭϬ ϲ͘ϯϬ ϭϯ͘ϯϬ ϲ͘Ϯ 
ϵ ϱ͘ϭϬ Ϯ͘ϱϬ ϰ͘ϮϬ ϭϬ͘ϬϬ ϰ͘Ϭ ϵ͘ϭϬ ϲ͘ϯϬ ϱ͘ϱϬ ϭϮ͘ϴϬ ϳ͘Ϭ 
ϭϬ ϰ͘ϵϬ Ϯ͘ϱϬ ϯ͘ϰϬ ϲ͘ϱϬ ϱ͘Ϭ ϴ͘ϯϬ ϰ͘ϲϬ ϱ͘ϳϬ ϭϭ͘ϬϬ ϲ͘Ϭ 
ϭϭ ϰ͘ϴϬ Ϯ͘ϭϬ ϯ͘ϰϬ ϲ͘ϭϬ ϰ͘Ϭ ϴ͘ϭϬ ϯ͘ϵϬ ϱ͘ϵϬ ϭϬ͘ϰϬ ϱ͘Ϭ 
ϭϮ ϲ͘ϬϬ Ϯ͘ϮϬ ϰ͘ϴϬ ϳ͘ϰϬ ϰ͘Ϭ ϵ͘ϴϬ ϲ͘ϭϬ ϲ͘ϯϬ ϭϯ͘ϯϬ ϲ͘Ϭ 
ϭϯ ϱ͘ϬϬ Ϯ͘ϯϬ ϯ͘ϱϬ ϲ͘ϱϬ ϰ͘Ϭ ϴ͘ϴϬ ϰ͘ϰϬ ϲ͘ϯϬ ϭϭ͘ϰϬ ϱ͘Ϭ 
ϭϰ ϰ͘ϴϬ ϱ͘ϲϬ ϯ͘ϭϬ ϲ͘ϰϬ ϱ͘Ϭ ϵ͘ϴϬ ϰ͘ϳϬ ϳ͘ϭϬ ϭϮ͘ϱϬ ϱ͘Ϭ 
ϭϱ ϰ͘ϵϬ Ϯ͘ϰϬ ϯ͘ϰϬ ϲ͘ϰϬ ϱ͘Ϭ ϳ͘ϴϬ ϯ͘ϳϬ ϱ͘ϴϬ ϭϬ͘ϬϬ ϱ͘Ϭ 
ϭϲ ϱ͘ϬϬ Ϯ͘ϱϬ ϯ͘ϰϬ ϲ͘ϲϬ ϱ͘Ϭ ϲ͘ϲϬ ϰ͘ϭϬ ϰ͘ϯϬ ϵ͘ϭϬ ϲ͘Ϭ 
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Table (25) continued 
 
ϭϳ ϱ͘ϯϬ ϭ͘ϬϮ ϰ͘ϳϬ ϱ͘ϵϬ Ϯ͘Ϭ ϭϭ͘ϰϬ ϲ͘ϯϬ ϳ͘ϳϬ ϭϱ͘ϬϬ ϲ͘Ϭ 
ϭϴ ϱ͘ϬϬ Ϯ͘ϯϬ ϯ͘ϱϬ ϲ͘ϱϬ ϱ͘Ϭ ϵ͘ϬϬ ϰ͘ϰϬ ϲ͘ϱϬ ϭϭ͘ϱϬ ϱ͘Ϭ 
ϭϵ ϱ͘ϮϬ Ϯ͘ϰϬ ϯ͘ϳϬ ϲ͘ϳϬ ϱ͘Ϭ ϵ͘ϱϬ ϱ͘ϱϬ ϲ͘ϰϬ ϭϮ͘ϳϬ ϲ͘Ϭ 
ϮϬ ϱ͘ϬϬ Ϯ͘ϳϬ ϯ͘ϯϬ ϲ͘ϳϬ ϱ͘Ϭ ϵ͘ϬϬ ϰ͘ϱϬ ϲ͘ϯϬ ϭϭ͘ϱϬ ϱ͘Ϭ 
Ϯϭ ϱ͘ϬϬ ϭ͘ϵϬ ϯ͘ϴϬ ϲ͘ϮϬ ϯ͘Ϭ ϭϭ͘ϯϬ ϴ͘ϭϬ ϲ͘ϲϬ ϭϲ͘ϬϬ ϳ͘Ϭ 
ϮϮ ϰ͘ϵϬ ϭ͘ϱϬ ϰ͘ϭϬ ϱ͘ϴϬ ϯ͘Ϭ ϳ͘ϵϬ ϰ͘ϮϬ ϱ͘ϱϬ ϭϬ͘ϯϬ ϱ͘Ϭ 
Ϯϯ ϰ͘ϴϬ ϭ͘ϯϬ ϰ͘ϭϬ ϱ͘ϱϬ Ϯ͘Ϭ ϲ͘ϯϬ ϭ͘ϰϬ ϱ͘ϱϬ ϳ͘ϭϬ Ϯ͘Ϭ 
Ϯϰ ϰ͘ϲϬ ϭ͘ϮϬ ϯ͘ϴϬ ϱ͘ϰϬ ϯ͘Ϭ ϭϬ͘ϴϬ ϳ͘ϴϬ ϲ͘ϮϬ ϭϱ͘ϯϬ ϳ͘Ϭ 
Ϯϱ ϰ͘ϴϬ ϭ͘ϴϬ ϯ͘ϲϬ ϱ͘ϵϬ ϰ͘Ϭ ϴ͘ϰϬ ϯ͘ϴϬ ϲ͘ϮϬ ϭϬ͘ϲϬ ϱ͘Ϭ 
Ϯϲ ϱ͘ϯϬ Ϯ͘ϯϬ ϯ͘ϵϬ ϲ͘ϳϬ ϰ͘Ϭ ϲ͘ϳϬ ϰ͘ϬϬ ϰ͘ϱϬ ϵ͘ϭϬ ϲ͘Ϭ 
Ϯϳ ϰ͘ϰϬ ϭ͘ϴϬ ϯ͘ϯϬ ϱ͘ϲϬ ϰ͘Ϭ ϳ͘ϳϬ ϱ͘ϭϬ ϰ͘ϴϬ ϭϬ͘ϳϬ ϳ͘Ϭ 
Ϯϴ ϰ͘ϱϬ ϭ͘ϵϬ ϯ͘ϯϬ ϱ͘ϳϬ ϰ͘Ϭ ϳ͘ϬϬ ϯ͘ϱϬ ϱ͘ϬϬ ϵ͘ϭϬ ϱ͘Ϭ 
Ϯϵ ϲ͘ϭϬ ϯ͘ϮϬ ϰ͘ϭϬ ϳ͘ϵϬ ϱ͘Ϭ ϴ͘ϯϬ ϱ͘ϬϬ ϱ͘ϱϬ ϭϭ͘ϮϬ ϲ͘Ϭ 
ϯϬ ϰ͘ϳϬ Ϯ͘ϲϬ ϯ͘ϬϬ ϲ͘ϯϬ ϱ͘Ϭ ϳ͘ϴϬ Ϯ͘ϴϬ ϲ͘ϮϬ ϵ͘ϱϬ ϰ͘Ϭ 
ϯϭ ϱ͘ϯϬ Ϯ͘ϱϬ ϯ͘ϵϬ ϲ͘ϰϬ ϱ͘Ϭ ϳ͘ϵϬ ϱ͘ϬϬ ϱ͘ϭϬ ϭϬ͘ϴϬ ϲ͘Ϭ 
ϯϮ ϱ͘ϯϬ ϭ͘ϱϬ ϰ͘ϰϬ ϲ͘ϭϬ ϯ͘Ϭ ϵ͘ϬϬ ϳ͘ϭϬ ϱ͘ϬϬ ϭϯ͘ϭϬ ϴ͘Ϭ 
ϯϯ ϰ͘ϮϬ ϭ͘ϴϬ ϯ͘ϭϬ ϱ͘ϯϬ ϰ͘Ϭ ϴ͘ϯϬ ϱ͘ϮϬ ϱ͘ϯϬ ϭϭ͘ϯϬ ϲ͘Ϭ 
ϯϰ ϱ͘ϰϬ ϭ͘ϵϬ ϰ͘ϯϬ ϲ͘ϱϬ ϰ͘Ϭ ϵ͘ϭϬ ϰ͘ϰϬ ϲ͘ϱϬ ϭϭ͘ϲϬ ϱ͘Ϭ 
ϯϱ ϰ͘ϭϬ Ϯ͘ϭϬ Ϯ͘ϴϬ ϱ͘ϰϬ ϱ͘Ϭ ϲ͘ϯϬ ϳ͘Ϭ ϱ͘ϵϬ ϲ͘ϳϬ ϭ͘Ϭ 
ϯϲ ϰ͘ϯϬ Ϯ͘ϬϬ ϯ͘ϭϬ ϱ͘ϲϬ ϱ͘Ϭ ϳ͘ϯϬ Ϯ͘ϴϬ ϱ͘ϳϬ ϴ͘ϵϬ ϰ͘Ϭ 
ϯϳ ϰ͘ϯϬ ϯ͘ϴϬ ϯ͘ϭϬ ϱ͘ϰϬ ϰ͘Ϭ ϴ͘ϬϬ ϯ͘ϮϬ ϲ͘ϱϬ ϭϬ͘ϮϬ ϰ͘Ϭ 
ϯϴ ϰ͘ϬϬ Ϯ͘ϬϬ Ϯ͘ϳϬ ϱ͘ϯϬ ϱ͘Ϭ ϴ͘ϯϬ ϰ͘ϬϬ ϲ͘ϬϬ ϭϬ͘ϲϬ ϱ͘Ϭ 
ϯϵ ϱ͘ϲϬ Ϯ͘Ϭ ϱ͘ϱϬ ϱ͘ϲϬ Ϯ͘Ϭ ϴ͘ϴϬ ϱ͘ϰϬ ϱ͘ϳϬ ϭϮ͘ϬϬ ϲ͘Ϭ 
ϰϬ ϱ͘ϵϬ Ϯ͘ϯϬ ϰ͘ϲϬ ϳ͘ϮϬ ϰ͘Ϭ ϴ͘ϲϬ ϰ͘ϭϬ ϲ͘ϯϬ ϭϭ͘ϬϬ ϱ͘Ϭ 
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ϰϭ ϰ͘ϬϬ Ϯ͘ϬϬ Ϯ͘ϴϬ ϱ͘ϯϬ ϱ͘Ϭ ϳ͘ϮϬ ϭ͘ϮϬ ϲ͘ϰϬ ϳ͘ϵϬ Ϯ͘Ϭ 
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Table (25) and figures (24-25a and 25b); showing comparison 
between group 1 patients using insulin infusion and group 2 
patients using sliding scale protocol. In group 1, the lowest mean 
blood glucose (MPG) was 4.0 mmol/l and the highest was 6.8 
mmol/l, while in group 2, the lowest was 4.2 mmol/l and the 
highest was 11.4 mmol/l. On the other hand, the lowest reading of 
coefficient of variation (CV) in group 1 was 0.2 and the highest 
(CV) was 0.5, while in group 2, the lowest (CV) was 0.2 and the 
Table (25) continued
42 4.02 1.80 2.90 5.20 .40 8.70 4.30 6.30 11.20 .50 
43 6.20 3.40 4.30 8.20 .50 9.60 5.50 6.40 13.00 .60 
44 5.30 1.80 4.30 6.40 .30 6.00 0 .94 5.40 6.40 .20 
45 5.40 1.20 4.70 6.10 .20 6.20 1.20 5.50 6.80 .20 
46 5.60 2.10 4.40 6.80 .40 6.70 .80 6.20 7.10 .20 
47 4.10 2.00 2.90 5.40 .50 7.50 3.70 5.40 9.70 .50 
48 5.70 1.80 4.60 6.70 .30 6.20 .90 5.60 6.70 .20 
49 4.00 2.00 2.80 5.30 .50 5.00 1.80 3.90 6.10 .40 
50 6.30 1.80 5.10 7.40 .30 4.20 1.20 3.40 5.00 .30 
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highest (CV) was 0.8. 
So the glycemic variability (CV <0.5) in group 1 was 62% and in 
group 2 was 28% which reflect a significant variability of blood 
glucose during treatment with insulin sliding scale. 
These finding points to the fact that, the blood glucose control was 
more likely controlled in insulin infusion group with a very limited 
fluctuation of blood glucose than that in patients on the sliding 
scale protocol.  
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Figure (1): Distribution plot of the age group for male 
and female (normal distribution) in the study group 
(n=150).  
 
 
 
 
 
Figures
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Figure (2): Mean value of the age for male and female 
in the study group (150).  
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
140 
 
 
 
 
 
Figure (3): An ECG showing ST segment elevation (STEMI) 
in one of our patient in the study.  
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Figure (4); Killip classification in the study groups 
(n=150) 
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Figure (5): Different categories of social class calcification of 
the study group (n=150).  
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Figure(6): Mean value of the BMI (body mass index) for 
male and female in the study group (n150).  
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Figure (7): Mean value of waist circumference for male 
and female in the study group (150).  
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Figure (8): Mean value of the waist hip ratio for male 
and female in the study group (150).
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 Figure (9): Frequency of the 
abnormality in the study group 
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Figure (9-A): Frequency of resting segmental wall motion 
abnormality in the diabetic group 
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Figure (10): Catheterization room where coronary 
angiography was performed in the cardiac centre at Al 
Thawra Teaching Hospital, Sana'a-Yemen. 
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Figure (11): Catheterization room where coronary 
angiography was performed in the cardiac centre at Al 
Thawra Teaching Hospital, Sana'a-Yemen 
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Figure (12): Left system affection of the coronary 
artery for one of the diabetic group 
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Figure (13):left system coronary artery disease of one 
patient in the study. 
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Figure (14): left system affection of the coronary artery 
in the study, 
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Figure (15): Multiple coronary artery disease of the one 
of the diabetic patient in the study. 
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Figure (16): Right coronary artery lesion of one of our 
patient in the study, 
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Figure (17): Right coronary artery lesion of one of our 
patient in the study, 
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Figure (18): Types of coronary artery lesions in the 
diabetic group (n=100). 
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Figure (19): Coronary system affection in the diabetic 
group (100). 
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Figure (20): Types of coronary artery lesions for the 
whole study group (n=150). 
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Figure (21): Sex distribution for male and female in the 
diabetic group (n=100). 
 
I.V infusion=diabetic patients treated by insulin infusion. Sliding scale= diabetic patients 
treated by sliding scale protocol.
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Figure (22); difference between the mean (95% CI) 
value of the admission blood glucose (ABG) for 
insulin infusion therapy (IIT) group and sliding 
scale insulin (SSI) group's p=0.94. 
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Figure (23); Difference between the mean (95%CI) 
value of the average blood glucose (ABG) for IIT 
and SSI group, p<0.0001. 
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Figure (24); Difference between the mean (95%CI) 
value of mean blood glucose (MBG) for IIT and SSI 
groups. 
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Figure (25a and 25b); Difference between the 
coefficient of variation (CV) of MBG for Insulin 
Infusion Therapy (IIT) group and Sliding Scale 
Insulin (SSI) group. 
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Figure (26): Echocardiography of one of the patient in the 
study with aneurismal changes. 
 
Figure (27): Echocardiography of one of the patient in the 
study with aneurismal changes and thrombus formation. 
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Discussion 
 
 
Diabetic  is  a  well-known  independent  risk  factor  for 
cardiovascular disease. In patients with diabetes mellitus, 
cardiovascular  disease  causes  approximately  70%  of all  deaths. 
According to population-based surveys  in the united state, white 
diabetic adult patients have an age-adjusted prevalence of 45% for 
coronary  heart  disease,  whereas  their  nondiabetic  counterparts 
have  a  prevalence  of 25%.       Although  the  incidence  of heart 
disease  is  declining  in  the  overall  population,  this  decrease  is 
much smaller in patients with type 2 diabetes mellitus and it may even 
be increasing in women with type 2 diabetes mellitus (126). 
 
Type 2 diabetes mellitus is a well established risk factor for 
cardiovascular disease.  Several observational studies have shown a 
positive correlation between biomarkers of glycemic control and both 
cardiovascular outcomes and microvascular disease, independent of 
risk factors known to cluster with diabetes. (127-131). 
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Patients  with  diabetes  are  at  a  higher  risk  for  coronary  artery 
disease and have worse outcomes. In a meta-analysis of 15 studies in 
patients with acute myocardial infarction, Capes et al compared the  
risk  of in-hospital  mortality  and  congestive  heart  failure  in 
hyperglycemic patients with and without a history of diabetes. In 
subjects without a known history of diabetes, the risk of death was 
significantly   higher   if   the   blood   glucose   concentration   at 
admission   was   more   than   109.8   mg/dL   (6.1   mmol/l).   The 
threshold for patients with a known history of diabetes was  over 
180mg/dL (10 mmol/l) (132). 
 
In ADVANCE trial, intensive treatment was reported to produce a 
relative reduction  of  10%  in  the  primary  composite  outcome  of 
major macrovascular and microvascular events, primarily as a 
consequence  of a  reduction  in  nephropathy.  However,  with  the 
respect  to  the  fundamental  question  of the  effect  of  glycemic 
control on macrovascular complications, there should be no 
misunderstanding that the trial had clearly negative results. In 
contrast, in the ACCORD trial, the intensive therapy group had an 
increased rate of death from any cause. 
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However, there were inconsistencies in the direction of the 
components of the composite outcome. For example, the rates of 
death from any cause and from cardiovascular causes were 
significantly higher in the intensive-therapy group than in the 
standard-therapy   group,   but   the   rate   of  nonfatal   myocardial 
infarction was  significantly lower in the intensive-therapy group. 
  
Both trial  showed  that  targeting  glycated  hemoglobin  level  that 
are below currently accepted standards  in high-risk patients with type 
2 diabetes did not have a beneficial effect on cardiovascular disease 
(133). 
 
Admission  blood  glucose  level  after  AMI   is   an   independent 
predictor  of  long-term  mortality  in  patients  with  and  without 
known diabetes.  Subjects with unknown diabetes  and  admission 
glucose level of 200 mg/dl (11.1 mmol/l) or more after AMI have 
mortality  rate  comparable  to  those  of subjects  with  established 
diabetes. Admission blood glucose may serve to identify subjects at  
high long-term mortality risk,  in  particular among those with 
unknown diabetes (134). 
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The  patients  subsequently received medical  care  during  hospital 
stay  and underwent regular follow up  over  3  months,  6  months 
and 12 months, looking at the outcomes of both protocols such as, 
recurrent  chest  pain,  re-hospitalization,  cardiovascular mortality, 
arrhythmia,  heart  failure  and   stroke.   Through  the   follow  up 
period,  the  patients were  submitted to  clinical  evaluation, ECG, 
lipid profile, fasting blood glucose and HbA1c investigations and 
Echocardiographic assessment. 
 
As indicated in tables (1-4); Male predominant was noted in our study 
(73% vs.  76%) with a mean age of 59 years, which can be considered  
as  a  risk  although  this  factor  was  non  significant (p=0.7).   This   
was   reported   by   Klas   Malmberg   et   al(149) (197),who found 
that long term outcome in diabetic patients with myocardial infarction 
is predicted by age, previous myocardial infarction, and not the least 
the actual glucometabolic state. 
  
This finding was also reported by Gunaid et al (1997) who studied the 
demographic and clinical features of diabetes mellitus in 1095 
Yemeni  patients   (256).     Most  of  the  patient's   in  our  study 
admitted with, typical chest pain, high plasma glucose, high HbA1c%, 
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increased troponin, high lipids, and STEMI. 
 
It is worth noticing the high mean HbA1c in the diabetic group at time 
of admission with AMI (11.4%).  This high value of HbA1c reflects 
that most of the  diabetic patients were poorly  controlled prior to the 
acute event of myocardial infarction. 
 
BMI  (kg/m2)  as  shown  in  table  (1)  was  between  diabetic  and 
control groups (30.7±7.4 vs. 33±14.6) respectively     could be one of 
the  risk  factor  for  the  bad  outcome  presented  in  our  study 
although the p value was non significant, p=0.2. 
 
This was reported in Samuel Klein et al (136), who said, men and 
women who have a BMI >30 kg/m2 are considered obese and are 
generally at higher risk for  adverse  health events  than are those who  
are  considered overweight (BMI between 25.0 29.9 kg/m2) or lean 
(BMI between 18.5 and 24.9 kg/m2). 
 
WC mean value comparing the diabetic group to the control group 
was   significantly  high  in  the   diabetic  patients   in   our  study 
(P=0.03) which can be considered as one of the risk factors that 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 170 
 
 
  
lead to  the composite end points.  This was proved by Harald J. 
Schneider  et  al  (137-142).    In  our  study,  waist  to  height  ratio 
(WHtR) was measured and found to be an independent cardiovascular 
risk predictor regardless of others risk factors such as, age, smoking, 
hypertension, and lipids, p=0.0037. This was consistent with some 
published studies (140), which showed that, WHtR represents the best 
predictor of cardiovascular risk and mortality followed by WHR and 
WC. 
 
Systolic and diastolic blood pressure comparison between diabetic 
group and control group showed no significant value in our study 
which  may be due to that the sample is small or the patient were 
aggressively treated .  This was not the picture in the main trials; that 
proved that lowering blood pressure had significant beneficial effect 
on the cardiovascular events outcome (143) (M R.  Law et al).  In  
this,    largest meta-analysis  of randomized trials  of blood pressure 
reduction published to date, shows that lowering  systolic blood 
pressure by  10mmHg or diastolic blood pressure by 5 mm Hg  using  
any  of the  main  classes  of   blood  pressure  lowering drugs, has 
reduced coronary heart disease(CHD) events (fatal and non-fatal)  by   
about   a  quarter   and   stroke   by   about  a  third, regardless  of the  
presence or absence of vascular disease and  of pre-treatment blood  
pressure  ,  with no  increase  in  non-vascular mortality. Heart failure 
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also was reduced by about a quarter. 
  
HbA1c% at the time  of admission was  (mean  10.3±1.1%  in the 
diabetic group (1) who were treated by  insulin infusion protocol and  
12.6±1.6%  in  the  diabetic  group  (2)  who  were  treated  by sliding  
scale  protocol.  At  3  months, HbA1c% was  6.0±0.2% in group (1) 
and 6.2±0.2% in group (2), with significant beneficial effect 
(p<0.0001) and less frequent of readmission, heart failure, stroke  and  
cardiovascular mortality  in  group(1)  as  compared to group (2). 
 
This is was inconsistent with what was reported in many studies. S 
Hadjadl et al. (144) found that, admission plasma glucose, even after 
adjustment on HbA1c, is a prognostic factor associated with mortality 
after acute myocardial infarction. Acute rather than the chronic   pre-
existing   glycometabolic   state   accounts    for   the prognosis after 
acute myocardial infarction.    Also the importance of HbA1c was 
stressed by the International Expert Committee. All of these  
observations  suggest that  a  reliable  measure  of chronic glycemic  
levels  such  as  HbA1C,  which  captures  the  degree  of glucose 
exposure over time and which is related more intimately to  the risk  
of complications than  single  or episodic  measures  of glucose  
levels,  may  serve  as  a  better  biochemical  marker  of diabetes and 
should be considered a diagnostic tool (145-148). 
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Our patients were admitted with high blood glucose concentration and 
high HbA1c and this high blood glucose could be one of the factors  
which  affect the  outcome  in  diabetic  patient with AMI. Some  
studies  confirm this  idea  and  proved  it.  In  patients  with acute 
MI,  elevated glucose levels  are  a predictor of mortality  in patients 
with and without diabetes.  In addition,  elevated glucose levels  have  
been  associated  with  larger  infarct  size  in  patients without a prior  
history  of diabetes  who  were  being  treated with perfusion therapy 
for ST-segment elevation MI.  A meta-analysis of  15  studies  of  
patients  who  were  hospitalized  for  acute  MI reported that blood 
glucose  levels  in  excess  of 110  mg/dL were associated  with  
proportionally  greater  mortality  and  increasing rates of congestive 
heart failure (231-237). 
 
In patients with type 2 diabetes the risk of diabetic complications was 
strongly associated with previous hyperglycaemia. Any reduction in 
HbA1c is likely to reduce the risk of complications, with  the  lowest  
risk  being  in  those  with  HbA1c  values  in  the normal range (< 
6.0%) (152). 
 
Increasing   blood   glucose   concentrations   are   associated   with 
adverse   clinical   outcomes   in   patients   with  AECOPD.   Tight 
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control of blood glucose reduces mortality in patients in intensive 
care or following myocardial infarction (253). 
  
Admission  plasma  glucose  and  HbA1c%  were  found  to  be  a 
predictor for the end point composite in our study and intensive 
control  of these  two  factors  lead  to  better  outcome  in  diabetic 
patients treated by  insulin  infusion pump protocol (IIT).  Similar 
finding and impression was reported by  several studies and they 
concluded   by,   over   all,    intensive   compared   with   standard 
glycemic control significantly reduces coronary events without an 
increase risk of death. However, the optimum mechanism, speed, and  
extent  of HbA1c  reduction  might  be  different  in  differing 
populations (127, 133-135, 163-190). 
 
Also, Extensive observational data have  shown a
 consistent, almost  linear relationship 
 between  blood  glucose  levels in hospitalized
 patients  and adverse clinical  outcomes,
 even in patients  without  established  diabetes.  It  has  never  
been  entirely clear,  however, whether Glycemia serves  as  a 
mediator of these outcomes or  merely as a  marker  of  the sickest  
patients,  who present with the well-known counter regulatory stress 
response to illness.  Several  early  studies  suggested  a  
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clinical  benefit  from strict glucose control during critical care but 
were weakened by a retrospective  design  or  other  methodological  
concerns  (134,191- 
205). 
 
Most of the diabetic patients in our study compared to the control 
patients  presented  with  Killip's  class  II  (p=0.008)  that  can  be 
  
explained that these patients may came late from the time of onset of 
AMI. 
Also  most  of  these  patients  were  current  smoker;  their  ECG 
showed STEMI and their lipid profile was high at the time of 
admission. 
 
Regarding the heart rate (HR), the majority of the patients in both 
groups (diabetic and control) were having a HR of 60-100 and > 
100 bpm and less presented with bradycardia and heart block. 
Tachycardia  at  the  time  of admission  could  play  a  role  in  the 
outcome. 
 
CK-MB and troponin were almost always high in both groups 
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(diabetic  and  control)  as  well  and  this  reflects  the  pathological 
effect of AMI of the cardiac muscles. 
 
Echocardiographic assessment as  indicated in table (4) of all our 
patients  (cases  and  controls)  showed  that  high  percentage  of 
patients found to have hypokinesia (p=0.03) and akinesia. 25% of the 
diabetic patients noted to have mitral regurge due to rupture of the 
papillary muscles. 
 
As  shown  in  table  (5),  Stroke  was  found to  occur more  in  the 
diabetic  group  compared to  the  control  group  especially  in  the 
patients who were treated by sliding scale. This was similar to that 
  
reported by Buse et al (150) who said, patients with diabetes have 
twice the risk of incident myocardial infarction and stroke as that of    
the     general     population.     Stroke     affects     more     than 
700,000individual each year;  it is the third largest cause of death and 
the largest cause of adult disability in the US.  Diabetes is  a major 
risk factor for the development of stroke (151-158). 
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In our study, mortality was higher among the diabetic patients as 
compared to control patient especially during the hospital stay and 
during the first 3 months follow-up. Also, the mortality among the 
diabetic  patients  treated  by  sliding  scale  was  higher  than  that 
among those treated by  insulin  infusion.  This  is  consistent with 
some  studies  (159-162),  who  reported  that,  a  large  numbers  of 
people with diabetes do not survive their first event, and if they do 
survive, their mortality rate over the subsequent months to years is 
generally greater than that of the general population. 
 
In non-diabetic patients with acute coronary syndrome and 
hyperglycemia  treatment  with   insulin   was   associated  with   a 
reduction  in  the  relative risk  of death,  evident within  7  days  of 
admission, which persists at 30 days. (239). 
 
During the  hospital stay  as  shown  in  (table 6),  diabetic patients 
treated  with  insulin  infusion  (IIT)  (group   1)  had  less  serious 
events than those treated with insulin sliding scale (SSI) (group 2), 
 
such as recurrent chest pain, arrhythmia, heart failure, stroke and 
mortality.  Patients  of group 2 who were  on  insulin  sliding  scale 
were found to have more heart failure, arrhythmia, recurrent chest 
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pain,  and  stroke  and  also  increased  incidence  of death noted  in 
this  group.   Rupture of the papillary muscle was  noted more  in 
group 2  during echocardiography follow-up.   So, patients in our 
study  who  were  treated with  insulin  infusion  protocol  found to 
have beneficial effect on short term outcomes of AMI more than on  
long  term  outcomes.  This  was  inconsistent  with  what  was 
reported in Silvio et al (259). But, the reverse was reported in 
Veterans  (VADT)  trial  which  concluded  by,  intensive  glucose 
control in patients with type 2 diabetes had no significant effect on 
the rates  of major cardiovascular events, death,  or microvascular 
complications (260). 
 
 
At the time of admission as indicated in table (7), we performed a 
coronary  angiography  for  all  of  our  patients;  It  revealed  that 
diabetic patients ( group1-IIP and SSI group 2)   had more single and 
multi vessels affection than the group 3 (control group). Also most  of 
the  diabetic  patients  underwent  a  PCI  or  CABG  more frequently 
as compared to the control group. 
 
Both group  1  and group 2 had long duration of diabetes mellitus as  
indicated in table  (8).  Table  (9),  showed the  plasma glucose 
concentration  and  HbA1c  at  admission  and  the  average  plasma 
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glucose concentration during the  first 3  days  of hospital stay.  It 
shows that insulin infusion was more effective in controlling the 
average plasma glucose with less glycemic variability over 3 days as 
compared to sliding scale insulin (p<0.0001). At the 3 e d ,6 t h , and 
12t h    months follow-up period (tables 10-12), it was clear that the 3 
groups  had  similar  incidence  of recurrent  chest  pain  and  well 
controlled plasma glucose and HbA1c in both group 1 and group 2 
patients. 
 
 
However  the   patients   on   sliding   scale   (group  2)   had   more 
aneurismal changes and papillary muscle rupture than patients on 
insulin infusion (group 1) as seen by ECHO study. 
Lipid profiles were well controlled in both group (1) and 2 as well 
during  the  periods  of follow up.  Group  (2)  patients  exposed to 
more re-admission need and had more frequent occurrence of HF, 
more stroke and mortality during this period of follow-up as 
compared to  group1.  These  findings  that  stroke,  mortality,  and 
need of re-admission were more likely associated with SSI may be 
explained by  the  fact that,  IIP was  more  effective than the  SSI 
during  the  time  of hospitalization.  Univariate  analysis  for  poor 
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outcome of AMI  in both groups during hospital stay (Table  13), has   
shown   that   stroke   was   unlikely   associated  with   insulin 
infusion   pump   as   compared  to   sliding   scale   protocol,   RR= 
0.15(95%CI;  0.02-0.99)  p=0.005).  This  is  consistent with  what 
was mentioned previously (151-158). 
Also  the  incidence  of recurrent  chest  pain,  HF,  arrhythmia  and 
mortality were less likely associated with IIT as compared to SSI yet 
the  difference was  not  significant.  So we  admit that insulin 
infusion  is  better than the  sliding  scale  in the  short outcome of 
acute myocardial infarction (AMI) in diabetic patients. 
In table (14) a univariate analysis and univariate relative risk for poor 
outcome of AMI in diabetic patients vs. non diabetic patients showed  
that,  HF,   arrhythmia  stroke  and  mortality  were  high among 
diabetic patients although the p value was not significant. The same 
result was reported by certain studies (151-162,239). 
Multivariate  Logistic  Regression  Analysis  of  poor  outcome  of 
AMI has confirmed what was reported by univariate analysis that 
stroke   unlikely   associated   with   IIT    as    compared   to    SSI 
(RR=0.092); 95%CI0.011-0.798 (p=0.03).  The finding that stroke 
was more likely associated with SSI may be explained by the fact 
that, this protocol is less effective in treating diabetic patients at the  
time  of  serious  events  like  AMI  (151-159)  or  this  was  a 
sequally of coronary angiography. 
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Other   variables   (HF,   arrhythmia,   recurrent   chest   pain,   and 
mortality) were found to occur more among the patients of group 
2   (SSI)  but  the   difference  was   not   significant.   Multivariate 
Logistic Regression Analysis of poor outcome of AMI in diabetic 
patients vs. non diabetic patients was computed to predict 
independent  risk   factors   associated   with   poor   cardiovascular 
outcome (table  16).   In this table, recurrent chest pain was found to 
be equally associated in both types of patients (p>0.05). 
Baseline   biochemical   characteristics   of  the   diabetic   patients 
(group  1  and group 2) presented in table (17) in the text showed that, 
these patients were having  higher admission blood glucose, HbA1c, 
and lipid profiles. On the other hand, (tables18-20) in the text 
presented the follow-up periods at 3, 6, and  12 months with well 
control of these variables mostly in those patients treated by insulin 
infusion protocol at the time of hospital stay and by medications    
directed   toward   controlling    cardiovascular   risk factors during 
follow up period. 
The one way analysis of variance (ANOVA) of the mean values of 
Glycemia  and  lipid  profiles  between  baseline,  3  months,  6 
months,  and  12  months  for  insulin  infusion  group  presented  in 
table (21)  showed well  control  of these variables throughout the 
periods of follow-up. 
Table  (22)  showed  the  same  variables  with  the  same  group  of 
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patients   without   the   baseline   and   there   is   a   good   reading 
especially for fasting plasma glucose (FPG) and triglyceride. 
Tables (23 and 24) presented the (ANOVA) with and without baseline 
for diabetic patients treated by sliding scale protocol and the  results  
were  good  all   over  the  period  of  admission  and throughout the 
follow-up period.  These  can be  explained by the fact  that  these  
patients  were  receiving  a  combination  of drugs throughout the 
time of follow-up. 
Comparison between the  two  groups  of patients  regarding  mean 
plasma   glucose   (MPG)   and   coefficient   variation   (CV)   was 
presented  in  table  (25).   The  lowest  reading  was  noted  with 
patients  treated  by   insulin   infusion  (IIT)   compared  to   those 
patients treated by sliding scale (SSI). More than 62% of patients who  
were  treated  with  IIT  had  CV  of  mean  plasma  glucose (MPG)  
<0.5  as  compared to  28%  in  patients  who  were  treated with SSI. 
Short term better  outcome was  noticed  in  our  study  in  patients 
treated  by  insulin  infusion  protocol,  especially  at  the  time  of 
hospital stay and in the first 3 months follow-up. This is in regards to,  
recurrent chest pain,  stroke, and mortality.  This reflects that, insulin 
infusion protocol was superior to sliding scale in diabetic 
patients with AMI and good glycemic control by this method has a  
good  impact  on  the  outcome.  Many  studies  were  with  this 
concept  and  proved that  good  glycemic  control  by  an  intensive 
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treatment is the best way. For those ICUs patients, a balanced 
recommendation could  be  that the  clinicians  gauge  how 
comparable their own patients and settings are to those in the 
different  studies  before  deciding  to  go  for  the  normal  for  age 
target or the intermediate NICE-SUGAR target. At this stage, the 
evidence for blood glucose control to the normal for age level is 
strongest for adult and pediatric surgical ICU patients (206-224). 
An  Inpatient Insulin  Pump  Protocol  (  IIPP)  provides  a 
standardized and safe approach to the use of continuous subcutaneous 
insulin infusion (CSII) in the hospital (254). 
 
Mortality was  more  among  patients treated by  sliding  scale  and 
less  among  those treated by  insulin  infusion  in  our study  (20% 
vs.6%).  This  was  reported  in  some  studies,  intensive  insulin 
therapy targeting arterial glucose levels of 80-110 mg/dl (4.4-6.1 
mmol/l)   in   a   surgical   ICU   patient  population  resulted   in   a 
significant decrease in morbidity and mortality (225,238). 
However,   implementation   of  the   identical   protocol   in   1,200 
medical  ICU  patients  by  the  same  investigators  in  the  same 
institution diminished morbidity but failed to reduce mortality. A 
sixfold  increase  in  severe  hypoglycemic  events  (BG _40  mg/dl 
[2.2mmol/l]) was observed in the  intensively treated group (18.7 vs.  
3.1%),  and  hypoglycemia was  identified  as  an  independent risk 
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factor for mortality (226). 
The Hyperglycemia Intensive Insulin Infusion in Infarction (HI-5) 
study randomly assigned patients with AMI to 24-h infusions of 
insulin  plus   glucose  for  24   h  (BG  goal  _180  mg/dl   [_10.0 
mmol/l]) or usual care.  There were no  significant differences in 
mortality, although there was a decreased incidence of congestive 
heart failure and reinfarction at 3 months in the intensively treated 
group (227). 
The   very   large   Clinical   Trial   of   Reviparin   and   Metabolic 
Modulation in Acute Myocardial Infarction Treatment Evaluation—
Estudios Cardiologicos Latin America (CREATE- ECLA),  with  
20,201patients,  tested  the  efficacy  of    glucose- insulin-potassium 
infusion in post-AMI patients and found no decrease  in  mortality  
(228).  A  failure to  achieve  a  prespecified glycemic target with 
intensive therapy that differed from those in the control group may 
have contributed to these negative results (228,229). 
In  our  study we  found that  insulin  infusion protocol achieved a 
good  glycemic  control  during  the  time  of  hospitalization  and 
prevent the effect of hyperglycemia and myocardial infarction on the 
outcome. This was reported in some studies, in the critical care 
setting, continuous IV insulin infusion has been shown to be the most 
effective method for achieving specific glycemic targets. Because  of  
the  very  short  half-life  of  circulating  insulin,  IV delivery allows 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 184 
 
 
rapid dosing adjustments to address alterations in the status of 
patients (230). 
There are two main reasons for using low-dose insulin infusions in  
diabetics  after  myocardial  infarction.  Firstly,  it  provides  a simple 
way  of correcting  hyperglycemia and maintaining normal blood  
glucose  concentrations.  Myocardial  infarction  initiates  a series  of 
metabolic  changes  (secretion  of catecholamines, glucagon, and 
corticosteroids and suppression of insulin secretion) that  culminates  
in  an  exacerbation  of  the  diabetes  which,  on occasion, may be 
difficult to control. Low-dose insulin infusion is an effective and 
simple way of regulating blood glucose in these patients.  Secondly,  
there  are  suggestions  that  raised  free  fatty acids seen in 
myocardial infarction may be deleterious: they may cause  
arrhythmias, reduce  contractility, and  increase  infarct size by 
increasing consumption of myocardial oxygen. Infusing insulin 
reduces  free  fatty  acid  levels  and  may  prevent  any  possible 
damage that they cause (240-250). 
Also,   several   investigators   have   established   that   controlling 
glucose with intensive insulin therapy (IIT) during hospitalization 
reduces morbidity and mortality among critically ill individuals (251). 
In  this  study,  patients  treated  by  sliding  scale  (SSI)  protocol 
showed no  more  benefit from this  method and the  incidence of 
heart failure, stroke, recurrent chest pain, and mortality were high in  
this  group  of patients.  Similar  belief was  reported  by  some 
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studies and they said, perhaps most importantly SSI, as defined in the 
traditional sense, has no track record of effectiveness. A MEDLINE 
search of 52 trials from 1966-2003 did not reveal even 
1 report  of  benefit  from  SSI.   In  fact,  the  concerns  of  this 
nonsensical practice were noted 45 years ago. 
2 SSL is clearly convenient and straight forward to administer, but it 
has  not been  shown to  provide benefit and  it may  induce  harm 
(255). 
One of the weakest points in our study is that the sample size was 
small  because  it  is  a  cohort  study  and  the  patients  need  strict 
follow up over one year and interventional procedures such as PCI 
and CABG. 
On the other hand, I followed my patients personally and I kept in 
touch with them either by meeting or through phone call. Also I 
 performed all the interventional and non interventional procedures by 
myself (ECG, ECHO, and PCI). 
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Conclusion 
 
Diabetic patients had more complications as compared to the control 
group during the hospital management. 
The patients who were treated by the insulin infusion (IIT) protocol in 
this study were found to have better short outcomes regarding 
recurrent chest pain, arrhythmia, heart failure, stroke, and mortality as 
compared to those treated by sliding scale (SSI) protocol. 
Three months follow up showed that the diabetic patients had more 
bad outcomes as compared to the control group. However, IIT treated 
diabetic patients had better outcomes as compared to those treated by 
SSI. 
On  the   six t h         and  twelft h s         months   follow  up,   there  
were  no significance differences were found between diabetic and 
non- diabetic,   and   between   diabetics   treated   by   different   
insulin regimen. 
Patients in our study who were treated with insulin infusion protocol 
found to have beneficial effect on short term outcomes of AMI but 
not on long term outcomes. 
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Recommendations 
Further studies should be done in this field on a large sample size.  
Insulin infusion protocol should replace the sliding scale protocol for 
the treatment of diabetic patients with AMI. 
The care providers at the intensive care units should be well trained 
and their knowledge should be updated for dealing with this diabetic 
patients. 
Diabetic patients with AMI must have a good strict and aggressive 
treatment to have a better outcome. 
Education and good follow up after discharge of these types of 
patients must be considered. 
Establishing diabetic health care programme covering the direct costs 
i.e. cost of diagnosis and treatment; and conducting educational 
programmes in diabetic to the patients and health care members in 
order to improve the quality of patients care and to reduce the 
occurrence of diabetic-related complications. 
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